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 Abstract 
Intracellular pathogens are recognized by a specialized subset of lymphocytes 
known as CD8+ T cells.  Pathogen recognition by CD8+ T cells occurs through binding 
of T cell receptors (TCR) to processed antigens in complex with major histocompatibility 
complex (MHC) class I proteins.  TCR engagement of antigens in complex with MHC 
class I typically lead to cytotoxic CD8+ T cell responses, which result in pathogen 
clearance.  Due to the large number of foreign antigens that might be encountered by any 
given host a diverse repertoire of TCRs must be available for immune recognition.  The 
main source of TCR diversity is generated by somatic recombination of the TCR genes.  
However, it has been suggested that selection eliminates so many recombined TCR 
sequences, that a high degree of TCR cross-reactivity must occur for the immune system 
to be able to recognize a large set of foreign pathogens.  The work presented in this thesis 
was directed towards the understanding of the molecular mechanisms of CD8+ T cell 
recognition and cross-reactivity.   
Chapter I of this thesis gives an overview of the immune system, with a focus on 
CD8+ T cells.   
Chapter II of this thesis describes the development of novel bi-specific MHC 
heterodimers that are specific towards cross-reactive CD8+ T cells.  Classically, MHC 
tetramers have been used for phenotypic characterization of antigen-specific T cells.  
However, identification of cross-reactive T cells requires the simultaneous use of two 
MHC tetramers, which was found to result in MHC tetramer cross-competition.  For this 
reason, we generated bi-specific MHC heterodimers, which would not be affected by the 
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affinity between the component peptide-MHC complexes for TCR.  We generated T cell 
lines, which cross-react with antigens from lymphocytic choriomeningitis virus (LCMV) 
and vaccinia virus (VV), to test our bi-specific MHC heterodimers.  We show that the 
heterobifunctional cross-linking utilized to generate bi-specific MHC heterodimers does 
not affect specific binding onto cross-reactive CD8+ T cells.   
Chapter III describes a mechanism for a cross-reactive CD8+ T cell response 
between the disparate antigens, lymphocytic choriomeningitis virus (LCMV)-GP34 
(AVYNFATM) and vaccinia virus (VV)-A11R (AIVNYANL), which share the three 
underlined residues.  The recognition determinants for LCMV-GP34 and VV-A11R were 
compared by an alanine/lysine scanning approach for both epitopes.  Functional analysis 
of the mutated peptides clearly indicates that the shared P4N residue between LCMV-
GP34 and VV-A11R is an important TCR contact for the recognition of both epitopes.  In 
addition, we determined the crystal structures of both Kb-VV-A11R and Kb-LCMV-
GP34.  Structural analysis revealed that the two complexes are nearly identical structural 
mimics, which was unexpected due to the primary sequence disparity.  Together with the 
functional studies, our results highlight that structural similarities between different 
peptide-MHC complexes can mediate cross-reactive T cell responses.   
Chapter IV of this thesis includes additional discussion, overall conclusions and 
future directions.   
Chapter V includes the protocols and the gene constructs that were used in this 
work.  Also included in Chapter V are results from two unrelated incomplete projects 
which have yielded significant findings.   
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Chapter I:  
Introduction 
 
 The immune system is a multi-faceted defense mechanism which protects the host 
from invasion by foreign pathogens.  This chapter will give an overview of the immune 
system, with an emphasis on CD8+ T cell recognition and CD8+ T cell Cross-reactivity.   
 
I.A. The Vertebrate Immune System 
 The innate immune response is an “ancient” defense system that provides 
immediate protection against pathogens.  The main strategy of the innate immune system 
is to target molecular patterns which are not found in the host.  This mode of recognition 
is commonly known as pattern recognition and plays a major role in the quick response 
of the innate immune response.  The receptors which act in the innate immune 
recognition are encoded in the germline, which predestines the recognition of these 
receptors towards a limited number of targets.  These targets may include components of 
the bacterial cell wall, such as lipids or peptidoglycans (Medzhitov and Janeway 2000; 
Janeway 2001; Maile 2006).   
 The first line of defense in the innate immune system includes the physical and 
the chemical barriers.  The physical barriers comprise of the skin and the mucus 
membranes which prevents entry for most foreign pathogens.  The chemical barriers 
include metabolites that inhibit bacterial growth, such as fatty acids found in sweat, the 
low pH environment generated by gastric secretions or lysozyme found in tears and 
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saliva that functions as an antibacterial agent, by catalyzing the breakdown of the 
bacterial cell wall (Janeway 2001; Maile 2006).   However, if a pathogen surpasses these 
initial barriers, recruitment of effector cells to sites of infection occurs, which is the main 
line of defense for the innate immune system.   
 Cells called phagocytes, which includes macrophages, function in the 
identification and removal of foreign pathogens or infected host cells through a process 
known as phagocytosis (Janeway 2001).  Phagocytes are also capable of recruiting other 
cell types to sites of infection by promoting inflammation, which is stimulated by 
chemical factors known as cytokines.   While innate immune responses are rapid, they are 
often ineffective against well-evolved pathogens such as viruses.  In cases where 
pathogens persist, the innate immune system is able to recruit the better evolved adaptive 
immune response through a process known as antigen presentation (Janeway 2001; 
Janeway and Medzhitov 2002).     
 In contrast to the rapidly occurring innate immune response which targets a 
predetermined set of pathogens, the adaptive immune system generates a pathogen-
specific response towards any pathogen that may arise in the host through a process 
known as selection.  This diverse response is achieved through somatic recombination of 
the antigen receptors involved, which include the T cell receptor (TCR) and the B cell 
receptor (BCR), expressed on T cells and B cells, respectively.  A broad range of 
specificities is generated through somatic recombination of the TCR V, D and J gene 
fragments, which randomly recombine with the aid of recombinase activating genes to 
form a competent TCR or BCR (Schatz, Oettinger et al. 1989).  Additional diversity is 
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introduced by nucleotide addition at the V, D and J gene junctions, which results in a 
large repertoire of diverse TCR sequences (Leiden and Strominger 1986).  Theoretical 
estimates indicate that 1015 different antigen-specific receptors can be generated through 
somatic recombination (Marrack and Kappler 1988).   
 The adaptive immune system is comprised of cells called leukocytes, better 
known as white blood cells.  A common subset of white blood cells is lymphocytes, 
which constitute 20-40% of the entire white blood cell population.  The major types of 
lymphocytes in the adaptive immune response include B lymphocytes and T 
lymphocytes, better known as B cells and T cells.  B cells and T cells are derived from 
the same hematopoietic stem cells, and are indistinguishable until post-activation 
(Janeway 2001).  B cells and T cells act in concert in the adaptive immune response, with 
B cells playing a major role in the humoral immune response and T cells playing a role in 
the cell-mediated immune response.  The major effector role of B cells is to secrete 
antigen-specific antibodies, which bind to foreign antigens in their native form and target 
them for degradation, through a process known as opsonization.  On the other hand, T 
cells recognize processed antigens in the context of Major Histocompatibility Complex 
(MHC) proteins.  Upon recognition, the major effector role for CD8+ T cells is to 
eliminate any infected host cells by inducing cytotoxic responses (Janeway 2001; Pancer 
and Cooper 2006).   
 Selection for lymphocytes occurs during T cell development and will be discussed 
in the T cell development subsection of this chapter.  Lymphocytes which survive the 
selection process migrate to peripheral lymphoid tissues where clonal expansion occurs, 
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which results in the clearance of pathogen (Pancer and Cooper 2006).  After pathogen 
clearance, some of the responding effector cells are converted into memory cells, which 
can quickly respond towards the same pathogen, should re-infection occur.  This 
hallmark feature of the adaptive immune response is known as immunological memory 
and will also be discussed later.  An equally important aspect of the adaptive immune 
response is the elimination of self-reactive cells.  Discrimination of foreign versus self 
antigens is paramount for the host, as autoimmune responses may result (Boehm 2011).   
   
  
I.B. The Major Histocompatibility Complex (MHC) 
 The major histocompatibility complex (MHC) is a polymorphic cell surface 
glycoprotein that is expressed on the surface of antigen presenting cells (APCs).  The 
main role for MHC molecules is to present antigens to T cells.  There are two main 
classes of MHC molecules, class I and class II.  The two different classes of MHC differ 
mainly in their intracellular processing and presentation pathways and the subtype of T 
cells which they present to.  The MHC class I pathway generates peptide-antigens for 
CD8+ T cells, while the MHC class II pathway generates peptide-antigens from CD4+ T 
cells.  The focus of this subsection will be directed towards the MHC class I complex.   
 
I.B.1. Antigen Presentation by the MHC Class I Complex 
 The MHC class I complex is a trimer consisting of a polymorphic heavy chain, a 
beta-2-microglobulin (β2M) light chain and an antigenic-peptide 8-10 amino acids long 
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(8-10mer) (See Figure I.1A).  MHC class I molecules are ubiquitously expressed on the 
extracellular surface of all nucleated cells and their major role is to present antigenic 
fragments to CD8+ T cells.  While the source of proteins is often misfolded self-proteins, 
sometimes foreign proteins are also displayed to CD8+ T cells, which alerts CD8+ T cells 
to the infection status of the host cell (Janeway 2001; Maile 2006).   
 Intracellular proteins are processed in the cytosol into 3-22mer peptides by the 
proteasome (Kisselev, Akopian et al. 1999) and subsequently translocated into the lumen 
of the endoplasmic reticulum (ER) by transporter associated with antigen processing 
(TAP) (Androlewicz, Anderson et al. 1993; Shepherd, Schumacher et al. 1993).  In the 
lumen, MHC class I molecules are assembled and folded with the aid of several other 
proteins, including tapasin, calnexin, calreticulum, ERp57 and TAP (Pamer and 
Cresswell 1998).  Initially, the MHC class I HC is stabilized by calnexin prior to β2M 
association (Degen, Cohen-Doyle et al. 1992).  After associating with β2M, the unstable 
complex formed between the MHC class I HC and β2M interacts with the ER chaperones 
calreticulin (Sadasivan, Lehner et al. 1996) and ERp57 (Silvennoinen, Myllyharju et al. 
2004; Wearsch and Cresswell 2007).  Next, tapasin facilitates the loading of 8-10mer 
peptides by linking the MHC class I complex to TAP (Ortmann, Androlewicz et al. 
1994).  Lastly, peptide-bound MHC class I complexes dissociate from TAP and are 
transported through the secretory pathway via the trans-golgi network to the plasma 
membrane where they present the processed antigens to CD8+ T cells  (Suh, Cohen-
Doyle et al. 1994) (See Figure I.1).  
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Figure I.1. The MHC Class I Antigen Presentation Pathway (Hewitt 2003).  1. 
Proteins are processed in the cytosol by the proteasome.  2. Peptides generated by 
proteolytic cleavage are translocated into the ER lumen by TAP.  3. MHC class I 
molecules consisting of the heavy chain and associated β2M subunits, fold and assemble 
in the ER lumen with the aid of ER chaperones calnexin, calreticulum and ERp57.  4. 
MHC class I subunits in complex with calreticulum and ERp57 associate with TAP and 
tapasin facilitates peptide binding.  5. Peptide loaded MHC class I complexes dissociate 
from TAP and are transported through the secretory pathway via the golgi network to the 
plasma membrane. This figure was reproduced with permission.   
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I.B.2. Structural Features of the MHC Class I Complex 
 The MHC class I complex consists of four distinct extracellular, transmembrane 
domains, three of which are from the MHC class I HC with β2M contributing a fourth 
domain.  The three distinct extracellular domains from the MHC class I heavy chain (HC) 
are the α1, α2 and α3 domains.  The α1 and α2 domains form the antigen binding site, 
which resembles a hotdog bun.  The base of the bun consists of a single, eight-stranded β-
pleated sheet and the two sides of the bun each contain a single α-helix, numbered α1 and 
α2 (See figure I.1).  The α3 domain is a membrane proximal IgG-like region, which 
anchors the MHC class I molecule to the plasma membrane (Bjorkman, Saper et al. 1987; 
Janeway 2001).  The β2M light chain that’s assembled with the MHC class I HC is not 
membrane bound, but instead, is stabilized in a non-covalent manner to the MHC class I 
HC via the α3 domain (Townsend, Elliott et al. 1990).   
 The vast majority of MHC class I peptides bind with both the amino and the 
carboxyl terminus of the peptide anchored into the MHC class I molecule through either 
hydrogen bonding or hydrophobic interactions (Matsumura, Fremont et al. 1992; 
Rammensee 1995), although exceptions for hydrogen binding at the amino terminus have 
been reported (Achour, Michaelsson et al. 2002; Velloso, Michaelsson et al. 2004).  Due 
to the diversity of MHC gene locus, peptide binding motifs differ amongst the various 
MHC class I alleles.  For example, 8mer peptides are naturally processed and presented 
by the murine MHC class I H-2Kb molecule (Van Bleek and Nathenson 1990).  The H-
2Kb molecule has two primary “pockets” or anchoring positions, which lock in the bound 
peptide.  These pockets occur at peptide position 5 (p5) and also at peptide position 8 
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(p8) (Fremont, Matsumura et al. 1992; Matsumura, Fremont et al. 1992).  The p8 pocket 
is commonly referred to as the C-terminal pocket, which prefers amino acids with 
hydrophobic side chains such as leucine, methionine, isoleucine or valine (Fremont, 
Matsumura et al. 1992; Matsumura, Fremont et al. 1992).  Meanwhile, the p5 pocket has 
a strong preference for tyrosine or phenylalanine (Falk, Rotzschke et al. 1991).  A 
secondary anchor residue is located at p3, which seems to have a slight preference for 
tyrosine (Falk, Rotzschke et al. 1991).   
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Figure I.2. Structural Features of the MHC Class I Complex. The MHC class I 
complex is a trimer consisting of heavy chain, β2M and peptide (PDBID: 3TID) and is 
represented as a ribbon diagram.  A. Side view looking down the helical groove of the 
MHC class I molecule.  The MHC class I heavy chain comprises of three distinct 
extracellular domains: α1, α2, and α3.  β2M noncovalently associates with the heavy 
chain and contributes a fourth extracellular domain.  The heavy chain is colored grey, 
β2M is colored cyan and peptide is colored magenta.  B. Top view of the MHC class I 
molecule.  The peptide binding groove is formed by the α1 and α2 domains which form 
helices.   
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I.C.  Recombinant MHC Class I Proteins 
 The use of recombinant MHC proteins in immunology has become widespread 
since the invention of MHC tetramers (Altman, Moss et al. 1996).  In this subsection, I 
will briefly review a commonly utilized method for purifying MHC class I complexes, 
some of the ways to generate MHC class I oligomers and the reported applications for 
recombinant MHC class I proteins.   
 
1.C.1. Production of Recombinant MHC Class I Proteins 
 The independent expression of the MHC Class I heavy chain and beta-2-
microglobulin subunits was first performed in E. coli (Parker, Carreno et al. 1992), which 
expresses these subunits as insoluble inclusion bodies (for procedure, see Chapter V.A.9).  
After expression, a procedure which includes washing (in the presence of detergents) and 
centrifugation (for procedure, see Chapter V.A.11) allows for purification of the insoluble 
inclusion body subunits (Garboczi, Hung et al. 1992).  The solubilized MHC class I 
heavy chain and beta-2-microglobulin subunits are subsequently refolded in vitro in the 
presence of excess 8-10mer peptide (Parker, Carreno et al. 1992).  The dilution of the 
urea solubilized subunits into denaturant-free buffer in the presence of peptide enables 
folding of the MHC class I complex (for procedure, see Chapter V.A.18).  A feature 
specific to MHC class I complexes is that the trimolecular complex consisting of heavy 
chain, beta-2-microglobulin and peptide does not fold in the absence of peptide or 
irrelevant peptide which does not bind MHC (Garboczi, Hung et al. 1992; Parker, 
Carreno et al. 1992).   
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 After refolding, there are two methods for isolating the purified complexes.  
Purification of the MHC class I complexes can be achieved by either size exclusion 
chromatography or anion exchange chromatography.  For size exclusion 
chromatography, the refolding mixture needs to be concentrated down into a volume that 
can be injected onto a size exclusion column, typically less than 1 mL.  Due to the large 
amount of refolded protein that is yielded by this particular refolding procedure (typically 
10-20 mg/L, personal experience), concentrating sometimes results in protein 
aggregation.  The method which I routinely use is buffer exchange by diafiltration (for 
protocol and setup, see Chapter V.A.4), which exchanges out the arginine refolding 
buffer for Tris pH 8, which is the buffer used in anion exchange chromatography along 
with it’s 1M NaCl salt counterpart.  The selected pH at 8.0 is a pH value that is greater 
than the calculated isoelectric point for MHC class I complex (~6.0 for Kb-GP34-41), 
which will result in proteins with a net negative charge.  The negatively charged MHC 
class I complexes can then be bound onto anion exchange chromatography columns 
where purified MHC class I complexes can be eluted off of the column at a salt gradient 
at approximately 30% (for anion exchange trace, see Figure V.D.1).   The arginine needs 
to be filtered out prior to anion exchange chromatography because it acts as a salt which 
causes the MHC class I complexes to self-elute.   
 
1.C.2. Applications for Recombinant MHC Class I Proteins 
A commonly utilized protocol for quantifying antigen-specific T cells is MHC 
oligomer staining.  Commonly known as MHC tetramer staining, this method depends on 
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the binding of TCR to recombinant peptide-MHC complexes, assembled into tetramers to 
account for low affinity of individual TCR molecules for peptide-MHC complexes 
(Altman, Moss et al. 1996).  Recombinant peptide-MHC complexes are frequently 
tetramerized by interaction with a fluorescently-labeled streptavidin via a biotin tag, 
which is incorporated into the C-terminus of the MHC class I HC construct by either 
chemical (i.e. thiols) or enzymatic (i.e. biotin ligase) addition (Duffy, Tsao et al. 1998).  
The fluorescently-labeled MHC oligomers can subsequently “stain” antigen-specific T 
cells by binding to their TCRs, which can be detected on the surface of T cells by flow 
cytometry.  A similar method that has been used for detection of antigen-specific T cells 
is the MHC dimer-Ig (Fahmy, Bieler et al. 2002).  In these molecules, the MHC class I 
complex is expressed as a genetic fusion at the N-terminus of an immunoglobulin heavy 
chain (Fahmy, Bieler et al. 2001).  MHC dimer-Ig was initially designed to study T cell 
activation requirements, but has been adopted for phenotyping antigen-specific T cell 
subsets (Fahmy, Bieler et al. 2002).  In addition to tracking antigen-specific T cells, MHC 
oligomers have been used to examine the role of multivalent TCR engagement in T cell 
activation (Boniface, Rabinowitz et al. 1998; Cochran, Cameron et al. 2001; Stone and 
Stern 2006)  Most recently, peptide-MHC heterodimers have recently been utilized to 
study the ligand requirements of positive and negative selection during T cell 
development (Juang, Ebert et al. 2010).  Chapter II of this thesis describes bi-specific 
peptide-MHC heterodimers as a novel staining reagent for visualizing cross-reactive T 
cells.   
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I.D. T cell Antigen Recognition 
I.D.1. The T cell Antigen Receptor 
 There are several different types of TCRs (Rudolph, Stanfield et al. 2006), but 
those found on the CD4+ and CD8+ T cells are disulfide-linked heterodimers consisting 
of one alpha (α) chain and one beta (β) chain, which forms the antigen binding site.  Each 
TCRα and TCRβ chain consists of variable and constant Ig-like domains, followed by a 
transmembrane domain and a short cytoplasmic tail.  TCRαβ heterodimers are found on 
all CD4+ and CD8+ T cells, which are the major T cell subsets.  The role for TCR is to 
bind to peptide-MHC complexes, hence the term “MHC restriction”.  The variable 
regions of the TCRαβ heterodimers which bind to peptide-MHC ligands are known as the 
complementarity-determining region (CDR) loops, and are numbered 1, 2 and 3 
(Janeway 2001).   
 Structural analysis of TCR and peptide-MHC co-crystal structures revealed that 
TCRαβ interacts with peptide-MHC using six different loops (Garboczi, Ghosh et al. 
1996; Garcia, Degano et al. 1996):  CDR1α, CDR1β, CDR2α, CDR2β, CDR3α and 
CDR3β.  Interactions with the variable peptide occur primarily with the CDR3α and 
CDR3β loops, while interactions with the MHC occur with the germline encoded CDR1 
and CDR2 loops (See Figure I.3) (Garboczi, Ghosh et al. 1996; Garcia, Degano et al. 
1996).  As a general rule of thumb, TCRs are positioned diagonally across the peptide-
MHC, such that the CDR1 and CDR2 loops of the TCRα chain are positioned over the 
MHC α1 helix and the CDR1 and CDR2 loops of the TCRβ chain are positioned over the 
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MHC α2 helix (Garboczi, Ghosh et al. 1996) (See Figure I.3).  A productive interaction 
between TCR and peptide-MHC results in downstream signaling cascades which have 
different biological consequences, ranging from positive selection to T cell activation, 
depending on the developmental state of the T cell (Janeway 2001).   
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Figure I.3. Structure of TCR in Complex with MHC Class I (Garcia, Degano et al. 
1998).  A. Ribbon diagram of the 2C TCR VαVβ domains complexed with the α1α2 
domains of Kb-dEV8.  A portion of the 2C TCR and H-2Kb structures are not displayed 
(PDBID: 2CKB).  2C TCR Vα is colored pink, 2C TCR Vβ is colored cyan, H-2Kb is 
brown and dEV8 peptide is yellow.  B. The ‘‘footprint’’ view showing the isolated CDR 
loops of 2C TCR as tubes over the surface rendering of Kb-dEV8.  The 2C TCR contact 
surface on the Kb-dEV8 is drawn in blue for the Vβ footprint and red for the Vα footprint. 
The dEV8 peptide is yellow.  This figure was reproduced with permission.   
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The complete T cell antigen receptor showed a complex cell surface structure and 
includes the TCRαβ heterodimer as well as the nonpolymorphic CD3 complex, which is 
formed by three distinct heterodimers, (CD3δε, CD3γε and CD3ζζ) (Borst, Coligan et al. 
1984) (see Figure I.4).  The stoichiometry and assembly of the TCRαβ and CD3 complex 
was shown by elegant immunoprecipitation experiments (Call, Pyrdol et al. 2002).  
Briefly, it was shown that three basic transmembrane residues in the TCRαβ heterodimer 
interact with six acidic transmembrane residues in the three distinct CD3 heterodimers. 
The TCRα transmembrane subunit has one lysine and one arginine residue, which 
interacts with two aspartic acid residues found on CD3δε and CD3ζζ, respectively.  
Meanwhile, the TCRβ transmembrane subunit has one lysine residue which interacts with 
one aspartic acid and one glutamic acid residue in CD3γε.  The order of receptor 
assembly is as follows:  the CD3δε heterodimer associates with the TCRα chain, the 
CD3γε heterodimer associates with the TCRβ chain, the CD3ζζ heterodimer associates 
with the TCRα chain (see Figure I.4) (Call, Pyrdol et al. 2002).   
 The complete T cell antigen receptor contains 10 immunoreceptor tyrosine 
activation motifs (iTAMs).  The CD3δ, CD3γ and CD3ε chains have a single iTAM 
while the CD3ζ chain has three iTAMs.  The role of the iTAMs in the CD3 complex was 
initially unclear because the CD3 chains alone have no effector function.  However, it 
was later demonstrated that phosphorylation of iTAMs on the CD3 chains leads to 
recruitment of downstream adaptors which can propagate signals leading to T cell 
activation (Smith-Garvin, Koretzky et al. 2009).    
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Figure I.4.  Arrangement and Assembly of the T cell Antigen Receptor (Call, Pyrdol 
et al. 2002).  The T cell antigen receptor consists of a single TCRαβ heterodimer and 
three distinct CD3 heterodimers.  Each of the three basic residues in the TCRαβ 
transmembrane regions serves as a critical contact for one of the three CD3 heterodimers 
that associate with TCRαβ.  The entire T cell antigen receptor contains 10 iTAM 
residues, which appear at the “tail” of the transmembrane region.  The extracellular 
domains of TCRαβ and CD3 are colored light/dark blue or light/dark orange orange, 
respectively.  The intracellular iTAM residues are colored light blue.  This figure was 
reproduced with permission.   
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  I.D.2. The T cell Co-receptor CD8  
 T cells also express a co-receptor which recognizes antigen in a nonspecific 
manner by directly engaging MHC, without regard for the peptide presented.  For CD8+ 
T cells, this co-receptor is CD8.  Unlike TCR, CD8 co-receptors can be expressed as 
either CD8αβ heterodimers or CD8αα homodimers.  CD8αβ heterodimers are expressed 
on the surface of TCRαβ expressing T cells, while CD8αα homodimers are found on the 
surface of γδ T cells and some NK cells (Poussier and Julius 1994).  CD8 interacts with 
MHC class I in the highly conserved region of the α3 domain, distal to the antigen 
binding site that engages TCR (Figure I.5).  The extracellular segments of both the CD8α 
and CD8β chains consist of a single immunoglobulin-like domain along with a stalk 
region that is highly glycosylated (Classon, Brown et al. 1992; Moody, Chui et al. 2001).   
The cytoplasmic tail of the CD8α chain associates with the protein tyrosine kinase p56lck 
and the binding of CD8αβ to the MHC class I was classically believed to initiate early 
signal transduction cascades leading to T cell activation (Kern, Teng et al. 1998).  
However, a recent report has shown that the kinase activity of p56lck initiates recruitment 
of the CD8 co-receptor to the same peptide-MHC which is bound by TCR (Jiang, Huang 
et al. 2011).  This report contradicts a previous theory, whereby CD8 engagement of 
peptide-MHC complexes precedes TCR engagement, which might increase the likelihood 
of an interaction between TCR and peptide-MHC.   
 In most cases, the importance of CD8 in T cell recognition and subsequent 
activation is supported by numerous reports (Potter, Rajan et al. 1989; Daniels and 
Jameson 2000; Dutoit, Guillaume et al. 2003; Wooldridge, van den Berg et al. 2005), 
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which have collectively shown that mutation of the CD8 binding site on the conserved 
MHC α3 domain abrogates TCR engagement of peptide-MHC ligands.  Similar results 
have been shown for the CD4 co-receptor, albeit to a lesser extent (Doyle and Strominger 
1987; Clayton, Sieh et al. 1989; Cammarota, Scheirle et al. 1992).   
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Figure I.5. Structure of MHC Class I in Complex with CD8αα co-receptor (Kern, 
Teng et al. 1998).  Ribbon diagram of MHC class I molecule in complex with CD8αα 
(PDBID: 1BQH).  CD8αα interacts with the MHC class I by making contacts with all six 
of its CDR-like loops to the conserved α3 domain of the MHC class I heavy chain.  The 
MHC class I heavy chain is colored grey, the β2M is colored cyan, the CD8α1 chain is 
colored red and the CD8α2 chain is colored green.   
21 
 
 
 
I.D.3. Post Translation Modifications Alter T cell Recognition 
 Essentially all cell surface receptors involved in T cell recognition are 
glycoproteins.   While modifications such as phosphorylation have been well 
characterized to play a role in T cell signaling, modifications such as glycosylation have 
been largely ignored.  The main reason why glycobiology is less studied is partially due 
to glycan complexity.  For example, each glycosylation site may have different patterns 
or numbers of the same glycan, which makes them almost impossible to monitor (Lowe 
2001; Daniels, Hogquist et al. 2002).  Regardless, the observation that carbohydrate 
binding proteins (i.e. phytohemagglutinin) can be used to artificially stimulate T cells by 
cross-linking cell surface glycoproteins indicates that glycan engagement can alter the 
immune response (Dustin and Chan 2000).   
 For T cell recognition, it has been shown that glycans might interfere with TCR 
and CD8 engagement of peptide-MHC complexes (Daniels, Hogquist et al. 2002).  The 
mechanism for this inhibition is unclear, but because glycans can be as large as 
immunoglobulin domains, approximately 30Å (Rudd, Wormald et al. 1999), the 
inhibition has been attributed to steric hindrance created by the glycans on the plasma 
membrane.  An alternate notion is that cell surface glycoproteins may interact with a 
group of glycan-binding proteins known as galectins, which has been suggested to inhibit 
recruitment of TCR or CD8 molecules to the immunological synapse (Demetriou, 
Granovsky et al. 2001).   
 To add to glycan complexity, individual glycosylation sites can also acquire the 
addition of sialic acids.  The precise role of sialic acids in T cell recognition has been 
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difficult to address, but results have shown that the addition of sialic acids to the CD8 
coreceptor inhibits CD8 co-engagement of the peptide-MHC and TCR complex (Daniels, 
Hogquist et al. 2002).  Furthermore, it was found that increased sialylation of cell surface 
glycoproteins on more developed thymocytes corresponded with decreased engagement 
of peptide-MHC ligands (Daniels, Devine et al. 2001).  This decrease in peptide-MHC 
engagement for the more mature thymocytes was attributed to decreased CD8 co-
engagement and was reversible by removal of sialic acids from the cell surface 
glycoproteins (Daniels, Devine et al. 2001; Moody, Chui et al. 2001).  The reduced CD8 
co-engagement is likely due to sialic acid binding proteins, which bind to CD8 and 
prevents co-engagement, but other possibilities such as steric inhibition may also play a 
role.   
 
I.E. T cell Differentiation 
I.E.1. T cell Development 
 Development of T cells is an education process that transforms lymphoid 
progenitor cells into mature lymphocytes with effector function.  Thymocytes, or 
immature T cells, originate from a common lymphoid progenitor that migrates into the 
thymus as early as day 11.5 in embryonic mice (Takahama 2006).  These progenitors first 
form double negative (DN) thymocytes, which are cells that express neither the CD4 nor 
the CD8 co-receptor.  DN thymocytes give rise to CD4+CD8+ double positive (DP) 
thymocytes, which migrate to the thymic cortex, where positive selection occurs.  
Positive selection enriches the thymocyte repertoire, which can react towards foreign 
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antigens.  This process depends on interactions between the peptide-MHC molecules 
presented by cortical thymic epithelial cells and the TCRs expressed on the thymocytes.  
Only thymocytes that productively interact with cortical thymic epithelial cells are 
granted survival signals, while those that do not are targeted for apoptosis (Shortman, 
Egerton et al. 1990; Takahama 2006).   
 Following positive selection, recombination activating genes are turned off to 
prevent further TCR recombination (Brandle, Muller et al. 1992).  DP thymocytes can 
differentiate into either CD8+ or CD4+ singly-positive thymocytes and undergo negative 
selection.  Negative selection occurs in the boundary between the thymic cortex and 
thymic medulla with the targeted goal of eliminating any thymocytes expressing self-
reactive TCRs (Kappler, Roehm et al. 1987).  During negative selection, any thymocytes 
that react towards self-antigens presented by medullary thymic epithelial cells are 
eliminated.  It has been estimated that less than 5% of all developing thymocytes survive 
both positive and negative selection (Takahama 2006).  Although selection is an elegant 
process which eliminates self-reactive T cells while enriching for potentially useful T 
cells, selection alone is often insufficient to prevent autoreactivity.  For this reason, 
various peripheral mechanisms have been suggested to account for either self-reactive 
TCRs which escape negative selection (Mueller 2010) or antigen diversity due to limited 
TCR pairings (Mason 1998).   
 
I.E.2. T cell Activation  
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 T cells are activated by a process which involves two distinct signals.  The 
commonly known “signal one” is provided by engagement of the TCR to its cognate 
peptide-MHC ligand, presented on the surface of APCs.  T cells also require a secondary 
signal, known as “signal two” which is provided by co-stimulatory molecules, also 
expressed on the surface of APCs.  Expression of costimulatory molecules occurs after 
APC activation, which for dendritic cells (DCs) is achieved by Toll-like receptor 
signaling.  Most pathogens contain a built-in adjuvant, such as lipopolysaccharide for 
gram negative bacteria, which is recognized by germline encoded Toll-like receptors 
expressed on DCs.  Ligation of Toll-like receptors activates DCs and stimulates the 
surface expression of costimulatory molecules (Banchereau, Briere et al. 2000).  DCs can 
also be induced to express costimulatory molecules by type I (α, β) interferon (IFN) 
(Siegal, Kadowaki et al. 1999; Biron 2001) or inflammatory molecules such as tumor 
necrosis factor alpha (TNFα) (Gallucci and Matzinger 2001).  T cells are fully activated 
only in the presence of both signals.  In the absence of costimulation, T cells enter an 
unresponsive state known as T cell anergy (Schwartz 2003).  Thus, costimulation 
provides an additional level of control over T cell activation as self-antigens do not 
activate the germline encoded Toll-like receptors to express costimulatory molecules 
(Janeway 2001; Sprent and Surh 2002).   
 Naïve T cells do not possess the migratory properties to recognize antigens at the 
site of infection, thus, activation of naïve T cells only occurs in the secondary lymphoid 
organs.  In order for naïve T cells to meet antigen, antigens must be transported from the 
site of infection to the spleen or lymph nodes, where antigen presentation occurs.  The 
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two main routes of antigen transportation to the secondary lymphoid organs are the 
lymphatic system to reach the lymph nodes and the bloodstream to reach the spleen 
(Banchereau, Briere et al. 2000).  For transportation of antigens to the lymph nodes, 
antigens are either phagocytosed by immature DCs, which process and transport antigens 
directly to the lymph nodes or transported in their native form through the lymphatics to 
the lymph nodes, where they are loaded onto lymph node-resident DCs (Sixt, Kanazawa 
et al. 2005; Clement, Cannizzo et al. 2010).  A similar pathway exists for antigen 
transport to the spleen.  There, antigens which are transported in the bloodstream to the 
spleen enter in soluble form and are phagocytosed and presented by immature DCs 
directly positioned in the spleen (Banchereau, Briere et al. 2000).   
 TCR ligation of peptide-MHC and costimulatory molecules activates a signal 
transduction cascade that ultimately leads to the activation of naïve T cells.  As 
previously mentioned, the CD8 coreceptor is associated with a Src family kinase known 
as lymphocyte-specific protein tyrosine kinase (p56Lck), which initiates the downstream 
signaling cascades via the signaling chains of the CD3 complex.  Recruitment of zeta 
chain associated protein 70 (ZAP70) occurs, followed by activation of ZAP70 by p56Lck.  
p56Lck and ZAP70 subsequently phosphorylate iTAM residues on many other molecules 
including linker for activated T cells (LAT), which subsequently activates other signaling 
cascade molecules that ultimately leads to T cell activation.  A notable cytokine that’s 
produced during activation is IL-2, which promotes the long term proliferation of 
activated T cells to ensure that pathogen clearance is achieved (Smith-Garvin, Koretzky 
et al. 2009).   
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I.E.3. Formation of T cell Memory 
 Multiple studies have shown that the T cell repertoire of memory CD8+ T cells is 
markedly similar to that found for naïve CD8+ T cells (Busch, Pilip et al. 1998; Sourdive, 
Murali-Krishna et al. 1998; Blattman, Sourdive et al. 2000), which suggests that memory 
T cells are derived from the effector pool.  After pathogen clearance by effector T cells, a 
contraction phase occurs where the majority of the effector T cells die, with a few 
surviving members forming the memory compartment.  The dying effector T cells have 
been found in the liver, which is regarded as the graveyard for dying effector T cells 
(Masopust, Vezys et al. 2001), but dying effector T cells have also be found in the spleen 
where they are phagocytosed (Sprent and Surh 2002).   
 There are two different models for how effector T cells are transformed into long-
living memory cells.  In the “decreasing potential” model, effector T cells which arrive 
late at the secondary lymphoid organs are thought to receive less stimulation and are 
consequently less polarized, which allows these effector T cells to avoid the contraction 
phase (Moskophidis, Lechner et al. 1993; Sprent and Surh 2002).  On the other hand, the 
“progressive differentiation” model states that T cells which receive more stimulation are 
better fit to survive contraction and transform into memory T cells (Lanzavecchia and 
Sallusto 2002).  The latter has been supported by the observation that increased 
stimulation correlates with an increased memory T cell pool during viral infection 
(Quigley, Huang et al. 2007).   
 The cell surface markers that are generally used to phenotype memory T cells are 
different for humans and mice.  The commonly used murine memory T cell markers are 
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low levels of CD62L expression and high levels of CD44 expression.  However, two 
specific populations of memory T cells have been characterized based on their migratory 
properties.  These subpopulations are known as “effector” memory T cells and “central” 
memory T cells (Sallusto, Lenig et al. 1999).  The main difference between these two 
subsets of memory T cells is that effector memory cells can migrate to the site of 
infection and display immediate effector function.  Effector memory cells have direct 
CTL activity, have rapid turnover and tend to express activation markers found on 
effector T cells (Zimmerman, Brduscha-Riem et al. 1996).  On the other hand, central 
memory T cells behave more like naïve T cells, due to their resting-phenotype.  Similar 
to naïve T cells, central memory cells home to the secondary lymphoid organs and have 
little or no effector function prior to antigen stimulation (Sallusto, Geginat et al. 2004).  
Although resembling naïve T cells, central memory cells express high levels of RNA, 
which suggests that these memory cells are in the G1 phase of cell cycle and maintained 
in a low activation state (Veiga-Fernandes, Walter et al. 2000).   
 
I.F. T cell Cross-reactivity 
 Multispecific interactions have been found to occur for a variety of different 
proteins, ranging from enzymes (Hult and Berglund 2007) and DNA-binding proteins 
(Badis, Berger et al. 2009), to receptors involved in immune recognition, such as the TCR 
(Mariuzza 2006).  In the specific case of TCR, multispecific TCR recognition of peptide-
MHC complexes serves to amplify the effective TCR repertoire which can respond 
towards foreign antigens.   
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 I.F.1. Mechanisms of T cell Cross-reactivity 
 In a general sense, it was thought that every antigen might be recognized by a 
unique T cell receptor.  While the theoretical number of different TCR chain pairings is 
~1015 (Marrack and Kappler 1988), the actual number of different TCR clonotypes found 
in a naive mouse is closer to ~106 (Casrouge, Beaudoing et al. 2000), which is much 
lower than the number of possible antigens, which could theoretically approach 209 (20 
amino acids in different 9mer combinations) or 511 for CD8+ T cell epitopes (Mason 
1998).  Despite a disparity between the number of different TCR clonotypes and possible 
antigens, T cells from immunologically naïve hosts are not precluded from mounting 
functional responses towards a wide array of antigens.  It has been suggested that the 
recognition of multiple antigens by a single T cell occurs, which is commonly referred to 
as T cell cross-reactivity (Mason 1998).    
 The simplest mechanism for multispecific interactions to occur between two 
interacting molecules is by utilizing different interaction sites.  While this is possible for 
larger proteins, this is not the mode by which cross-reactive TCR recognition occurs.  
Instead, all TCRs recognize different peptides that are bound in the “peptide-binding 
groove”, that is formed in between the α1 and α2 helices of the MHC Class I molecule.  
Consequently, cross-reactive TCRs utilize overlapping interaction sites.  To date, five 
different concepts of cross-reactive TCR recognition have been defined, which are 
illustrated in figure I.6 (Yin and Mariuzza 2009).   
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 TCR cross-reactivity might rely on structural adjustments in the TCR, in the 
MHC or in the peptide, all of which facilitate the interaction between cross-reactive TCR 
and different peptide-MHC ligands.  Structural modifications to the TCR molecule to 
accommodate different peptide-MHC ligands include: the induced fit mechanism, the 
differential TCR docking mechanism and the structural degeneracy mechanism.  For the 
induced fit mechanism, a TCR may readjust its CDR3 loops to best accommodate cross-
reactive antigens presented by the same MHC molecule (Mazza, Auphan-Anezin et al. 
2007).  Alternatively, a single TCR may globally reposition itself over two different 
peptide-MHC complexes, by shifting the TCRα and TCRβ chains to form the majority of 
the peptide-MHC and TCR interactions that occur with either the MHCα1 helix or the 
MHCα2 helix (Differential TCR docking mechanism) (Colf, Bankovich et al. 2007).  
Alternatively, the absence of hydrogen bonding and salt bridges between TCR and 
peptide may allow for the majority of the contacts to occur between the TCR and the 
MHC, without regard for the peptide (Structural degeneracy mechanism) (Li, Huang et 
al. 2005).   
 Cross-reactive TCR engagement also occurs as a result of structural modifications 
to the peptide-MHC ligand.   For the molecular mimicry mechanism, two different 
peptide-MHC complexes may structurally rearrange themselves to form two structurally 
similar interfaces with a single cross-reactive TCR (Macdonald, Chen et al. 2009).  On 
the other hand, two structurally identical peptide-MHC complexes can undergo 
conformation changes in the peptide and the MHC molecules after TCR binding, which 
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leads to altered TCR engagement (antigen-dependent tuning of peptide-MHC flexibility 
mechanism) (Borbulevych, Piepenbrink et al. 2009).   
 An alternate explanation for cross-reactive T cell responses is the dual expression 
of two different TCRs, which has been found to occur in either the absence of allelic 
exclusion (Padovan, Casorati et al. 1993; Hardardottir, Baron et al. 1995; He, Janeway et 
al. 2002) or through TCR sharing between two different T cell clonotypes (Chaudhri, 
Quah et al. 2009).  The function of the two distinct TCRs is unclear, but the general sense 
is that dual TCR expression occurs when one TCR does not recognize self or foreign 
antigens bound to self-MHC; therefore the expression of a second TCR allows these T 
cells to surpass selection (Hardardottir, Baron et al. 1995; He, Janeway et al. 2002).  
After selection, there has been some controversy as to the role of the non-selected TCR.  
Typically, allelic exclusion occurs to prevent the expression of two different TCRα 
chains (Niederberger, Holmberg et al. 2003).  However, the “non-selected TCR” has been 
observed to mount responses in the periphery, which could lead to cross-reactive T cell 
responses (He, Janeway et al. 2002).   
 Most of the studies addressing the mechanisms of cross-reactive TCR engagement 
have evaluated some form of molecular mimicry, whereby structural homology between 
self and foreign epitopes leads to autoreactivity (Mazza, Auphan-Anezin et al. 2007; 
Macdonald, Chen et al. 2009; Borbulevych, Piepenbrink et al. 2011; Borbulevych, 
Santhanagopolan et al. 2011) (See Table I.1 for summary).  For example, structural 
homology between self peptides and viral epitopes from vesicular stomatitis virus 
(Mazza, Auphan-Anezin et al. 2007) or human T lymphotrophic virus (Borbulevych, 
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Piepenbrink et al. 2011) has been found to underlie cross-reactive TCR engagement.  
Furthermore, all of the reported studies have focused on the structural basis for cross-
reactive TCR engagement, with little attention paid to functionally relevant T cell 
responses.   
 Only one known study has evaluated cross-reactive T cell epitopes between two 
distinct foreign pathogens (Borbulevych, Piepenbrink et al. 2009).  In that study, the 
cross-reactive epitopes studied were from human T lymphotrophic virus (LLFGYPVYV) 
and Saccharomyces cerevisiae (MLWGYLQYV) and share significant sequence 
homology, underlined at 6 of 9 positions.  Therefore, the observed cross-reactive TCR 
recognition of similar epitopes in two distinct pathogens is not unexpected on the basis of 
sequence homology.  The work presented in Chapter III will demonstrate a mechanism 
by which disparate epitopes from unrelated and pathogenic viruses are recognized by 
cross-reactive TCRs.   
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Figure I.6.  Mechanisms for an Individual TCR to Cross-react with Different 
Peptide-MHC Ligands (Yin and Mariuzza 2009). The top row, from left to right: 
Cross-reactivity through an induced fit. A single TCR has a conformationally flexible 
binding site, which can accommodate different peptide-MHC ligands without changes to 
the docking orientation. Cross-reactivity through differential TCR docking. The same 
TCR binds different peptide-MHC ligands using different docking orientations. Cross-
reactivity through structural degeneracy. Suboptimal contacts between peptide and TCR 
allows for the majority of contacts to occur between TCR and MHC.  The bottom row, 
from left to right: Cross-reactivity through molecular mimicry. Different peptides in 
complex with MHC can form very similar interfaces with a cross-reactive TCR if the 
ligands are close structural mimics. Cross-reactivity through antigen-dependent tuning of 
peptide-MHC flexibility. Conformational dynamics in the peptide-MHC ligand allows for 
structural reorganization of the peptide, the MHC or the TCR molecules after TCR 
engagement.  This figure was reproduced with permission. 
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Table I.1. Summary of some Cross-reactive CD8+ T cell Epitopes from Previous 
Publications.   
 
Epitopes1 Source Reference 
LLFGYPVYV 
MLWGYLQYV 
Tax from HTLV 
Tel1P from S. Cereviseae 
(Borbulevych, Piepenbrink et 
al. 2009) 
EEYLQAFTY 
EEYLKAWTF 
ATP binding cassette protein  
Generated from randomized library 
(Macdonald, Chen et al. 
2009) 
LLFGYPVYV 
LGYGFVNYI 
Tax from HTLV 
Neuronal self protein HuD 
(Borbulevych, Piepenbrink et 
al. 2011) 
EAAGIGILTV  
AAGIGILTV 
Overlapping tumor antigens from  
melanoma associated protein 
(Borbulevych, 
Santhanagopolan et al. 2011) 
SQYYYNSL 
RGYVYQGL 
Self-antigen 
VSV8 antigen 
(Mazza, Auphan-Anezin et 
al. 2007) 
1Shared residues between the two epitopes in each study are underlined.  
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I.F.2. Cross-reactive T cell Responses between LCMV and VV 
 Cross-reactive T cells may recognize similar or different antigens from two 
different pathogens or two variants of the same pathogen.  In mice, it is clear that cross-
reactive CD8+ T cells play a major role during subsequent viral infections with 
consequences ranging from protective immunity (Selin, Varga et al. 1998; Walzl, Tafuro 
et al. 2000) to altered immunopathology (Chen, Fraire et al. 2003).  This section will 
briefly review cross-reactive CD8+ T cell responses that occur between the unrelated 
viruses, lymphocytic choriomeningitis virus (LCMV) and vaccinia virus (VV), which is 
the model system under investigation in this thesis.   
 LCMV is an enveloped single-stranded RNA virus, which belongs to the 
arenavirus family.  LCMV is a non-lytic virus that naturally infects rodents.  Viral 
particles are propagated in many different tissue types, including the blood, liver, spleen, 
lymph nodes, lung, kidneys and brain. A common symptom of LCMV infection is 
encephalitis or inflammation of the brain.  The peak of LCMV viral titers occur at four to 
five days post infection, and declines drastically as the result of strong T cell responses, 
which peaks at 8 days post infection (Buchmeier, Welsh et al. 1980).   
 LCMV contains a very small genome, which encodes only 4 proteins.  The 
compact size of the LCMV genome has allowed for extensive characterization of T cell 
epitopes, which in turn, has made LCMV a commonly used virus for studying T cell 
responses.  A notable characteristic of the LCMV-specific immune response is a large 
CD8+ T cell response.  Acute LCMV infection of C57BL/6 mice elicits 28 known CD8+ 
T cell responses.  Despite having 28 known epitopes, three immunodominant epitopes 
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(GP33-41, GP34-41, NP396-404) account for the large majority of the LCMV-specific CD8+ T 
cell response (Kotturi, Peters et al. 2007; Kotturi, Scott et al. 2008).    
 An early indication that LCMV and VV might contain cross-reactive epitopes was 
determined when LCMV-immune mice challenged with VV showed altered 
immunopathology in the form of panniculitis or inflammation of the visceral fat (Selin, 
Varga et al. 1998).  It was later shown that VV challenge of LCMV-immune hosts 
expanded three different epitope-specific responses from LCMV, all presented by H-2Kb:  
LCMV-NP205-212, LCMV-GP34-41 and LCMV-GP118-125.  On average, LCMV-NP205-212 
accounts for 50% of the LCMV-specific response upon VV challenge, with LCMV-GP34-
41 and LCMV-GP118-125 specific responses each accounting for less than 25% (Kim, 
Cornberg et al. 2005).  The particular LCMV epitope that expands after VV challenge 
depends on the responding T cell repertoires from the individual mice tested, which may 
be “private” or specific for any given mouse (Welsh, Che et al. 2010).  Even genetically 
identical mice raised in similar environments have been found to contain different 
responding T cell repertoires (Bousso, Casrouge et al. 1998).    
 The observation that VV challenge of LCMV-immune mice expands LCMV-
specific epitopes indicates the presence of a VV-specific epitope which is cross-reactive 
with LCMV.  Screening the VV genome for a cross-reactive epitope homologous to 
LCMV-NP205-212 revealed two candidate epitopes in VV-E7R130-137 and VV-A11R198-205 
(Cornberg, Sheridan et al. 2007).  In functional assays, VV-E7R130-137-specific T cells 
were found to cross-react with other VV epitopes (Cornberg, Sheridan et al. 2007), but 
were never found to be cross-reactive with any epitopes from LCMV (Welsh, Che et al. 
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2010).  However, the subdominant VV-A11R198-205 epitope was found to be individually 
cross-reactive with LCMV-NP205-212, LCMV-GP34-41 and LCMV-GP118-125 (Cornberg, 
Clute et al. 2010).  Our recent study which utilized the cross-reactive T cell response 
between VV-A11R198-205 and LCMV-GP34-41 indicated that these two ligands are 
recognized by cross-reactive TCRs.  The mechanism for this cross-reactive T cell 
response will be the focus of Chapter III.   
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Chapter II.  
Bi-specific MHC heterodimers for Characterization of Cross-reactive T Cells 
 
II.A. Abstract 
T cell cross-reactivity describes the phenomenon whereby a single T cell can 
recognize two or more different peptide antigens presented in complex with MHC 
proteins.  Cross-reactive T cells previously have been characterized at the population 
level by cytokine secretion and MHC tetramer staining assays, but single-cell analysis is 
difficult or impossible using these methods. In this study, we describe development of a 
novel peptide-MHC heterodimer specific for cross-reactive T cells.  MHC-peptide 
monomers were independently conjugated to hydrazide or aldehyde-containing cross-
linkers using thiol-maleimide coupling at cysteine residues introduced into recombinant 
MHC heavy chain proteins.  Hydrazone formation provided bi-specific MHC 
heterodimers carrying two different peptides.  Using this approach we prepared 
heterodimers of the murine class I MHC protein H-2Kb carrying peptides from 
lymphocytic choriomeningitis virus (LCMV) and vaccinia virus (VV), and used these to 
identify cross-reactive CD8+ T cells recognizing both LCMV and vaccinia virus 
antigens.  A similar strategy could be used to develop reagents to analyze cross-reactive 
T cell responses in humans.  
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II.B. Introduction 
The cellular immune response to foreign antigens depends on T cell receptor 
(TCR) recognition of short peptides bound to cell-surface Major Histocompatibility 
Complex (MHC) proteins. For a CD8+ T cell, antigen specificity is determined by the 
interaction of TCR with 8-10mer peptides presented by class I MHC proteins (Garboczi, 
Hung et al. 1992).  During T cell development, TCR genes are assembled by somatic 
recombination of V, D, J, and C gene fragments, with additional diversity introduced by 
nucleotide addition at the junctions, resulting in a vast repertoire of clonally distributed 
TCR proteins, with hypervariable regions concentrated in the TCR loops that contact 
MHC and bound peptide antigen.  Despite the diversity of TCR sequences, the diversity 
of foreign antigens is equally large or larger, and individual TCR are able to recognize 
multiple peptide sequences. During the negative selection phase of T cell development, 
autoreactive T cells capable of binding self MHC-peptide complexes at high affinity are 
deleted, and it has been suggested that negative selection removes so many TCR 
sequences that a high level of TCR cross-reactivity is required for the immune system to 
be able to recognize a sufficiently large set of foreign peptides (Mason 1998). T cell 
cross-reactivity has been observed in many systems (Udaka, Wiesmuller et al. 1996; 
Boen, Crownover et al. 2000; Dai, Huseby et al. 2008; Cornberg, Clute et al. 2010) and 
the structural basis for the phenomenon is beginning to be clarified (Borbulevych, 
Piepenbrink et al. 2009; Macdonald, Chen et al. 2009). T cell cross-reactivity appears to 
provide a molecular basis for T cell heterologous immunity, in which exposure to one 
pathogen provides protection against another (Cornberg, Sheridan et al. 2007).  For 
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example, prior infection by lymphocytic choriomeningitis virus (LCMV) protects mice 
from a lethal dose of vaccinia virus (VV), with  LCMV-immune mice showing alterations 
in their T cell response to VV infection due to  LCMV-specific T cells cross-reacting 
with VV (Selin, Varga et al. 1998; Chen, Fraire et al. 2001). Similar patterns of T cell 
cross-reactivity have been suggested to underlie protective heterologous immunity 
between influenza A virus,  Epstein Barr virus (EBV) (Clute, Watkin et al. 2005), and 
hepatitis C virus (Wedemeyer, Mizukoshi et al. 2001), and also immunopathology 
following sequential infection with Dengue virus subtypes (Rothman 2009).  T cell cross-
reactivity in these systems has been difficult to study, in part because reagents are not 
available for isolation and characterization of the cross-reactive T cells.  
MHC tetramer staining is a very effective method for isolating and characterizing 
antigen-specific T cell populations (Altman, Moss et al. 1996).  In this technique, biotin-
labeled recombinant MHC molecules loaded with specific antigenic peptides are 
oligomerized using fluorescent streptavidin, to form highly specific reagents for analysis 
of antigen-specific T cells in mixed populations using flow cytometry.  The use of 
oligomeric species is necessary because the MHC-TCR interaction is characterized by 
low affinity and rapid dissociation kinetics (Altman and Davis 2003), which precludes 
use of labeled MHC-monomers as specific staining reagents (Stone and Stern 2006). 
MHC tetramers conventionally are used in T cell staining protocols, mostly because of 
the ease of introducing biotin labels into recombinant proteins and the availability of a 
wide variety of fluorescent streptavidin conjugates (Altman, Moss et al. 1996).  In 
addition to MHC tetramers, other oligomeric forms of MHC proteins including dimers, 
40 
 
 
 
trimers, and higher order oligomers are available and also have been used as effective 
staining reagents (Cochran, Cameron et al. 2001; Fahmy, Bieler et al. 2002). Antigen-
specific analysis and isolation of T cells using MHC tetramers and similar reagents is a 
mainstay of current immunological practice, and for example has been used to 
characterize the fine specificity of the T cell response to VV and LCMV (Chen, Fraire et 
al. 2001; Kim, Cornberg et al. 2005; Cornberg, Clute et al. 2010).   However, MHC-
based staining reagents currently are available only as homo-oligomers with identical 
MHC-peptide components, and as such have not been used extensively to characterize T 
cell cross-reactivity.  In principle two MHC tetramers could be used in co-staining 
experiments to evaluate the ability of a particular T cell to cross-react with different 
MHC-peptide complexes, but in practice competition between the two tetramers severely 
limits this approach (Cornberg, Clute et al. 2010) .  As an alternate approach to the 
specific detection and analysis of cross-reactive T cells, we describe here the 
development of novel bi-specific MHC-peptide dimers, and their use in characterization 
of cross-reactive T cells by flow cytometry.  We employed thiol-maleimide and 
hydrazine-carbonyl chemistries (Kitagawa and Aikawa 1976; King, Zhao et al. 1986) to 
functionalize and then cross-link specific peptide complexes of the murine class I MHC 
molecule H-2Kb, and used fluorescent versions of these MHC heterodimers to 
specifically stain CD8+ T cells cross-reactive towards LCMV and VV.  A previous 
strategy for production of class II MHC heterodimers has been reported (Krogsgaard, Li 
et al. 2005), but that strategy relies on sequential differential affinity purification for 
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isolation of heterodimers after non-specific cross-linking, and was not used for T cell 
staining or characterization of T cells in mixed populations.  
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II.B. Materials and Methods 
II.B.1. Production of Class I H-2Kb Complexes 
Extracellular domains of the murine MHC class I H-2Kb heavy chain carrying a 
C121R mutation and a non-native C-terminal cysteine introduced at position 282 (Stone 
and Stern 2006), and full length human light chain β2 – microglobulin, were expressed 
separately as inclusion bodies in Escherichia coli and were folded in vitro by dilution in 
the presence of excess peptide, as previously described for human class I MHCs 
(Garboczi, Hung et al. 1992).  Synthetic peptides purified by reverse phase-HPLC were 
purchased from 21st Century Biochemicals.  Folded H-2Kb monomers were purified by 
anion exchange chromatography on Poros HQ columns (Roche) using a gradient of NaCl 
from 0-0.5M in 20 mM Tris buffer (pH 8.0).  The concentration of each H-2Kb monomer 
was calculated by absorbance spectroscopy after anion exchange chromatography using 
ε280 = 74955 cm-1 M-1 for H-2Kb heavy chain, ε280 = 20003 cm-1 M-1 for β2 – microglobulin 
light chain and varied ε280  for peptides depending on sequence.   Purified H-2Kb 
monomers were adjusted to a concentration of 10-20 mg/mL using regenerated cellulose 
filters (Amicon) and stored in 5 mM DTT to prevent disulfide-linked species.   
 
II.B.2. Cross-linking of Soluble MHC Class I H-2Kb Complexes 
Reduced H-2Kb monomers were purified by size exclusion chromatography using 
NAP-5 columns (GE healthcare) to remove DTT prior to thiol modification.  H-2Kb 
monomers were reacted with heterobifunctional cross-linkers MTFB (maleimido trioxa 
formyl benzaldehyde) or MHPH (3-N-maleimido-6-hydraziniumpyridine hydrochloride) 
43 
 
 
 
in a 6-fold molar excess for 3 hours in 100 mM NaH2PO4, 150 mM NaCl, pH 6.0 buffer 
(Solulink).  Cross-linker-modified H-2Kb monomers were purified away from free cross-
linker by size exclusion chromatography using a Superdex 200 column (GE healthcare).  
MHPH-modified H-2Kb monomers and MTFB-modified H-2Kb monomers were mixed 
together in a 1:1 molar ratio.  The concentration of the reaction mixture (containing 
MHPH modified H-2Kb monomer and MTFB modified H-2Kb monomer) was adjusted to 
1-2 mg/mL using a regenerated cellulose filter (Amicon) and incubated for 20 hours at 
room temperature in the presence of 5 mM aniline (Acros Organics), which was found to 
catalyze hydrazone formation (Dirksen, Dirksen et al. 2006).  Chemically cross-linked H-
2Kb dimers were purified away from H-2Kb monomers by size exclusion chromatography 
using a Superdex 200 column (GE healthcare).  Purified, unlabeled H-2Kb dimers were 
stored at 4°C at a concentration of ~1 µM for upwards of a month.   
 
II.B.3. Alexa 647 Labeling of H-2Kb Monomers, Cross-linked MHC Dimers, and 
Tetramers 
H-2Kb monomers were purified by size exclusion chromatography using NAP-5 
columns (GE healthcare) to remove DTT prior to thiol modification.  Reduced H-2Kb 
monomers were reacted with a 5-fold molar excess of Alexa 647 maleimide (Invitrogen) 
for 2 hours at room temperature.  Alexa 647 labeled H-2Kb monomers were purified by 
size exclusion chromatography using a Superdex 200 column (GE healthcare).   H-2Kb 
homodimers and heterodimers, prepared as described above, were adjusted to a 
concentration of greater than 10 µM and labeled with a 20-fold molar excess of Alexa 
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647 succinimidyl ester (Invitrogen).  The labeling reaction was quenched using a 50-fold 
molar excess of ethanolamine (Sigma), and H-2Kb dimers were re-purified by size 
exclusion chromatography using a Superdex 200 column (GE healthcare). Reaction yield 
and labeling efficiency were determined by absorbance spectroscopy after gel filtration 
purification, using ε280 = 265000 cm-1 M-1 for Alexa 647 succinimidyl ester and the above 
mentioned ε280 for H-2Kb heavy chain, β2 – microglobulin light chain and peptides.  All of 
the H-2Kb dimers were labeled with approximately two Alexa 647 per H-2Kb dimer with 
the exception of the A11R-A11R-H-2Kb homodimer which was labeled with 
approximately four Alexa 647 per dimer. For preparation of Alexa 647-labelled 
streptavidin-linked H-2Kb tetramers, H-2Kb monomers first were purified by size 
exclusion chromatography using NAP-5 columns (GE healthcare) to remove DTT prior 
to thiol modification, and then were biotinylated by reacting with a 5-fold molar excess 
of biotin maleimide (Pierce) for 2 hours at room temperature and subsequently re-purified 
by size exclusion chromatography using a Superdex 200 column (GE healthcare).  
Biotinylation yield was determined by adding a 2-fold molar excess of streptavidin to the 
biotinylated H-2Kb monomers with analysis by 12% SDS-PAGE.  The biotinylated H-
2Kb monomers were subsequently oligomerized by stepwise addition of Alexa 647 
streptavidin (Invitrogen) to the biotinylated H-2Kb to a final molar concentration of 1:6.   
 
II.B.4. Mass Spectroscopy 
Alexa 647-labeled H-2Kb tetramers/dimers/monomers were checked for the 
presence of intact peptide by Matrix-Assisted Laser Desorption/Ionization (MALDI).  
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Alexa 647-labeled H-2Kb complexes were purified by size exclusion chromatography 
using a Superdex 200 column (GE healthcare) and purified fractions were mixed with 
UV absorbing matrix (alpha-cyano-4-hydroxy-cinnaminic acid) prior to laser desorption, 
ionization and detection of ionized species.  The sample was analyzed on a Waters 
MALDI LR spectrometer.   
 
II.B.5. Isolation of Antigen-Specific CTL 
LCMV (Armstrong strain), an RNA virus in the Old World arenavirus family, 
was propagated in BHK-21 baby hamster kidney cells as previously described (Selin, 
Nahill et al. 1994).  BL/6 mice were infected intraperitoneally (i.p.) with a non-lethal 
dose of 5 x 104 PFU of LCMV as previously described (Selin, Nahill et al. 1994).  Mice 
were considered immune at greater than 6 weeks after infection (Cornberg, Sheridan et 
al. 2007). Splenocytes from LCMV-immune mice were co-cultured with mouse RMA 
cells that were pulsed with 1 µM GP34 peptide, washed and then γ-irradiated (3000 rads) 
as previously described (Cornberg, Sheridan et al. 2007). RMA is a Kb-positive, Rauscher 
virus-induced, T-lymphoma cell line of BL/6 origin. Briefly, the co-culture of 
splenocytes and GP34-pulsed RMA cells were grown in RPMI supplemented with 100 
U/ml penicillin G, 100 μg/ml streptomycin sulfate, 2 mM L-glutamine, 10 mM HEPES, 1 
mM sodium pyruvate, 0.1 mM MEM nonessential amino acids, 0.05 mM β-
mercaptoethanol, and 10% FBS for 5 days at 37°C at 5% CO2. Following this initial 
culture period, cells were harvested and stimulated with GP34 peptide-pulsed RMA cells 
in the presence of 10% BD T-Stim (BD Biosciences), an IL-2 culture supplement. 
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LCMV-GP34 peptide-pulsed RMA stimulation was repeated every 4 to 5 days. After 20 
to 25 days of stimulation (four or five stimulations), T-cell lines were characterized by 
intracellular cytokine staining or MHC staining with the panel of MHC class I H-2Kb 
monomers/dimers/tetramers. 
 
II.B.6. Cell Surface and MHC Staining by Flow Cytometry 
Cell suspensions were incubated in staining buffer (phosphate-buffered saline 
containing 1% FBS and 0.2% sodium azide) containing anti-mouse CD16/CD32 (Fc-
block, clone 2.4G2). Cells were washed once with staining buffer and then stained with 
H-2Kb monomers/dimers/tetramers for 90 min.  Thereafter, cells were washed twice with 
staining buffer and fixed in Cytofix (BD Pharmingen).   Samples were analyzed using a 
Becton Dickinson LSRII flow cytometer (BD Biosciences) and FlowJo software (Tree 
Star).   
 
II.B.7. Intracellular Cytokine Staining (ICS) 
A suspension of 106 cells was stimulated with 1 μM synthetic peptide or a 
medium only control  Stimulations were performed for 5 h at 37°C in a total volume of 
200 μl RPMI medium supplemented with 10% FBS, 10 U/ml of human recombinant 
interleukin-2 (IL-2), and 0.2 μM of brefeldin A (GolgiPlug; BD Pharmingen). After 
incubation, cell-surface antibody staining with anti-CD8α (clone 53-6.7), and anti-CD44 
(clone IM7) was performed.  Thereafter, cells were washed twice with staining buffer, 
and then fixed and permeabilized (Cytofix/Cytoperm; BD Pharmingen). Intracellular-
47 
 
 
 
cytokine-producing cells were detected with PE-labeled anti-mouse interferon-gamma 
(IFN-γ, clone XMG1.2) and APC-labeled anti-mouse tumor necrosis factor alpha (TNF-
α, clone MP6-XT22) monoclonal antibodies. Antibodies were purchased from BD 
Pharmingen. The samples were analyzed as described above for cell surface staining.   
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II.C. Results 
 
II.C.1. Isolation and Characterization of a Cross-reactive CD8+ T Cell Line 
To evaluate the utility of bispecific MHC heterodimers in analysis of T cell cross-
reactivity, we made use of a previously described system of heterologous immunity, in 
which infection of mice with the old-world arenavirus LCMV confers partial T cell 
immunity to infection with the poxvirus VV (Kim, Cornberg et al. 2005).  Some T cells 
responding to the LCMV peptide GP34 (AVYNFATM) can cross-react with VV peptide 
A11R (AIVNYANL) (Cornberg, Clute et al. 2010). The GP34 and A11R peptides have 
side chains that are identical at three of the eight positions (underlined in sequences 
above), and are conservatively substituted at three other positions.  A crystal structure is 
available for the H-2Kb-GP34-41 complex (Achour, Michaelsson et al. 2002), and shows 
that the bound GP34 peptide places peptide side chains at the P2(V), P5(F), and P8(M) 
positions into pockets in the Kb binding site, with the intervening peptide side chains 
available for TCR interaction (Achour, Michaelsson et al. 2002). T cells recognizing this 
peptide form a substantial component of the overall Kb-restricted response to LCMV 
(Puglielli, Zajac et al. 2001).  The A11R peptide conforms to the Kb-binding 
motif(Achour, Michaelsson et al. 2002), and would be expected to bind similarly.  No 
structural information is available for the Kb-A11R complex, but the peptide is known to 
bind to Kb (Cornberg, Sheridan et al. 2007), forming a subdominant epitope that persists 
in the Kb-restricted response to VV (Cornberg, Clute et al. 2010).  These peptides, 
together with two unrelated Kb-binding LCMV-derived peptides NP205 and GP118, and 
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control  tight-binding designed peptide SIY (Udaka, Wiesmuller et al. 1996) (Table II.1), 
were used in the experiments reported below.  
T cell cross-reactivity in this system was addressed first by intracellular cytokine 
staining (ICS) (Figure II.1A). BL/6 mice were infected with LCMV and allowed to 
recover for 6 weeks.  Splenocytes from the LCMV-immune mice were stimulated in vitro 
with Kb-expressing RMA cells pre-pulsed with LCMV-GP34 peptide, in order to expand 
the population of T cells that respond to this peptide, and were rested for 3-4 days prior to 
experimentation.  After expansion, intracellular cytokine staining experiments (Figure 
II.1A) showed that the majority (56.3%) of the CD8+, CD44+ T cells secreted both 
TNFα (X axis) and IFNγ (Y axis) in response to the GP34 peptide.  The same cells were 
tested for their response to other peptides.  In response to VV-A11R peptide, 31.5% of T 
cells secreted both IFNγ and TNFα.  Thus, at least a portion of the LCMV-GP34 specific 
T cells must be cross-reactive for VV-A11R. Similarly, if only the cells secreting TNFα 
are considered, 34.6% were positive in response to VV-A11R.  Because nearly all 
(96.3%) were positive in response to LCMV-GP34, a majority of the 34.6% positive to 
VV-A11R must also cross-react with LCMV-GP34.  The T cell population showed no 
reactivity against two other peptide-epitopes from LCMV, GP118 and NP205 (Figure 
II.1A).  
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Table II.1.  Relevant Epitopes from VV and LCMV used for the Bi-specific MHC 
Heterodimer work presented in Chapter II 
 
Source Protein Abbreviation Sequence 
VV Nonstructural protein A11R198-206 A11R AIVNYANL 
LCMV Glycoprotein34-41 GP34 AVYNFATMa 
LCMV Nucleoprotein205-212 NP205 YTVKYPNL 
LCMV Glycoprotein118-125 GP118 ISHNFSNL 
Control (designed sequence) SIY SIYRYYGL 
a This peptide carries a C-terminal Met->Cys mutation relative to the native LCMV 
sequence.  The substitution has been used in previous studies (Achour, Michaelsson et al. 
2002; Khanolkar, Fuller et al. 2004) and does not have a significant impact on interaction 
with MHC or T cell receptors. 
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Figure II.1.  CD8+ T Cells Specific for VV-A11R and LCMV-GP34.   A. CD8+ T cell 
response against VV-A11R and LCMV-GP34 was measured by intracellular IFNγ (y 
axis) and TNFα (x axis) staining in response to 1 µM of the indicated peptides.  T cells 
from an LCMV-immune mouse were isolated and expanded in vitro using LCMV-GP34 
peptide, and then were analyzed for cytokine secretion in response to Kb-expressing cells 
pulsed with VV-A11R or LCMV-GP34 peptides, using an intracellular cytokine staining 
assay, with the results presented as dot plots.  B. Visualization of CD8+ T cell response 
against VV-A11R and LCMV-GP34 by peptide-Kb tetramer staining using 300 nM 
tetramer.  The T cell line from panel A was used.  T cells were stained with R-
phycoerythrin (PE) or allophycocyanin (APC) labeled streptavidin-based Kb tetramers 
folded with VV-A11R, LCMV-GP34, LCMV-GP118, or control SIY peptides.  The 
indicated tetramer stain (blue traces) was overlaid with control-SIY tetramer stain (red 
traces), with results presented as histograms.   
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MHC tetramer staining similarly demonstrates that a portion of the T cell 
population can engage both VV-A11R and LCMV-GP34 peptide-epitopes (Figure II.1B).  
T cells were stained with fluorescently labeled streptavidin-linked tetramers carrying VV 
or LCMV peptides bound to biotinylated H-2Kb, or with control tetramers carrying an 
unrelated SIY peptide (SIYRYYGL). The SIY peptide is a self-antigen not expected to 
induce T cell responses in Kb+ mice (Udaka, Wiesmuller et al. 1996).   In Figure II.1b, 
cognate tetramer staining (blue traces) is overlaid with control-SIY tetramer staining (red 
traces). Staining with A11R tetramer and GP34 tetramer clearly identifies in both cases 
positive and negative populations, with the negative staining population overlapping with 
the control tetramer stain.  The fraction of cells staining positive for the VV-A11R 
tetramer is 50.9% and the fraction staining positive for LCMV-GP34 is 63.7%, again 
indicating that at least some of the T cells cross-react with both VV-A11R and LCMV-
GP34 peptide complexes.  The specificity of the MHC tetramers is further confirmed by 
the lack of staining for the related LCMV-GP118 tetramer, which completely overlaps 
with the control-SIY tetramer staining (Figure II.1B).   
 
II.C.2. Competition between MHC Tetramers in Conventional Staining Experiments 
In principle, cross-reactive T cell populations could be identified by co-staining 
with two differently-labeled tetramers, but in practice competition between the two MHC 
tetramers greatly complicates this approach.  We evaluated such tetramer cross-
competition using the VV-A11R and LCMV-GP34 cross-reactive cell line.  Double MHC 
tetramer staining experiments were performed using various mixtures of cognate MHC 
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tetramers (VV-A11R and LCMV-GP34) and noncognate MHC tetramers (LCMV-
GP118, control-SIY).  In each experiment one MHC-tetramer was prepared using 
streptavidin coupled to R-phycoerythrin (PE), with another prepared using streptavidin 
coupled to allophycocyanin (APC), so that binding of both tetramers could be monitored 
simultaneously (Figure II.2). Prior to coupling to streptavidin, each MHC-peptide 
complex was evaluated by an SDS-PAGE mobility-shift assay (Figure II.3) to ensure 
essentially complete biotinylation.  When cognate VV-A11R-PE tetramer was mixed 
with non-cognate LCMV-GP118-APC tetramer or with the control-SIY-APC tetramer, 
the T cell staining percentages and intensities were similar to staining experiments 
performed with VV-A11R-PE tetramer alone. For example, the VV-A11R-PE tetramer in 
the presence of non-cognate LCMV-GP118-APC stained 52.8% of the cells (Figure 
II.2A), as compared to 50.9% for the VV-A11R-PE tetramer alone (Figure II.1B), or 
50.5% for VV-A11R-PE in the presence of control SIY-APC tetramer (Figure II.2B).  
Similarly, staining of the cross-reactive cell population by the cognate LCMV-GP34-
APC tetramer, which stained 63.7% of the cells (Figure II.1B), was not greatly altered in 
the presence of the non-cognate LCMV-GP118-PE tetramer, which stained 59.9% 
(Figure II.2C).  However, staining of the LCMV-GP34-APC tetramer was dramatically 
reduced in the presence of the cognate VV-A11R-PE tetramer, with only 15.5% of the 
cells staining positively (Figure II.2E).  For the VV-A11R-PE tetramer, the presence of 
the LCMV-GP34-APC tetramer had a much smaller effect, with the reduction in staining 
barely discernable (48.7% positive, Figure II.2E). The fluorescence intensity changes 
followed the same pattern, with the VV-A11R-PE tetramer exhibiting mean fluorescence 
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intensity (MFI) of 843 in single tetramer stain, 825 and 793 in double tetramer stain with 
non-cognate tetramers LCMV-GP118-APC and SIY-APC, respectively, and 727 in a 
double tetramer stain with cognate LCMV-GP34-APC.  LCMV-GP34-APC MFI was 
1268 as a single tetramer, 1082 in the presence of non-cognate SIY-PE, and decreased 
substantially to 551 in the presence of cognate VV-A11R-PE. Overall, the presence of 
cognate tetramer causes a shift in the LCMV-GP34-APC staining intensity, so that the 
double positive population (upper right quadrant) now significantly overlaps with the 
singly positive VV-A11R-PE single positive population (upper left quadrant), with only 
12.5% of the cells clearly identified as positive for both tetramers (Figure II.2E).  
Presumably the stronger competition by VV-A11R-PE tetramers as compared to LCMV-
GP34-APC tetramers is due to stronger binding of Kb-VV-A11R as compared to Kb-
LCMV-GP34 to TCR on most of the cells in the cross-reactive population. In summary, 
both the LCMV-GP34-APC tetramer and VV-A11R-PE tetramer can engage TCR to 
stain cells. However, in double staining experiments with LCMV-GP34 and VV-A11R, 
the tetramers compete with each other. This competition between MHC tetramers for 
binding to cross-reactive receptors on T cells interferes with the use of tetramer staining 
in distinguishing cross-reactive from mono-specific T cells, and seriously complicates the 
use of MHC tetramers in investigation of heterologous immunity.   
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Figure II.2.  Cross-reactive T Cells Engage Cognate Peptide-MHC Tetramers in a 
Manner which Reveals that there Exists Cross-reactive TCR on these Cells.  
Visualization of VV-A11R and LCMV-GP34 specific T cells by double MHC tetramer 
staining at 300 nM. Double MHC tetramer staining experiments were set up using a PE-
labeled peptide-Kb tetramer and a APC-labeled peptide-Kb tetramer as follows.  A. A11R 
tetramer (PE) and GP118 tetramer (APC); B. A11R tetramer (PE) and SIY tetramer 
(APC); C. GP118 tetramer (PE) and GP34 tetramer (APC); D. SIY tetramer (PE) and 
GP118 tetramer (APC); and E. A11R tetramer (PE) and GP34 tetramer (APC).  F. 
Overlay of data shown in panels B. (in red) and E. (in blue) to facilitate comparison.  
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Figure II.3. Comparable Biotinylation Levels for the Different Peptide-MHC 
Monomers Used for Tetramer Staining.  12% SDS-PAGE analysis of pep-Kbbio 
monomers in the presence of streptavidin (SA) under reducing conditions.  MHC 
oligomers are formed to a similar yield among the different peptide-Kbbio monomers upon 
addition of SA. Molecular weight markers are indicated on the left. 
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II.C.3. Construction of Heterodimeric MHC-based Staining Reagents by Keto-
Hydrazide Coupling 
Since cross-reactive T cell populations can be difficult or impossible to identify 
by MHC tetramer co-staining experiments due to competition between the tetramers, we 
investigated the possibility of developing reagents that would be individually specific for 
the cross-reactive population of interest.  One such reagent would be a bi-specific, MHC 
heterodimer carrying two different MHC-peptide complexes.  MHC homodimers, 
prepared as fusion proteins using immunoglobulin Fc domains (Fahmy, Bieler et al. 
2002) or by cysteine-mediated coupling (Cochran, Cameron et al. 2001),  already have 
been developed for use as staining reagents, and can be used similarly to MHC 
(homo)tetramers, although with somewhat lowered binding avidity (Stone and Stern 
2006). If MHC heterodimers were available, they would be expected to exhibit specific 
binding only to T cells carrying receptors able to bind to both component MHC-peptide 
complexes, as the affinity of monomeric MHC-peptide engagement by T cell receptors 
(~10µM, (Cole, Pumphrey et al. 2007)) generally is too low to survive typical washing 
protocols (unpublished data). 
Our strategy for production of a novel, bi-specific H-2Kb heterodimer is shown in 
Figure II.4. This strategy takes advantage of heterobifunctional cross-linkers, MTFB and 
MHPH, and previously developed H-2Kb proteins carrying C-terminal cysteine residues 
(Stone and Stern 2006).  MTFB and MHPH each contain a maleimide moiety, which can 
be used to couple the cross-linkers onto thiols, such as unpaired cysteine residues 
introduced into the membrane-proximal domains of MHC proteins (Cochran, Cameron et 
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al. 2001).  Opposite the maleimide group is an aldehyde or hydrazine, which can be used 
in cross-linking to form the desired hydrazone-linked dimers (King, Zhao et al. 1986; 
Dirksen, Dirksen et al. 2006).  Both maleimide-thiol coupling (Kitagawa and Aikawa 
1976) and aldehyde-hydrazine cross-linking reactions can be carried out under relatively 
mild conditions appropriate for maintaining MHC peptide binding and native structure 
(Figure II.5). 
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Figure II.4. Chemical Reaction Scheme of Heterobifunctional Cross-linkers MHPH 
and MTFB.  Peptide-Kb monomers (R1, R2) containing a free thiol at the C-terminus of 
the class I heavy chain (position 282) were reacted with heterobifunctional linkers, 
maleimido trioxa formyl benzaldehyde (MTFB) or 3-N-maleimido-6-
hydraziniumpyridine hydrochloride (MHPH) through their maleimide moeities.  The 
hydrazine on the MHPH modified peptide-Kb monomer subsequently cross-links with the 
benzaldehyde on the MTFB modified peptide-Kb monomer (when mixed in a 1:1 molar 
ratio) to generate a hydrazone cross-linked peptide-Kb dimer.    
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In independent tubes, H-2Kb monomers containing a C-terminal cysteine (P282C) 
were conjugated with MHPH and MTFB heterobifunctional linkers via their respective 
maleimides.  The MHPH and MTFB H-2Kb modified monomers (R1, R2) were isolated 
by gel filtration and subsequently cross-linked through their aldehyde (MTFB) or 
hydrazine (MHPH) moieties to form a hydrazone-bonded, bi-specific H-2Kb heterodimer 
(Figure II.4).  The extent of dimerization of the MHPH-modified A11R-H-2Kb monomer 
with the MTFB-modified GP34-H-2Kb monomer was approximately 40% as evaluated 
by analytical size exclusion chromatography (“Dimer reaction mix” trace, Figure II.5A).  
The hydrazone-linked A11R-H-2Kb, GP34-H-2Kb heterodimer was isolated by gel 
filtration and labeled with the amine-reactive fluorescent dye Alexa647-succinimidyl 
ester, to a ratio of approximately ~2 dye per MHC molecule.  Importantly, after Alexa 
647 succinimidyl ester labeling, the purified, labeled MHC heterodimer exhibited the 
expected apparent molecular weight, as did the unlabeled dimer in the reaction mixture, 
with no evidence of appreciable aggregation or dissociation (Figure II.5A).  Furthermore, 
neither MHPH-modified A11R-H-2Kb monomer nor MTFB-modified GP34-H-2Kb 
monomer exhibited appreciable homo-dimerization, which potentially would interfere 
with specific staining of cross-reactive cells (Figure II.5A).  Because no cross-linking is 
observed in the absence of either MHPH or MTFB, it appears that the heterobifunctional 
cross-linking reaction is quite specific.   
Reducing SDS-PAGE analysis also was used to characterize the maleimide 
coupling and hydrazone cross-linking reactions (Figure II.5B). MHPH and MTFB 
coupling reactions do not compromise the purity of the H-2Kb heavy chain through 
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cleavage or degradation, as judged by SDS-PAGE, and the MHPH-modified A11R-H-
2Kb and MTFP-modified GP34-H-2Kb appear to be essentially completely homogenous 
(the small β2m subunit and peptide components of the MHC-peptide complexes migrate 
with the dye front and are not visible by this analysis) (Figure II.5B).  Analysis of the 
A11R-GP34-H-2Kb heterodimer reaction mixture shows that slightly less than half of the 
total monomers react to form the desired heterodimer, confirming the results from size 
exclusion chromatography.  Reducing SDS-PAGE also reveals that A11R-GP34-H-2Kb 
heterodimer is covalently linked and not formed as a consequence of disulfide bonding or 
non-covalent interaction, because no appearance of a monomeric species (around 37,000 
daltons) is observed for the Alexa 647-labeled, A11R-GP34-H-2Kb heterodimer after 
boiling and reduction (Figure II.5B).  Finally, Alexa 647-labelled MHC monomers also 
exhibited no tendency to form disulfide-linked dimers (Figure II.7).  
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Figure II.5. Heterobifunctional Cross-linking of Peptide-Kb Monomers.  Kb 
monomers modified with MTFB (GP34 MTFB) or MHPH (A11R MHPH), cross-linked 
Kb heterodimer reaction mixture (GP34-Kb MTFB and A11R-Kb MHPH) and Alexa 647 
labeled, cross-linked Kb heterodimer (A647 labeled A11R-GP34 dimer) were analyzed 
by size exclusion chromatography and 12% SDS-PAGE.  The MTFB-MHPH chemistry 
is specific because the A11R MHPH Kb monomer and GP34 MTFB Kb monomers do not 
form cross-linked Kb dimers independently.  Additionally, Alexa 647 succinimidyl ester 
labeling does not alter the hydrodynamic radius or purity of the cross-linked Kb dimer.  A. 
In the A11R-GP34 dimer reaction mix, cross-linked Kb dimer with a retention volume 
~14 mL was purified from Kb modified monomers (retention volume ~15.5 mL) by size 
exclusion chromatography using a Superdex 200 column.  The molecular weight 
standards are indicated along with the approximate retention volumes.  B.   Reducing 
SDS-PAGE confirms the purity of the modified Kb monomers and cross-linked Kb 
dimers.  Proteolysis is not observed after modification (GP34 MTFB, A11R MHPH) or 
cross-linking (A11R-GP34 dimer reaction mix).  Molecular mass markers are indicated 
on the left.    All of the Alexa 647-labeled, H-2Kb dimers used in this study were 
analyzed by matrix-assisted laser desorption/ionization (MALDI) mass spectroscopy to 
confirm that the peptide antigens are present in unmodified form in the MHC complexes 
(Figure II.6).  In the A11R-H-2Kb monomer and A11R-H-2Kb homodimer, a peak at 899 
daltons, corresponding to the molecular weight of A11R peptide, was observed, and in 
the GP34-H-2Kb monomer and GP34-H-2Kb homodimer, a peak at 938 daltons, 
corresponding to the molecular weight of GP34 peptide, was observed.  For the A11R-
GP34-H-2Kb heterodimer, peaks at both 899 daltons (A11R peptide) and 938 daltons 
(GP34 peptide) were observed.  
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Figure II.6. Peptides are not Modified after Heterobifunctional Cross-linking and 
Labeling. Mass spectroscopy using Matrix-Assisted Laser Desorption/Ionization 
(MALDI) of peptide (control) and peptide-Kb monomers and dimers shows that the 
peptide is intact in its native, unmodified form after heterobifunctional cross-linking and 
Alexa 647 labeling. 
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Figure II.7. Binding of Alexa 647 Labeled Monomers cannot be Attributed to the 
Formation of Disulfide Linked Dimers. The presence of disulfide linked species was 
not detected in the Alexa 647 labeled peptide-Kb monomers used to stain CD8+ T cells. 
Labeled monomers were analyzed by SDS-12% SDS PAGE under non-reducing 
conditions (lanes 2-5) and reducing (lanes 7-10) conditions. No disulfide-linked Kb 
dimers were apparent. Molecular mass markers are indicated on the left. 
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II.C.4. Identification of Cross-reactive TCR on T cells using MHC Heterodimers 
The previously characterized VV-A11R, LCMV-GP34 cross-reactive T cells 
(Figure II.2) were re-stimulated with LCMV-GP34 peptide-pulsed targets prior to use to 
maintain the cells during in vitro culture.  To ensure that the T cells did not change 
specificity from VV-A11R and LCMV-GP34 after re-stimulation, MHC tetramer staining 
was performed on the re-stimulated line (Figure II.8A).  The cells exhibited strong 
staining with A11R tetramer (88.5%) and GP34 tetramer (80.9%), and little staining with 
LCMV-GP118 tetramer (2.0%) or control-SIY tetramer (3.7%), both of which overlap 
almost completely with the unstained population (Figure II.8A, red curves).  This 
confirms that the specificity of the T cells did not change upon re-stimulation with 
peptide-pulsed targets, although the percentage of VV-A11R and LCMV-GP34 tetramer 
positive cells increased as expected because of preferential expansion of the specific 
population.   
In order to attribute H-2Kb heterodimer binding to cross-reactive T cell receptors, 
it was necessary to ensure that H-2Kb monomers do not exhibit appreciable binding under 
our experimental conditions.  For this reason, binding of all H-2Kb monomers was tested 
on VV-A11R, LCMV-GP34 specific T cells (Figure II.8B).  No binding of any of the H-
2Kb monomers (VV-A11R, LCMV-GP34, LCMV-GP118, control-SIY) was observed 
above the unstained background.  Thus, as expected, MHC-peptide binding to T cells 
requires more than a single cognate MHC-TCR and MHC-CD8 interaction. 
Our MHPH-MTFB cross-linking strategy generates a novel MHC-MHC linkage, 
and we wanted to ensure that the hydrazone linked H-2Kb dimers could engage T cells 
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with sufficient affinity and specificity for use in conventional staining protocols.  For this 
purpose cognate (VV-A11R, LCMV-GP34) and noncognate (control-SIY) H-2Kb 
homodimers were made using the same MHPH-MTFB chemistry described above, and 
binding was tested on the re-stimulated VV-A11R, LCMV-GP34 cross-reactive T cells.  
As shown in Figure II.9, both cognate A11R-A11R-H-2Kb homodimer and GP34-GP34-
H-2Kb homodimer stain the T cells, with MFI = 1093 and 395 respectively. (The 
increased staining intensity for the A11R-A11R-H-2Kb homodimer reflects the greater 
degree of Alexa 647 labeling, approximately twice that of the other H-2Kb dimers; see 
Methods for details). In contrast, the non-cognate SIY-SIY-H-2Kb homodimer control 
staining (MFI=199) is only slightly higher than the unstained background (MFI = 132).  
These results parallel the tetramer staining results (Figure II.8A) in terms of specificity 
and demonstrate that heterobifunctional cross-linking does not alter the ability of H-2Kb 
homodimers to engage TCRs.    
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Figure II.8.  MHC Tetramer and MHC Monomer Staining of Cross-reactive T 
Cells.  A.  T cells previously characterized by tetramer staining as specific for both VV-
A11R and LCMV-GP34 maintained their specificity after additional restimulation with 
LCMV-GP34 peptide pulsed targets.  After restimulation and passage in vitro, T cells 
were stained with the indicated streptavidin-based Kb tetramers at 300 nM (blue trace) 
shown overlaid with an unstained control (red trace).  The MFI of the positive staining 
population is indicated in the upper right in each histogram. Positive staining with the 
VV-A11R tetramer and the LCMV-GP34 tetramer shows that the specificity of the T 
cells is maintained after passage. B.  MHC monomers do not have sufficient affinity 
required for T cell staining.  The T cell culture from panel A was stained with peptide-Kb 
monomers at 2 µM as indicated.  The indicated monomer stain (blue trace) was overlaid 
with the unstained control (red trace) in each histogram. Positive staining of T cells is not 
observed with any of the monomers. 
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Finally, we wanted to evaluate whether T cells which express cross-reactive TCR 
could be identified using the bi-specific, cognate H-2Kb heterodimer.  As shown in 
Figure II.9B, the bi-specific, A11R-GP34-H-2Kb heterodimer is able to stain the cross-
reactive T cell population (MFI = 377), with 32% positive as compared to 4.9% positive 
for the SIY-SIY homodimer (MFI =199).  The staining signal is clearly distinguishable 
from the unstained background, and the staining intensity is similar to that observed for 
the specific GP34-GP34-H-2Kb homodimer (MFI = 395) with 49% positive (Figure 
II.9B).  To confirm that MHC heterodimer binding depends on MHC-TCR contacts with 
both cognate peptide-epitopes, we generated “control” H-2Kb heterodimers where one H-
2Kb monomer is folded with a self-peptide (control-SIY) and the other with a cognate 
peptide (VV-A11R or LCMV-GP34), and compared staining of these reagents to the 
A11R-GP34-H-2Kb heterodimer of interest (Figure II.8B). These controls are necessary 
for two reasons.  First, if either the VV-A11R monomer or LCMV-GP34 monomer 
undergoes unexpected dimerization, an artifactual H-2Kb “homodimer” would result and 
binding would be observed.  Second, relative to the non-binding MHC monomers, the 
non-cognate MHC heterodimers carry an additional CD8-MHC contact as well as an 
additional non-specific pMHC-TCR contact, either or both of which potentially could 
provide sufficient binding affinity to allow significant staining under typical experimental 
conditions.  However, significant staining by the non-cognate A11R-SIY-H-2Kb (MFI = 
162) and SIY-GP34-H-2Kb (MFI = 215) control heterodimers was not observed, with 
2.8% and 4.6% positive, respectively, values similar to those for the control SIY-SIY 
homodimer. Thus, staining of the cross-reactive T cell line by the A11R-GP34-H-2Kb 
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heterodimer requires bivalent engagement involving both MHC-peptide components, and 
reflects specific detection of cross-reactive T cells within the population.   
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Figure II.9. MHC Heterodimer Staining of Cross-reactive T Cells.  The T cell culture 
shown in Figure II.8 was stained with the indicated Kb-homodimers (A.) or Kb-
heterodimers (B.) at 1 µM.  A.  MHC homodimer staining demonstrates that the novel 
hydrazone linkage does not disturb MHC engagement of TCR and confirms that the T 
cells are cross-reactive for LCMV-GP34 and VV-A11R as seen in the tetramer staining 
experiment.  B.   Bi-specific MHC heterodimer (A11R-GP34-Kb) staining shows that 
cross-reactive T cells can be readily identified.   All of the indicated MHC homodimers 
and heterodimers (blue trace), were overlaid with an unstained control (red trace).  The 
MFI of the positive staining population is indicated in the upper right in each histogram.   
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II. D. Discussion 
We developed a specific hetero-dimerization strategy to prepare hydrazone-linked 
MHC dimers carrying two different MHC-peptide complexes. As expected from previous 
work using other disulfide or Ig-linked MHC dimers, the avidity of such complexes was 
sufficient to allow for specific staining and flow cytometric analysis of T cell cultures.  
Unlike previous work, the heterodimers were specific for cross-reactive T cells, i.e. T 
cells able to bind to two different MHC-peptide complexes.  Unlike dual-tetramer 
staining, the MHC heterodimer experiments do not suffer from cross-competition 
between their component MHC-peptide complexes.  A cross-reactive T cell with 
significantly greater affinity for one of the two component MHC-peptide complexes was 
easily detected.  We expect that such MHC heterodimers will find application in analysis 
of heterologous T cell responses induced by vaccination, infection, or autoimmune 
stimuli. 
One potential pitfall in development of the heterobifunctional cross-linking 
strategy was the high reactivity of the hydrazine moiety in the MHPH cross-linker, such 
that the MHPH-modified H-2Kb monomers (and particularly Alexa 546-labeled MHPH-
modified H-2Kb monomers) exhibited a propensity to self-react upon extended storage in 
higher concentrations in 4°C degrees (data not shown).  For this reason, MHPH-modified 
H-2Kb monomers were kept at low concentrations after modification, and were promptly 
mixed with previously prepared MTFB-modified H-2Kb monomers, so that once 
conjugated the hydrazine moieties (MHPH) could preferably react with aldehyde 
moieties (MTFB) as compared to other more sluggish side reactions which may occur.  
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Our cross-linking results from Figure II.5 coupled with the results from mass 
spectroscopy (see Figure II.6), indicate that this method is effective in achieving the 
desired dual-specificity for the H-2Kb heterodimer.  Another potential limitation of the 
heterobifunctional cross-linking strategy described here is that both thiols and amine 
groups are used for coupling (cross-linker conjugation and fluorescent labeling, 
respectively).  Thus, the peptides used in heterobifunctional cross-linking of H-2Kb 
complexes should not have exposed side chains from cysteine residues (to prevent 
peptide-cross-linking) or lysine residues (to prevent direct labeling of peptide which 
might interfere with TCR interaction).  In such cases the cysteine and/or lysine residues 
could be conservatively substituted to remove the reactive species.  For example, 
substitution of the original cysteine at position 41 by methionine in the LCMV-GP34-41 
used in this study does not substantially impact T cell recognition (Achour, Michaelsson 
et al. 2002; Khanolkar, Fuller et al. 2004).  Alternatively, a photo-exchangeable peptide 
strategy (Toebes, Coccoris et al. 2006) could be employed to allow for peptide loading 
after fluorescent labeling. 
In this study we examined a polyclonal T cell line exhibiting cross-reactivity 
between two different viral antigens bound to the murine class I MHC H-2Kb, one 
derived from LCMV and one from VV.  Such T cells are known to arise after natural 
infection with these viruses, and are believed to play a role in heterologous immune 
responses observed upon infection with one virus after prior exposure to the other (Kim, 
Cornberg et al. 2005). GP34-A11R cross-reactivity has been observed for T cell lines 
obtained by a variety of immunization/culture protocols (Cornberg, Sheridan et al. 2007; 
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Cornberg, Clute et al. 2010). The fraction of cross-reactive cells in the overall LCMV-
responsive and VV-responsive populations varies between individual mice because of the 
“private” nature of the T cell response (Cornberg, Chen et al. 2006; Cornberg, Sheridan 
et al. 2007; Cornberg, Clute et al. 2010), and the fraction of cross-reactive T cells present 
after in vitro culture depends on the conditions used to expand the antigen-specific cell 
population (unpublished observations).  The particular T cell line investigated here 
exhibited an unusually high degree of cross-reactivity, thus providing an opportunity to 
evaluate the novel MHC heterodimer staining strategy, and to characterize in detail the 
nature of the cross-reactive T cell population.  
If MHC monomers bound to TCRs, it would be difficult to distinguish cross-
reactive from singly-reactive T cell populations.  In this system, we confirmed that 
binding of MHC monomers is not observed on the T cells bearing cross-reactive TCRs 
(Figure II. 8B).  Furthermore, clear absence of observable binding by control MHC 
heterodimers carrying one cognate and one non-specific peptide demonstrates that both 
peptides need to be cognate in order for MHC heterodimer binding to be observed 
(Figure II.9B). This contrasts with an observation of binding of non-cognate MHC-
tetramers to human peripheral blood T cells via CD8 interactions (Laugel, van den Berg 
et al. 2007), although in that study MHC oligomer staining was performed at higher 
concentrations and temperatures (Schott and Ploegh 2002).  We cannot exclude the 
possibility that exceptionally tight-binding T cells, with MHC-TCR affinity significantly 
higher than those observed to date (Cole, Pumphrey et al. 2007), might be able to engage 
MHC-peptide monomers. 
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Cross-reactive T populations may represent one of three situations: 1) a mixture 
of two T cell sub-populations, each specific for a different antigen, but with no cross-
reactivity at the single cell level, 2) a population of T cells expressing two distinct TCR 
as a result of incomplete allelic exclusion at the TCRα locus (Padovan, Casorati et al. 
1995) or possibly TCR sharing (Chaudhri, Quah et al. 2009) (i.e. with cross-reactivity at 
the single cell but not single receptor level (Padovan, Casorati et al. 1993; Hardardottir, 
Baron et al. 1995; He, Janeway et al. 2002), or 3) a T cell population carrying T cell 
receptors that individually react with two (or more) different MHC-peptide complexes.  
Since monomeric engagement is not sufficient to observe binding of the MHC 
heterodimers (Figure II.8B and II.9B), individual T cells staining positively with the 
MHC heterodimers must express receptors for both of the component MHC-peptide 
complexes. Thus, we can rule out 1) as an explanation for the observed cross-reactivity of 
the LCMV-VV cross-reactive T cell population, i.e the cross-reactivity is apparent at the 
single cell level, and not just at the population level.  The MHC heterodimer staining 
experiment by itself cannot distinguish between cases 2) and 3), both of which have been 
proposed to be relevant in T cell responses to infectious agents (He, Janeway et al. 2002; 
Macdonald, Chen et al. 2009).  However, our observation of competition between MHC 
tetramers in the (homo-)tetramer staining experiments indicates that, for most or all of the 
T cells in the LCMV-VV cross-reactive population, individual TCR able to bind H-2Kb-
LCMV-GP34 also were able to bind H-2Kb-VV-A11R, i.e. case 3) the cross-reactivity is 
apparent at the single receptor level.  We note however that this demonstration depends 
on the relative avidities of the two tetramers.  For example, we could observe competition 
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of H-2Kb-LCMV-GP34-tetramers by the tighter-binding H-2Kb-VV-A11R, but not the 
reverse.  Although it was clear from previous studies that the LCMV-VV cross-reactive T 
cell populations are present after subsequent infections with LCMV and VV (Kim, 
Cornberg et al. 2005; Cornberg, Sheridan et al. 2007), and cross-reactive T cells were 
observed in (BL/6 x TCRα KO) F1 mice, whose T cells express only a single TCRα 
chain and are not subject to allelic exclusion(Welsh, Kim et al. 2006), the present study 
confirms the idea that LCMV-VV cross-reactive T cell populations utilize T cell 
receptors individually cross-reactive with Kb-LCMV-GP34 and Kb-VV-A11R complexes.   
T cells with receptors specific for class I MHC proteins like H-2Kb typically 
express the CD8 co-receptor, which binds to class I MHC in a peptide-antigen 
independent manner through an interaction outside the peptide binding site (Gao, Tormo 
et al. 1997; Kern, Hussey et al. 1999).  The CD8-MHC  interaction is substantially 
weaker (Kd for H-2Kb ~90 µM (Moody, Xiong et al. 2001) than that of typical MHC-
TCR interactions (~10 µM) (van der Merwe and Davis 2003), but nonetheless 
engagement of MHC by CD8, particularly multivalent engagement, could potentiate 
MHC dimer binding as it does MHC tetramer binding (Dutoit, Guillaume et al. 2003; 
Kerry, Buslepp et al. 2003; Nugent, Renteria et al. 2005)  However, the clear absence of 
observable binding by control MHC heterodimers carrying one cognate and one non-
specific peptide demonstrates that both peptides need to be cognate in order for MHC 
heterodimer binding to be observed (Figure II.9B).  This contrasts with an observation of 
binding of non-cognate MHC-tetramers to human peripheral blood T cells via CD8 
interactions (Laugel, van den Berg et al. 2007), although in that study MHC oligomer 
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staining was performed at higher concentrations and temperatures (Schott and Ploegh 
2002).  
In conclusion, the hetero-dimerization strategy developed here for the murine 
class I MHC molecule H-2Kb provides specific fluorescent MHC heterodimers composed 
of one MHPH-linked MHC-peptide monomer and one MTFB-linked MHC monomer 
carrying a different peptide, with no apparent perturbation of the MHC-peptide complex 
or its interaction with T cell receptors.   Using H-2Kb heterodimer carrying peptides VV-
A11R198-205 and LCMV-GP34-41, we showed that a unique subset of LCMV-VV cross-
reactive T cells can be characterized.  Double MHC tetramer staining on these cross-
reactive T cells highlighted the problems with MHC tetramer cross-competition, but also 
revealed that these cross-reactive T cells express a single cross-reactive TCR able to bind 
to both VV-A11R198-205 and LCMV-GP34-41 peptides.  Similar strategies could be used to 
develop human peptide-MHC reagents for quantifying T cell cross-reactivity during 
human viral infections. For example, cross-reactive influenza virus-specific T cells have 
been observed in EBV-induced infectious mononucleosis (Clute, Watkin et al. 2005) and 
implicated in hepatitis C virus-induced fulminating hepatitis (Wedemeyer, Mizukoshi et 
al. 2001) and they could be quantified by this method.  
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Chapter III: 
Disparate Epitopes Mediating Protective Heterologous Immunity to Unrelated 
Viruses share Peptide-MHC Structural Features that are recognized by Cross-
reactive T cells  
 
Abstract 
Closely related T cell peptide epitopes can, not surprisingly, be recognized by the 
same T cells and contribute to the immune response against pathogens encoding those 
epitopes.  However, sometimes cross-reactive epitopes share little homology, and the 
degree of structural homology required for such disparate ligands to be recognized by 
cross-reactive TCR remains unclear.  Here, we examined the mechanistic basis for cross-
reactive T cell responses between two disparate epitopes from unrelated and pathogenic 
viruses, lymphocytic choriomenigitis virus (LCMV) and vaccinia virus (VV).  Cross-
reactive T cell responses were measured by IFNγ production and in vivo cytotoxicity, 
with TCR specificity checked by peptide-MHC tetramer binding.  Our results show that 
the LCMV-cross-reactive T cell response towards VV is dominated by a shared 
asparagine residue at the P4 position, together with other shared structural elements 
conserved in the structures of Kb-VV-A11R and Kb-LCMV-GP34.  Based on analysis of 
the Kb-VV-A11R and Kb-LCMV-GP34 crystal structures, which we report in this study, 
and previously reported Kb-OVA structures, we were able to predict and generate a 
LCMV-cross-reactive T cell response towards a variant of the OVA null peptide.  
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Combined, our results demonstrate that shared structural features formed by peptide-
MHC complexes mediate cross-reactive T cell responses.   
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III.A. Introduction 
Memory T cell populations generated against a previously encountered pathogen 
can alter the outcome of a subsequent exposure to an unrelated pathogen (Selin, Cornberg 
et al. 2004; Selin, Brehm et al. 2006; Welsh, Che et al. 2010).  This phenomenon, known 
as heterologous immunity, has been well documented in humans and mice for both 
related and unrelated pathogens (Mathew, Kurane et al. 1998; Wedemeyer, Mizukoshi et 
al. 2001; Clute, Watkin et al. 2005; Urbani, Amadei et al. 2005; Cornberg, Clute et al. 
2010; Chen, Cornberg et al. 2012).  For example, cross-reactive T cells have been found 
to mediate heterologous immune responses between different serotypes of dengue 
virus(Spaulding, Kurane et al. 1999), between the closely related arenaviruses Pichinde 
and lymphocytic choriomeningitis virus (LCMV) (Chen, Cornberg et al. 2012), and 
between two completely unrelated viruses, LCMV and vaccinia virus (VV) (Cornberg, 
Sheridan et al. 2007; Cornberg, Clute et al. 2010).  For LCMV and VV, previous 
exposure to LCMV results in either protective immunity or altered immunopathology in 
mice that are challenged with VV (Selin, Vergilis et al. 1996; Chen, Fraire et al. 2001).  
The demonstrated impact on the overall immune response for T cell crossreactivity 
highlights the importance of understanding the underlying mechanisms.   
VV challenge of LCMV-immune mice results in proliferative T cell responses 
towards three previously characterized LCMV epitopes: LCMV-GP34, LCMV-GP118 
and LCMV-NP205 (See Table III.1) (Kim, Cornberg et al. 2005).  We previously showed 
that VV-A11R crossreacts in vitro with LCMV-GP34 in a cross-reactive T cell line 
(Shen, Brehm et al. 2010), with the cross-reactive response mediated through T cell 
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receptors (TCR) that could recognize both epitopes (Shen, Brehm et al. 2010).  However, 
the underlying mechanism for this cross-reactive response was not studied.  The sequence 
disparity between LCMV-GP34 (AVYNFATM) and VV-A11R (AIVNYANL), which 
share only three of eight residues, made it seemingly unlikely that structural mimicry 
could be the underlying mechanism.   
There are two basic concepts by which cross-reactive T cells can recognize 
heterologous antigens.  The simplest method is that cross-reactive T cells express T cell 
receptors that are individually cross-reactive towards two or more epitopes (Yin and 
Mariuzza 2009).  Alternatively, it has been shown that cross-reactive T cell responses 
might be mediated by two different T cell receptors present on a single T cell.  The dual 
expression of two different TCRs may occur through TCR sharing, where two 
clonotypically different T cells transfer cell surface TCRs amongst each other (Chaudhri, 
Quah et al. 2009) or in the absence of allelic exclusion, where the non-selected TCRα 
chain is retained on the cell surface (Hardardottir, Baron et al. 1995; He, Janeway et al. 
2002).   
For individually cross-reactive TCRs, structural similarities between different 
peptide-MHC ligands, either through structural reconfiguration of the peptide and/or the 
MHC, is one of a few reported mechanisms for cross-reactive T cell responses 
(Macdonald, Chen et al. 2009).  However, the degree of structural homology required 
before TCR engagement remains unclear as many studies have been focused on peptide-
epitopes which share greater than 50% sequence homology (Borbulevych, Piepenbrink et 
al. 2009; Macdonald, Chen et al. 2009; Borbulevych, Santhanagopolan et al. 2011).  
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Furthermore, most studies have focused on the cross-reactive TCR engagement of self 
epitopes that mimic foreign epitopes, leading to aberrant autoreactivity (Mazza, Auphan-
Anezin et al. 2007; Macdonald, Chen et al. 2009; Borbulevych, Piepenbrink et al. 2011; 
Borbulevych, Santhanagopolan et al. 2011).  Only one study has evaluated beneficial 
immune responses towards two distinct foreign pathogens (Borbulevych, Piepenbrink et 
al. 2009).  In that particular study, the epitopes in question share greater than 50% 
homology, which makes the cross-reactive TCR engagement less surprising.   
Structural rearrangements for cross-reactive TCR have also been shown as a 
mechanism for cross-reactive TCR engagement (Colf, Bankovich et al. 2007; Mazza, 
Auphan-Anezin et al. 2007).  One example is the cross-reactive TCR BM3.3, which was 
found to modify its CDR loops to accommodate three different peptides, all presented by 
H-2Kb, using the same overall docking strategy (Mazza, Auphan-Anezin et al. 2007).  
Another example is the 2C TCR, which globally repositions itself over two different 
cross-reactive peptide-MHC ligands (Colf, Bankovich et al. 2007).  The 2C TCR is able 
to accommodate a self-ligand and a foreign ligand by shifting its TCRα and TCRβ chains 
(Colf, Bankovich et al. 2007).   
To determine the mechanistic basis for the LCMV-VV cross-reactive T cell 
response, we compared the recognition determinants for LCMV-GP34 and VV-A11R 
using site-specific mutations at the predicted non-MHC binding residues in both epitopes.  
We studied the impact of these mutations by using a combination of intracellular 
cytokine staining (ICS), MHC tetramer staining and in vivo cytotoxicity assays.  The 
studies were conducted on either acute LCMV-infected mice or GP34-A11R cross-
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reactive T cell lines, which were derived from LCMV-immune mice and expanded in 
vitro with peptide-pulsed targets.  In addition, we determined X-ray crystal structures of 
the Kb-LCMV-GP34 and Kb-VV-A11R peptide-MHC complexes recognized by cross-
reactive T cells.  Structural analysis revealed that the cross-reactive ligands are nearly 
identical structural mimics that share a conserved asparagine at P4 for both LCMV-GP34 
and VV-A11R, corresponding with the requirement of the P4N for the LCMV-cross-
reactive T cell response against VV.  Using the functional and structural requirements for 
the cross-reactive T cell response, we were able to predict and generate a cross-reactive 
response towards a variant of the null OVA peptide.  Together, our results highlight that 
shared structural features of the Kb-LCMV-GP34 and Kb-VV-A11R molecular surfaces 
underlie the LCMV-VV cross-reactive T cell response.   
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III.B. Materials and Methods 
III.B.1. Production of Class I H-2Kb complexes  
Extracellular domains of the murine MHC class I H-2Kb heavy chain and full length 
human light chain β2 – microglobulin, were expressed separately as inclusion bodies in 
Escherichia coli and were folded in vitro by dilution in the presence of excess peptide, as 
previously described for human class I MHCs (1).  Synthetic peptides purified by reverse 
phase-HPLC were purchased from 21st Century Biochemicals.  Folded H-2Kb monomers 
were purified by anion exchange chromatography on Poros HQ columns (Roche) using a 
gradient of NaCl from 0-0.5M in 20 mM Tris buffer (pH 8.0).  The concentration of each 
H-2Kb monomer was calculated by absorbance spectroscopy after anion exchange 
chromatography using ε280 = 74955 cm-1 M-1 for H-2Kb heavy chain, ε280 = 20003 cm-1 M-1 
for β2 – microglobulin light chain and varied ε280  for peptides depending on sequence.   
Purified H-2Kb monomers were adjusted to a concentration of 10-20 mg/mL using 
regenerated cellulose filters (Amicon) and stored at -80ºC.   
 
III.B.2. Isolation of Antigen-Specific CTL 
LCMV (Armstrong strain), an RNA virus in the Old World arenavirus family, was 
propagated in BHK-21 baby hamster kidney cells as previously described (Selin, Nahill 
et al. 1994).  C57BL/6 (B6) mice were infected intraperitoneally (i.p.) with a non-lethal 
dose of 5 x 104 PFU of LCMV as previously described (Selin, Nahill et al. 1994).  Mice 
were considered immune at greater than 6 weeks after infection (Cornberg, Sheridan et 
al. 2007). Splenocytes from LCMV-immune mice were co-cultured with mouse RMA 
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cells that were pulsed with 1 µM VV-A11R peptide, washed and then γ-irradiated (3000 
rads) as previously described (Cornberg, Sheridan et al. 2007). RMA is a Kb-positive, 
Rauscher virus-induced, T-lymphoma cell line of B6 origin. Briefly, the co-culture of 
splenocytes and VV-A11R-pulsed RMA cells were grown in RPMI medium 
supplemented with 100 U/ml penicillin G, 100 μg/ml streptomycin sulfate, 2 mM L-
glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 0.1 mM MEM nonessential amino 
acids, 0.05 mM β-mercaptoethanol, and 10% FBS for 5 days at 37°C at 5% CO2. 
Following this initial culture period, cells were harvested and stimulated with GP34 
peptide-pulsed RMA cells in the presence of 10% BD T-Stim (BD Biosciences), an IL-2 
culture supplement. VV-A11R peptide-pulsed RMA stimulation was repeated every 4 to 
5 days. After 30 to 35 days of stimulation (six or seven stimulations), T-cell lines were 
characterized by intracellular cytokine staining or MHC tetramer staining. 
 
III.B.3. Cell Surface and MHC Staining by Flow Cytometry 
Cell suspensions were passed through lympholyte M gradient (Cedarlane) to exclude 
dead cells and subsequently washed and incubated in staining buffer (phosphate-buffered 
saline containing 1% FBS and 0.2% sodium azide). Cell suspensions were incubated in 
staining buffer containing anti-mouse CD16/CD32 (Fc-block, clone 2.4G2). Cells were 
washed once with staining buffer and then stained with H-2Kb tetramers for 40 min 
followed by cell-surface antibody staining with anti-CD8β (clone 53-6.8), anti-CD44 
(clone IM7) and Live/Dead aqua exclusion dye (Invitrogen) for 20 min.  Thereafter, cells 
were washed twice with staining buffer and fixed in Cytofix (BD Pharmingen).   Samples 
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were analyzed using a Becton Dickinson LSRII flow cytometer (BD Biosciences) and 
FlowJo software (Tree Star).   
 
III.B.4. Intracellular Cytokine Staining (ICS) 
A suspension of 106 cells was stimulated with 1 μM synthetic peptide or a medium only 
control  Stimulations were performed for 5 h at 37°C in a total volume of 200 μl RPMI 
medium supplemented with 10% FBS, 10 U/ml of human recombinant interleukin-2 (IL-
2), and 0.2 μM of brefeldin A (GolgiPlug; BD Pharmingen). After incubation, cell-
surface antibody staining with anti-CD8β (clone 53-6.8), anti-CD44 (clone IM7), and 
Live/Dead aqua (Invitrogen) was performed.  Thereafter, cells were washed twice with 
staining buffer, and then fixed and permeabilized (Cytofix/Cytoperm; BD Pharmingen). 
Intracellular-cytokine-producing cells were detected with PE-labeled anti-mouse 
interferon-gamma (IFN-γ, clone XMG1.2) and APC-labeled anti-mouse tumor necrosis 
factor alpha (TNF-α, clone MP6-XT22) monoclonal antibodies. Antibodies were 
purchased from BD Pharmingen. The samples were analyzed as described above for cell 
surface staining.   
  
III.B.5. In vivo CTL assay 
RBC-lysed, single-cell spleen suspensions from naive B6 mice were pulsed at 107 
cells/ml with 1 μM peptide RPMI containing 10% FBS for 45 min at 37°C.  For a four 
peak CTL assay (Figure III.1B), each peptide-pulsed spleen cell population was labeled 
with a dilution of carboxyfluorescein succinimidyl ester (CFSE, Invitrogen) at 5µM, 
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2.5µM, 1.25nM and 0.63nM along with 0.5 µM of 7-hydroxy-9H-(1,3-dichloro-9,9-
dimethylacridin-2-one) (DDAO, Invitrogen) at a cell density of 2 x 107 cells/ml in HBSS. 
Labeling was stopped by addition of excess HBSS.  For an eight peak CTL assay (Figure 
III.3E), 1µM of Violet (Invitrogen) was used in addition to the CFSE and DDAO.  One 
million cells of each peptide-pulsed population were mixed together, and 500µL was 
injected i.v. into LCMV infected and uninfected syngeneic mice. 
 
III.B.6. Crystallization and Data Collection   
H-2Kb complexes were crystallized in 14-16% PEG 8K, 0.1 M Na cacodylate, 0.2 M 
magnesium acetate at 4°C. Typically, 1 μl of a 10 mg/ml protein solution in 10 mM Tris 
Cl (pH 7.0) was mixed with equal volumes of the crystallization reservoir.  Crystals were 
transferred to a reservoir solution containing 30% glycerol and flash frozen using liquid 
nitrogen.  X-ray diffraction data were collected as 1° oscillations at 100 K with 1.08 Å 
radiation at beamline X29A in the National Synchrotron Light Source. Data were 
processed and scaled using HKL2000 (Minor, Cymborowski et al. 2006). Data collection 
and refinement statistics are shown in Table 1. 
 
III.B.7. Structure Determination and Refinement 
Phases were estimated by molecular replacement using PHASER(McCoy, Grosse-
Kunstleve et al. 2007) with PDB ID# 1S7R, peptide GNYSFYAL removed) as a search 
model. To validate the molecular replacement solution, composite omit maps (CNS) 
(Brunger 2007) were generated and inspected using COOT (Emsley and Cowtan 2004). 
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During refinement, the peptide was omitted to reduce model bias.  The peptide was later 
built into the observed electron density, which was unambiguous within the peptide 
binding groove.  Crystallographic rigid body, positional, B-factor, and TLS refinement 
was performed in PHENIX (Adams, Afonine et al. 2010). Ramachandran statistics 
showed all residues in the allowed regions. Diffraction data and coordinates were 
deposited into the Protein Data Bank (PDB ID# 3TID and 3TIE) (Moskophidis, Lechner 
et al. 1993). 
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III.C. Results 
III.C.1. VV-A11R and LCMV-GP34 are Cross-reactive CD8+ T cell Epitopes Elicited 
by LCMV Infection 
Previous work indicated that VV challenge of LCMV-immune mice stimulates 
expansion of T cell populations recognizing LCMV-GP34 (Cornberg, Clute et al. 2010).  
To show that these cross-reactive T cell responses were elicited in mice infected with 
only LCMV, we infected B6 mice with LCMV for 8 days, and at the peak of the infection 
performed an ex vivo intracellular cytokine staining (ICS) assay for cross-reactive VV-
A11R T cell responses in immunized as compared to control naïve B6 mice.  The results 
from a representative LCMV-infected mouse show an IFN response to the cross-reactive 
VV-A11R peptide at ~1%  of total CD8 T cells, with only background levels of VV-
A11R cross-reactivity observed in a representative naïve mouse (Figure III.1A).  A T cell 
response to the control-SIY peptide was not observed, and the response to cognate 
LCMV-GP34 was observed at ~5% of total CD8 T cells (Figure III.1A).  See Table III.1 
for relevant epitopes.   
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Table III.1. Relevant Epitopes from VV and LCMV used for the study on GP34-
A11R Cross-reactive T cell Responses presented in Chapter III  
 
Source Protein Abbreviation Sequence 
VV Nonstructural protein A11R198-206 A11R AIVNYANL 
VV E7R130-137 E7R STNLFNNL 
LCMV Glycoprotein34-41 GP34 AVYNFATMa
LCMV Nucleoprotein205-212  NP205 YTVKYPNL 
- Designed sequence SIY SIYRYYGL 
- Ovalbumin257-264 OVA SIINFEKL 
- Designed sequence OVA-AA SIINFAAL 
- Designed sequence OVA-AT SIINFATL 
a This peptide carries a C-terminal Met -> Cys mutation relative to the native LCMV 
sequence.  The substitution has been used in previous studies (Achour, Michaelsson et al. 
2002; Khanolkar, Fuller et al. 2004) and does not have a significant impact on interaction 
with MHC or T cell receptors.   
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To determine if VV-A11R is recognized in vivo in acute LCMV-infected mice, 
we set up an in vivo cytotoxicity assay using uninfected mice as controls.  Briefly, 
splenocytes from syngeneic B6 mice were isolated, peptide-pulsed and then 
fluorescently-labeled with different dilutions of carboxyfluorescein succinimidyl ester 
(CFSE) and a constant concentration of 7-hydroxy-9H-(1,3-dichloro-9,9-dimethylacridin-
2-one) (DDAO) to monitor the target cell populations.  The peptide-pulsed, DDAO- and 
CFSE-double labeled target populations were then injected intravenously into either acute 
LCMV-infected mice or uninfected controls.  The cytolytic response was monitored by 
flow cytometry 3 hours after injection.  Flow cytometry data from a representative mouse 
is shown in Figure III.1B, with percent specific lysis calculated for 5 mice plotted in 
Figure III.1C.  The results show that cells from LCMV-infected mice can specifically 
lyse both VV-A11R and LCMV-GP34 peptide-pulsed targets in vivo (Figure III.1B).  
Killing was not observed in naïve mice, and background killing levels were observed 
with the non-cross-reactive peptide VV-E7R (Figure III.1B). These data clearly show that 
LCMV infection generates a specific T cell population which is cross-reactive in vivo 
against VV-A11R.   
To study the cross-reactive T cell response specifically between VV-A11R and 
LCMV-GP34, we generated cross-reactive T cell lines, which were tested for TCR 
specificity using an ICS assay.  From an LCMV-immune mouse, we generated a VV-
cross-reactive T cell line (TCL), which was cross-reactive for LCMV-GP34 and VV-
A11R (TCL #1). We also generated non-cross-reactive TCL, also from an LCMV-
immune mouse, responding to VV-A11R only (TCL #2) for use as a control.  We 
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performed ICS assays to show specific crossreactivity between VV-A11R and LCMV-
GP34.  For the ICS assay, the peptides utilized were VV-A11R, LCMV-GP34 and the 
control peptides SIY and OVA.  The results indicate that nearly the entire (97%) memory 
CD8+ T cell population in the cross-reactive TCL #1 produces IFNγ in response to the 
VV-A11R peptide (Figure III.1D).  In response to the LCMV-GP34 peptide, 23% of 
these T cells produce IFNγ, which was not observed in the VV-A11R singly-reactive 
TCL #2.  Because essentially the entire T cell population in TCL #1 reacts against VV-
A11R, any T cells that are reactive against VV-A11R must therefore also be cross-
reactive against LCMV-GP34.   
To test for the presence of cross-reactive TCRs, we designed a MHC tetramer 
competition experiment using the GP34-A11R cross-reactive TCL (TCL #1) and used the 
A11R singly-reactive TCL (TCL #2) as a control.  For the MHC tetramer competition 
assay, we utilized a fixed concentration of 125 nM LCMV-GP34 tetramer and 2-fold 
dilutions of VV-A11R tetramer ranging from 125 nM down to 8 nM (Figure III.1E,F).  
We reasoned that if cross-reactive TCRs are present in the cross-reactive TCL, the 
binding of the VV-A11R tetramer would alter the binding of the LCMV-GP34 tetramer, 
due to tetramer competition for the same pool of cross-reactive TCRs.  However, if two 
non-cross-reactive TCRs are present, the binding of LCMV-GP34 tetramer and the VV-
A11R tetramer would be mutually exclusive, due to two different populations of cell 
surface TCRs.  In this experiment, the LCMV-GP34 tetramer was prepared using 
streptavidin coupled to R-phycoerythrin (PE) with the VV-A11R tetramer prepared using 
streptavidin coupled to allophycocyanin (APC) so that binding of both tetramers could be 
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monitored simultaneously.  The overall MHC tetramer binding MFI for APC-A11R 
(A11R+) versus PE-GP34 (GP34+) is plotted in Figure III.E.  The arrows represent two 
representative FACs plots for 8 nM APC-A11R or 125 nM APC-A11R versus the fixed 
amount of 125 nM PE-GP34 (shown in Figure III.1F).  With increasing concentrations of 
the APC-A11R tetramer, specific GP34 tetramer staining of the cross-reactive TCL (#1) 
decreased (Figure III.1E, top panel), whereas the specific GP34 tetramer staining was not 
observed at any concentration of APC-A11R tetramer (Figure III.1E, bottom panel). This 
demonstrates the presence of cross-reactive TCRs on the cross-reactive TCL (#1) which 
dually recognizes VV-A11R and LCMV-GP34. 
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Figure III.1.  VV-A11R and LCMV-GP34 are Cross-reactive CD8+ T cell Epitopes 
Elicited by LCMV Infection. A. CD8+ T cells from acute day 8 LCMV-infected mice 
(n=15) and uninfected mice (n=3) were isolated and analyzed for IFNγ production using 
an ICS assay, with results from a representative mouse presented as dot plots. B+C. A 
four peak in vivo cytotoxicity assay was set up using two different fluorophores as 
described in the materials and methods.  Briefly, naïve B6 splenocytes were peptide-
pulsed and then labeled with a dilution of CFSE and DDAO.  Peptide-pulsed, and CFSE 
and DDAO double-labeled cells were injected (i.v.) into uninfected (naïve, n=3) or 
LCMV-infected (D8 LCMV, n=5) mice.  Three hours after transfer, spleens were 
harvested and analyzed by flow cytometry.  Plots from a representative infected and 
naïve mouse are shown in b.  Percent specific lysis was calculated based on the “SIY” 
peptide-pulsed population and plotted in c. D. Splenocytes from an LCMV-immune 
mouse were isolated and expanded in vitro using VV-A11R peptide-pulsed targets to 
generate a GP34-A11R cross-reactive T cell line (TCL #1) and an A11R singly-reactive 
T cell line (TCL #2).  T cell lines were analyzed for IFNγ production in response to the 
indicated peptides, with the results presented as dot plots.  The results are representative 
of three different T cell lines. E+F. The T cell lines from panel d were stained with R-PE 
or APC-labeled streptavidin-based Kb tetramers folded with VV-A11R or LCMV-GP34 
peptides.  Double MHC tetramer staining experiments were set up using a PE-labeled 
LCMV-GP34-Kb tetramer and an APC-labeled VV-A11R-Kb tetramer.  The VV-A11R 
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tetramers were used at concentrations starting at 125 nM titrated down two-fold to 8 nM 
while the LCMV-GP34 tetramer concentration was maintained constant at 125 nM.  The 
percent tetramer positive for every concentration is plotted in f.   
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III.C.2. Recognition Determinants for the Cross-reactive T cells 
To further characterize the cross-reactive T cell responses between LCMV-GP34 
and VV-A11R, we compared the recognition determinants for LCMV-GP34 and VV-
A11R individually.  We reasoned that a comparison of the important TCR contact 
residues for both epitopes would highlight similarities and differences in recognition 
determinants, which might hint at the mode(s) of TCR engagement.  Alanine 
substitutions were generated at the predicted non-MHC binding residues (underlined) in 
LCMV-GP34 (AVYNFATM) and VV-A11R (AIVNYANL).  Peptide binding to MHC 
class I H-2Kb depends on the peptide positions 5 (P5) and 8 (P8) as primary anchors, and 
peptide positions 2 (P2) and 3 (P3) as secondary anchors (Fremont, Matsumura et al. 
1992; Matsumura, Fremont et al. 1992).  We modified the other positions and included 
the P3 secondary anchor position, in order to test the potential TCR contact residues. 
Residues with alanines present already were mutated to either glycine for a conservative 
substitution or to lysine for a non-conservative substitution.  The substituted peptides 
were first tested for binding to Kb by using an RMA-S stabilization assay, and the EC50 
values for peptide binding were plotted (Figure III.2). We observed that the substituted 
LCMV-GP34 and VV-A11R peptides do not bind significantly different from the WT 
peptides (Figure III.2), with the exception of the P3A variants, which were not utilized 
further. 
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Figure III.2. Mutated Peptides from LCMV-GP34 and VV-A11R Bind to H-2Kb 
with Similar Affinities with the Exception of the P3A variants. An RMA-S 
stabilization assay was utilized to measure relative binding affinity of WT and variant 
peptides from LCMV-GP34 and VV-A11R.  EC50 values were calculated for each 
peptide titration series (n=3) and represented as bar graphs.   
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Next, we performed an ICS assay to test the substituted peptides from LCMV-
GP34 and VV-A11R for reactivity with T cells from acutely LCMV-infected mice.  Flow 
cytometry data from a representative mouse are shown for the LCMV-GP34 and VV-
A11R peptide variants in Figure III.3A and Figure III.3B, respectively.  Relative T cell 
responses, which are the proportion of IFNγ responses to WT GP34 or A11R controls, 
from 15 mice are shown in Figure III.3C and Figure III.3D, for the LCMV-GP34 and 
VV-A11R peptide variants, respectively.  Substitutions in LCMV-GP34 at the P4N, the 
P6A and the P7T residues resulted in loss of IFNγ production (Figure III.3A,D).  For 
LCMV-GP34 P6A, substitution by lysine (P6K) blocked T cell recognition but 
substitution by glycine (P6G) did not, which suggests that the P6A side chain is not a 
direct TCR contact (Figure III.3B,D).  As for the cross-reactive ligand VV-A11R, a 
different pattern was observed, where substitution at the P1, P4 and P6 but not P7 
positions resulted in loss of IFNγ production (Figure III.3C,E).  For VV-A11R P1A, 
substitution by lysine (P1K) but not glycine (P1G) reduced T cell recognition, suggesting 
that for this peptide the P1A side chain is not directly involved in T cell recognition 
(Figure III.3C,E).  For LCMV-GP34, substitutions at this position had no effect.   For the 
VV-A11R P4N, substitution by alanine (P4A) blocked recognition, as it did for LCMV-
GP34.  The shared recognition determinant at P4 suggests that cross-reactive TCRs 
utilize this residue for T cell responses. At P6, both VV-A11R P6G and P6K substitution 
resulted in decreased IFNγ production, differently from LCMV-GP34 where the P6G 
mutation had no effect.  Finally, the VV-A11R P7 residue was not important for IFNγ 
production on average, but there was a broad range of reactivity amongst the different 
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mice tested.  In summary, cognate recognition of LCMV-GP34 is dependent on P4N and 
P7T whereas cross-reactive recognition of VV-A11R depends mainly on P4N.   
To determine whether the P4 and the P7 residues are required for the cross-
reactive recognition of VV-A11R in vivo, we performed a dual label in vivo cytotoxicity 
assay as described in the methods, utilizing dilutions of CFSE and DDAO for target cells 
pulsed with the GP34 variants or dilutions of CFSE and Celltrace violet for cells pulsed 
with the A11R variants (Figure III.3E,F).  Flow cytometry data from a representative 
naïve mouse and LCMV-infected mouse is shown in Figure III.3E, with percent specific 
lysis calculated for 7 LCMV-infected mice plotted in Figure III.3F. We asked if CD8+ T 
cells from acute LCMV-infected mice could specifically lyse WT, P4A and P7A variants 
of LCMV-GP34 and VV-A11R, using the non-cross-reactive peptides OVA and SIY as 
controls.  The P4A substitution in VV-A11R resulted in a log reduction in percent 
specific lysis (Figure III.3F), showing that T cells which crossreact with VV-A11R from 
LCMV-infected mice require the P4N in VV-A11R for specific lysis in vivo.  These 
functional data demonstrate that P4N is a major recognition determinant that is required 
for the polyclonal LCMV-cross-reactive T cell response against VV-A11R.  To confirm 
that cross-reactive T cell responses towards VV-A11R are not unique to one T cell clone, 
we evaluated the T cell receptor repertoire from LCMV-infected mice that respond 
towards VV-A11R (Figure III.4). A polyclonal response including at least six different 
TCRβ genes was observed, which indicates that the polyclonal, cross-reactive T 
responses towards VV-A11R require the P4N as a major recognition determinant.   
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Figure III.3.  Recognition Determinants for Cross-reactive T cells.  Recognition 
determinants for CD8+ T cell responses against VV-A11R and LCMV-GP34 were 
mapped by mutational analysis.  Non-H-2Kb binding residues from LCMV-GP34 and 
VV-A11R, which include p1, p4, p6 and p7, were mutated to alanine, with alanine 
residues mutated to either glycine or lysine.  A+B. CD8+ T cells from acute LCMV-
infected mice were tested for IFNγ production in response to 1 µM of the indicated 
peptides with representative results from a single mouse shown as dot plots (n=15).   
C+D.  IFNγ production results from acute LCMV-infected mice (n=15) were normalized 
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to WT LCMV-GP34 for the LCMV-GP34 variants or WT VV-A11R for the VV-A11R 
variants.  E+F.  To test the necessary contact residues at p4 and p7 in vivo, an eight peak 
cytotoxic T lymphocyte assay was set up like previously described in Figure III.1.  
Briefly, the 8 peak assay was split into two simultaneous four peak assays using dilutions 
of either CFSE vs. DDAO or CFSE vs. violet as described in the Materials and Methods.  
Target cell populations were injected (i.v.) into acute LCMV-infected mice (n=7) or 
uninfected mice (n=3). Percent specific lysis in panel f was calculated based on either the 
“SIY” peptide-pulsed population or the “OVA” peptide-pulsed population.   
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Figure III.4.  Acute LCMV-infected mice have a Polyclonal Cross-reactive T cell 
Response towards VV-A11R.  CD8+ T cells from acute LCMV-infected mice (n=15) 
were stained with VV-A11R tetramer and TCR Vβ antibodies.  The percentage of TCR 
Vβ utilized for the recognition of VV-A11R tetramer is plotted.    
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Although a clear role for the P4N in LCMV-cross-reactive T cell responses 
against VV-A11R was observed in vivo, the experiments reported in Figure III.3 used 
highly polyclonal populations, making it difficult to evaluate the contribution of cross-
reactive TCRs relative to recognition by different T cell populations.  Therefore, we 
tested for the P4N dependence on cross-reactive T cell lines that have narrowed T cell 
receptor repertoires due to repeated in vitro expansion (results from previous in vitro 
expanded TCLs, see Figure III.5).  We performed ICS assays followed by tetramer 
staining assays using the P4A and P7A variants of both LCMV-GP34 and VV-A11R.  
For both assays, we tested the variant peptides on an LCMV-GP34 and VV-A11R cross-
reactive T cell line (TCL #3) and used a VV-A11R singly-reactive T cell line (TCL #2) 
as a control. The results of the ICS assay show that for the cross-reactive TCL #3, IFN 
production in response to LCMV-GP34 was dependent on both P4N and P7T, while 
recognition of the VV-A11R was dependent only on P4N (Figure III.6A), consistent with 
the in vivo results.  In contrast, for the VV-A11R singly-reactive T cell line (TCL #2), 
recognition of VV-A11R was dependent on both P4N and P7N.   
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Figure III.5.  Cross-reactive T cell lines have Narrowed TCR Repertoires.  TCR Vβ 
profiling of CD8+ T cells from a GP34-A11R cross-reactive TCL (TCL #1) was 
performed.   Briefly, CD8+ T cells from TCL#1 were stained with TCR Vβ antibodies 
purchased from BD Pharmingen.  The percentage of TCR Vβ expressed is plotted.    
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For the tetramer staining assay, we monitored binding of LCMV-GP34 WT, VV-
A11R WT, VV-A11R P4A, and VV-A11R P7A or control OVA tetramers on the 
LCMV-GP34 and VV-A11R cross-reactive (TCL #3), and  VV-A11R singly-reactive 
(TCL #2) T cell lines (Figure III.6B).  The tetramer staining patterns paralleled the results 
from the ICS assay.  The GP34-A11R cross-reactive TCL #3 stains with WT GP34, WT 
A11R and A11R P7A tetramers, while the A11R singly-reactive TCL #2 stains only with 
the WT A11R tetramer (Figure III.6B).  Taken together, these results show that cross-
reactive TCRs that recognize LCMV-GP34 depend on the P4N for the cross-reactive 
recognition of VV-A11R. 
Using the notion that the LCMV-cross-reactive T cell response directed towards 
VV-A11R is dominated by the P4N, we hypothesized that an increased LCMV-GP34, 
VV-A11R, cross-reactive T cell response would correspond with an increased 
dependence on the P4N.  To address this, we used the GP34-A11R cross-reactive T cell 
line from Figure III.1 (TCL #1), which was nearly 100% reactive towards VV-A11R, and 
we selectively expanded the population that also recognizes LCMV-GP34 (23%) by 
stimulating in vitro with the LCMV-GP34 peptide for two additional passages (TCL #1-
GP34, Figure III.6C, left panel).  For comparison, we stimulated the same T cell line 
using the VV-A11R peptide for two additional passages (TCL #1-A11R, Figure III.6C, 
right panel).  We tested for functional responses by performing an ICS for IFNγ 
production in response to WT, P4A or P7A variants of the LCMV-GP34 or the VV-
A11R peptides, with OVA used as a control (Figure III.6C).  Cross-reactive T cells 
stimulated with A11R only responded to LCMV-GP34 WT (~25%, plain bars), VV-
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A11R WT (~100%, horizontally striped bars) and VV-A11R p7A (~25%, vertically 
striped bars).  After the same TCL was expanded in vitro with the LCMV-GP34 peptide 
to select for the LCMV-GP34 and VV-A11R cross-reactive T cells, we observed an 
increase in IFNγ production in response to LCMV-GP34 WT and VV-A11R P7A. By 
skewing the T cell response in favor of LCMV-GP34 reactivity in this entirely VV-A11R 
cross-reactive TCL, we observed a proportional decrease in the dependence on the P7 
residue in the VV-A11R peptide.  These results indicate that VV-A11R cross-reactive T 
cells that respond towards LCMV-GP34 do not require the P7 residue.   
106 
 
 
 
 
Figure III.6. Recognition Determinants for GP34-A11R Cross-reactive T cell 
receptors.  GP34-A11R cross-reactive (TCL #3) and A11R singly-reactive (TCL #2) T 
cell lines were generated as described for Figure III.1.  A.  Cross-reactive T cell lines 
were tested for IFNγ production against WT, p4A or p7A variant peptides from LCMV-
GP34 and VV-A11R along with the control-peptide, OVA.  The results are represented as 
dot plots and are representative of three independent experiments.  B.  Single MHC 
tetramer staining experiments were performed on both the GP34-A11R cross-reactive 
(TCL #3) and the A11R singly-reactive (TCL #2) T cell lines.  Briefly, WT LCMV-
GP34, VV-A11R (WT, p4A, p7A) and control-OVA peptide-MHC tetramers were tested 
at 125 nM with the results represented as histograms.  In each histogram, the indicated 
tetramer (blue trace) was overlaid with the control-OVA tetramer (red trace). C.  The 
GP34-A11R cross-reactive T cell line from Figure III.1 (TCL #1) was re-stimulated in 
vitro using LCMV-GP34 peptide-pulsed targets, to selectively expand the GP34-A11R 
cross-reactive population (TCL #1 - GP34).  For comparison, TCL #1 was also re-
stimulated in vitro using VV-A11R peptide-pulsed targets (TCL #1 - A11R).  After two 
rounds of stimulation, CD8+ T cells were analyzed for IFNγ production in response to 
WT, P4A and P7A variants of both LCMV-GP34 peptide and VV-A11R peptide along 
with the control-OVA peptide.  The data is represented in the bar graph.   
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To address whether cross-reactive TCR recognition could also depend on contacts 
with the H-2Kb molecule, we tested previously identified LCMV- and VV-derived Kb 
epitopes which have the same important P4N or the P7 residue with either LCMV-GP34 
or VV-A11R (Table III.2).  These peptides have all been tested for T cell responses in 
ICS assays, which measured IFNγ production on T cells from either acutely LCMV-
infected mice or GP34-A11R cross-reactive TCLs.  Cross-reactive T cell responses have 
not been observed with any of these peptides (data not shown),  indicating that the shared 
aspects leading to cross-reactive T cell responses depend predominantly on peptide 
contacts with TCR.  This result highlights the importance of the P4N that is shared 
between LCMV-GP34 and VV-A11R. 
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Table III.2.  Tested Kb-binding epitopes which share either the P4N residue or the 
P7 residue with LCMV-GP34 or VV-A11R 
 
Source Protein Sequence 
VV E7R130-137 STNLFNNL 
VV A3L270-277 KSYNYMLL 
LCMV Nucleoprotein205-212 YTVKYPNL 
LCMV Glycoprotein118-125 ISHNFCNL 
LCMV L775-782 SSFNNGTL 
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III.C.3.Analysis of the Kb-VV-A11R and Kb-LCMV-GP34 Molecular Surfaces 
To understand the dependence of P4N for cross-reactive T cell recognition, we 
determined the crystal structures of Kb-VV-A11R (PDB ID# 3TIE) and Kb-LCMV-GP34 
(PDB ID# 3TID) complexes, using data extending to 2.2Å and 1.7Å resolution 
respectively (Table III.3).  The overall structures of Kb-VV-A11R and Kb-LCMV-GP34 
differ very little with an RMSD of 0.472 Å.  A side profile comparison of the antigen 
binding cleft from Kb-VV-A11R and Kb-LCMV-GP34 reveal that both VV-A11R and 
LCMV-GP34 are bound and presented similarly in Kb (Figure III.7A,B).  Both peptides 
at P4 and P7 have solvent exposed side chains, which protrude away from the Kb heavy 
chain and are available for TCR contact (Figure III.7A,B).  The main chain at P6 also 
appears solvent accessible, while side chains at P2, P3, P5 and P8 are buried in the Kb 
molecule (Figure III.7A,B).  In the top views of Kb-VV-A11R and Kb-LCMV-GP34 
(Figure III.7D,E), it is clear that most of the surfaces of LCMV-GP34 and VV-A11R are 
virtually identical when presented by Kb, particularly at the asparagine at P4, which 
appears to be in the same conformation (Figure III.7G).  The P7 side chain is a notable 
exception, with differences clearly observed when the Kb-VV-A11R and the Kb-LCMV-
GP34 structures are overlaid (Figure III.7G).   
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Table III.3.  Data Collection and Refinement Statistics for Kb-GP34 and Kb-A11R 
 
Data Collection K
b-LCMV-GP34 
(AVYNFATM) 
Kb-VV-A11R 
 (AIVNYANL) 
Space group C2 P21 
Wavelength 1.0809 1.0809 
Unit cell parameters a= 172.261, b= 47.649, c= 70.539  Å,  = 106.39° 
a= 69.264  , b= 84.710 , c= 
87.895   Å, = 98.12° 
Resolution (Å) 50-1.7 50-2.2 
Rsym (%) 5(26) 10(28) 
I/sI 22.1 (7.8) 15.1 (5.7) 
Completeness (%) 98 (96.7) 99.4 (99.3) 
Redundancy 3.8 (3.8) 6.2 (6.3) 
Refinement 
Resolution (Å) 40-1.7 40-2.2 
No. reflections 59,404 50,967 
Rwork/Rfree (%) 0.167/0.190 0.177/0.219 
No. atoms   
    Protein 3081 6160 
    Water 665 464 
Average B-factor (A2) 20.7 37.4 
R.M.S. Deviations   
    Bond length (Å) 0.006 0.008 
    Bond angles (o) 1.036 1.054 
Ramachandran Plot   
    Most favored (%) 98.9 98.5 
    Allowed (%) 1.1 1.4 
   Disallowed (%) 0 0.1 
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As a comparison, we overlaid the previously reported crystal structure of the 
highly defined and studied Kb-OVA, which was not recognized by T cells cross-reactive 
with LCMV-GP34 or VV-A11R.  Similar to the Kb-LCMV-GP34 and the Kb-VV-A11R 
structures, the OVA peptide has solvent accessible side chains at P4, P6 and P7, whereas 
the P2, P3, P5 and P8 residues are all buried in Kb (Figure III.7C). The Kb-OVA surface 
appears quite different than those of Kb-LCMV-GP34 and the Kb-VV-A11R, with bulky 
side chains placed at P6 and P7.  These might sterically inhibit interactions with the TCR 
(Figure III.7F,H).  Furthermore, the P4N, which is shared by all the peptides in OVA, 
adopts a different rotamer as compared to VV-A11R and LCMV-GP34 (Figure III.7F,H).  
The combination of the bulky side chains at P6 and P7 with the P4N in a different 
conformation may help to explain the absence of a cross-reactive T cell response towards 
OVA.  In summary, the structures of Kb-VV-A11R and Kb-LCMV-GP34 have markedly 
similar surfaces for TCR recognition and contrast greatly with that of Kb-OVA.   
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Figure III.7.  Analysis of the Kb-VV-A11R and Kb-LCMV-GP34 Molecular 
Surfaces.  A-C.  The peptide-MHC structures of Kb-VV-A11R198-206, Kb-LCMV-GP34-41, 
and Kb-OVA257-264 (PDB ID# 1VAC) are shown from a side profile view.  In each panel, 
the peptide is represented as a stick model, while the H-2Kb molecule is represented by 
its surface.  Residues T143, K144, K146, W147, A150, G151, E152, R155, L156, A158, 
Y159, T163, and C164 from H-2Kb are excluded.  D-F.  The peptide-MHC structures of 
Kb-VV-A11R198-206, Kb-LCMV-GP34-41, and Kb-OVA257-264 (PDB ID# 1VAC) are 
represented as surfaces and viewed from above.  The peptides are colored magenta for 
VV-A11R198-206, cyan for LCMV-GP34-41 and yellow for OVA257-264 with the H-2Kb 
molecule shown in grey.  The residues in the peptide are labeled as “P” followed by the 
peptide position.  G.  The peptide-MHC structures of Kb-VV-A11R198-206 and Kb-LCMV-
GP34-41 have been overlaid for comparison.  The presented view is looking down towards 
the N terminus of the peptide.  The peptide in each structure is represented as stick model 
and colored using the same coloring scheme used in a-c, while the H-2Kb molecule is 
shown as cartoon and colored grey.  H.  The peptide-MHC structures of Kb-OVA257-264 
and Kb-LCMV-GP34-41 have been overlaid for comparison using the same view from f.  
Pymol was used to generate all the images.   
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III.C.4. Skewing of Cross-reactive T cell Responses against VV-A11R and LCMV-
GP34 
The functional and structural data presented thus far support the idea that the 
cross-reactive T cell response against VV-A11R is dominated by the P4 asparagine.  We 
hypothesized that VV-A11R cross-reactive T cell responses would be selected against by 
in vitro stimulation with a P4A variant which lacks the important asparagine contact.  To 
test for this, we generated T cell lines from three LCMV-immune mice (Figure III.8A) 
and expanded them in vitro using either the LCMV-GP34 WT peptide or the LCMV-
GP34 P4A mutant peptide (TCLs #4,5,6).  In each case, expansion with the LCMV-GP34 
P4A peptide selects against a cross-reactive VV-A11R T cell response.  Interestingly, the 
cognate response towards LCMV-GP34 was maintained, perhaps through selecting for T 
cells which recognize the P7T residue.     
Next, we wanted to utilize the requirement for the P4N in our system to generate a 
novel cross-reactive T cell response.  To address this, we utilized the OVA peptide, 
which contains a P4N, but has never been found to be cross-reactive.  Our structural 
analysis suggests that the cross-reactive T cell response against OVA might be absent 
because of the bulky residues at P6 and P7 in OVA (SIINFEKL), which might sterically 
inhibit TCR docking.  To address this, we generated OVA variants with the P6 and P7 
residues from LCMV-GP34 (OVA-AT, SIINFATL), or with both P6 and P7 as alanines 
(OVA-AA, SIINFAAL).  We performed an ICS assay on a GP34-A11R cross-reactive T 
cell line (TCL #7) to test for the recognition of VV-A11R, LCMV-GP34, OVA, OVA-
AA and OVA-AT (Figure III.8B).  The results show that while the native OVA peptide 
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does not crossreact, 41% of the CD8+ T cells respond towards the modified OVA-AT 
peptide (Figure III.8B).  Because >90% of T cells respond to both VV-A11R and LCMV-
GP34, most cells that respond against VV-A11R or LCMV-GP34 must also crossreact 
against OVA-AT.  Interestingly, we found that OVA-AA is not cross-reactive, indicating 
that the cross-reactive recognition of OVA-AT requires the P7T.  Because the hybrid 
OVA peptides have not been reported previously, we needed to exclude the possibility 
that these cross-reactive responses were unique to our in vitro T cell line.  To test if the 
hybrid OVA peptides could be recognized ex vivo, we performed an ICS assay on 
splenocytes from acute-LCMV infected mice or naïve mice as controls (Figure III.8C).  T 
cell responses were observed towards the OVA-AT peptide, with IFNγ production 
measured at ~3%.  T cell responses were not observed towards the OVA-AA peptide, 
matching the results in vitro from the GP34-A11R cross-reactive TCL (Figure III.8D).  T 
cell responses towards VV-A11R (~2%) and LCMV-GP34 (~10%) were elevated, but 
within the range that has been previously observed (data not shown). Taken together, 
these results highlight the pervasive nature of cross-reactive T cell responses, as even the 
null OVA peptide can be made cross-reactive simply through substitution of side chains 
that may inhibit TCR engagement.  
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Figure III.8.  Skewing of Cross-reactive Responses against both VV-A11R and 
LCMV-GP34. A.  T cell lines (TCL #4,5,6) were generated using the splenocytes from 
three LCMV-immune mice. T cells were expanded in vitro for four passages by 
stimulation with either WT-GP34 or GP34 p4A peptide-pulsed targets.  T cell lines were 
analyzed for IFNγ production in response to VV-A11R peptide, LCMV-GP34 peptide 
and OVA peptide with the results presented as dot plots.  B.  Cross-reactive T cell lines 
were tested for IFNγ production against LCMV-GP34, VV-A11R, OVA or the OVA 
hybrid peptides, OVA-AA and OVA-AT.  The results are represented as dot plots and are 
representative of three independent experiments.  C.  CD8+ T cells from acute LCMV-
infected mice (n=3) or uninfected mice (n=2) were tested for IFNγ production in response 
to 1 µM of the indicated peptides with the results presented in the graph.    
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III.D. Discussion 
Protective heterologous immunity plays an important role in the immune 
response.  The ligand requirements for T cell recognition of disparate epitopes from 
unrelated pathogens are unclear.  In this study, we observed that LCMV-GP34 and VV-
A11R tetramers compete with each other for TCR.  This clearly indicates the presence of 
individually cross-reactive TCRs which can dually recognize both LCMV-GP34 and VV-
A11R (Figure 1E).  We compared the recognition determinants for LCMV-GP34 and 
VV-A11R by generating site-specific mutations in both epitopes at potential TCR contact 
residues.  We tested the mutated peptides for IFNγ production on either acute LCMV-
infected mice or cross-reactive TCLs and found different recognition patterns for LCMV-
GP34 and VV-A11R.  The cognate response towards LCMV-GP34 was dependent on the 
P4N and P7T, whereas the cross-reactive T cell response towards VV-A11R depended 
mainly on P4N.  Interestingly, we found that the P4A variant of VV-A11R protected 
against cytotoxic T cell responses in acutely LCMV-infected mice, in vivo.   Combined, 
our results clearly indicate that the P4N, which is shared between LCMV-GP34 and VV-
A11R, mediates the LCMV-cross-reactive T cell response towards VV-A11R  
Analysis of the Kb-LCMV-GP34 and Kb-VV-A11R crystal structures revealed 
that these cross-reactive peptide-MHC complexes have nearly identical surface 
structures, with the P4N conserved in both structures.  Structural mimicry was somewhat 
unexpected due to the sequence disparity between LCMV-GP34 (AVYNFATM) and 
VV-A11R (AIVNYANL), which share only three of eight residues (underlined).  
Consistent with overall structural similarity between Kb-LCMV-GP34 and Kb-VV-A11R, 
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which includes the conserved P4N, our functional data indicate that the P4N is an 
important recognition determinant that is shared for the cognate response towards 
LCMV-GP34 as well as the cross-reactive T cell response towards VV-A11R.  Using 
information about the requirement for P4N in the VV-A11R cross-reactive T cell 
response, we were able to selectively eliminate the VV-A11R cross-reactive T cell 
response while maintaining a non-cross-reactive cognate LCMV-GP34 T cell response by 
expanding T cells in vitro with the LCMV-GP34 P4A peptide.  Additionally, we were 
able to predict and generate a novel cross-reactive T cell response by simply substituting 
the P6 and P7 residues of the null OVA peptide.  These modifications probably facilitated 
recognition of the important P4N.  Collectively, our results highlight that shared aspects 
of the molecular surface formed by peptide-MHC complexes can be utilized for cross-
reactive T cell recognition.   These findings highlight the pervasive nature of cross-
reactive T cell responses, but more importantly, demonstrate that cross-reactive T cell 
responses can be controlled and even manipulated.  The ability to skew cross-reactive T 
cell responses in a specific manner highlights the potential for vaccine design.   
The CD8 memory population is not stable in vivo, as infections with cross-
reactive viruses can elicit expansions of subsets of the antigen specific memory pool and 
result in memory pools with altered affinities to and protective capacities against the first-
encountered pathogen (Cornberg, Chen et al. 2006; Chen, Cornberg et al. 2012). This is 
an important issue to evaluate when designing vaccines against viruses known to have 
highly mutable epitopes or epitopes cross-reactive with other pathogens. Of note, we 
have shown that altering the epitope used in an ICS assay by a peptide substitution can 
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sometimes lead to a much higher T cell response to that epitope, indicating that a cross-
reactive response may sometimes be more detectable and effective than the response to a 
homologous peptide.  Thus, by understanding the parameters of cross-reactivity one 
might be able to construct a vaccine with an altered peptide that would stimulate an 
improved response against the desired targeted epitope.   
In conclusion, the results presented in this study highlight the pervasive nature of 
cross-reactive T cell responses.  A detailed understanding of the LCMV-GP34 and VV-
A11R cross-reactive T cell response revealed that the shared P4N residue is utilized for 
cross-reactive TCR recognition.  Using our understanding of this system, we were able to 
selectively eliminate VV-A11R cross-reactive T cell responses or generate novel cross-
reactive T cell responses to a variant of the OVA peptide.  A better mechanistic 
understanding of protective heterologous immune responses is needed to improve vaccine 
design strategies.   
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Chapter IV:   
Conclusions and Future Directions 
 
The work presented in this thesis was directed at understanding the molecular 
mechanisms of CD8+ T cell recognition and cross-reactivity.  Chapter II described the 
development of bi-specific MHC heterodimers and its advantages as a staining reagent 
for cross-reactive CD8+ T cells.  Chapter III described the molecular mechanism of a 
cross-reactive CD8+ T cell response that occurs between LCMV-GP34-41 and VV-
A11R198-205.  In this chapter, I will provide additional discussion, overall conclusions and 
future directions for the results presented.   
 
IV. A. The Bi-specific MHC Heterodimer  
 The results in Chapter II describe a novel bi-specific MHC heterodimer approach, 
which can be used to monitor cross-reactive T cells capable of recognizing two different 
peptide-MHC complexes.  Conventionally, MHC tetramers are used for phenotypic 
characterization of T cells.  However, when we first employed two MHC tetramers to 
identify cross-reactive T cells, we observed MHC tetramer cross-competition.  The cross-
competition between the MHC tetramers indicates that individually-cross-reactive TCRs 
are capable of recognizing both LCMV-GP34 and VV-A11R, which disproves the notion 
that expression of two different TCRs on a single cell (Hardardottir, Baron et al. 1995; 
He, Janeway et al. 2002) underlies the cross-reactive T cell response between LCMV-
GP34 and VV-A11R.  In the scenario where two different TCRs could be expressed on 
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the surface of a single T cell, the binding of the two different MHC tetramers would be 
mutually exclusive.   
The observation that two MHC tetramers compete for cross-reactive TCRs, 
resulting in reduced tetramer staining for the lower affinity peptide-MHC and TCR 
complex, complicates the use of MHC tetramers for the identification of cross-reactive T 
cells.  However, the observed MHC tetramer competition can be avoided.  For example, 
if the concentrations of the two tetramers were titrated, it could be possible to use two 
MHC tetramers to identify cross-reactive T cells.  While this is feasible for 
experimentation on cross-reactive T cells from in vitro T cells lines with relatively large 
numbers of cells to perform titration experiments, the numbers of T cells from human 
samples are much more limited.  Additionally, due to the polyclonal nature of T cell 
responses, the avidities between different TCRs may vary, which would make MHC 
tetramer titration experiments a necessity for each and every experiment targeted at 
visualizing cross-reactive T cells.  Therefore, we developed bi-specific MHC 
heterodimers through heterobifunctional cross-linking.  We observed that our 
heterobifunctional cross-linking strategy does not perturb the integrity of the peptide-
MHC complex or its interaction with TCR.  Most importantly, our bi-specific MHC 
heterodimers were found to be specific for T cells that have individual TCRs which are 
cross-reactive for LCMV-GP34 and VV-A11R.   
There were some issues with the heterobifunctional cross-linking strategy, which 
have not been mentioned.  As previously noted, we observed that the cross-linker-
modified peptide-MHC monomers were particularly sensitive to side reactions, especially 
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upon storage.  In addition to the tendency for the hydrazide-reactive cross-linker (MHPH) 
to self-react, we observed that the presence of the Alexa fluorophores prior to cross-
linking, induced non-specific dimerization.  This complicated our initial strategy, which 
was to uniformly label the peptide-MHC complexes with an amine-reactive Alexa 
fluorophore, followed by cross-linker addition onto the MHC monomers using a free 
thiol placed at the C-terminus of the MHC class I heavy chain.  Through trial and error, 
we discovered that the nonspecific dimerization did not occur if heterobifunctional cross-
linking preceded Alexa-labeling of the MHC monomers.  Despite the unexpected side 
reactions, we observed that the hydrazide moiety found on MHPH would preferentially 
react with the aldehyde of the MTFB cross-linker.   
To control for non-specific dimerization, we utilized “control” MHC heterodimers 
which consist of a cognate peptide-MHC monomer paired with a null peptide-MHC 
monomer.  In the scenario where self-dimerization should occur, a “homo”-dimer 
consisting of two MHPH-modified monomers or MTFB-modified monomers might be 
generated, which would appear as a single peak ~90 kDa on a gel filtration profile.  
While mass spectroscopy experiments clearly indicated the presence of both peptides in 
the bi-specific MHC heterodimer (Figure II.6), the precise amount of either peptide was 
unknown.  For example, within a single MHC heterodimer preparation, there could be 
some heterodimers formed by heterobifunctional cross-linking and some undesirable 
“homo”-dimers formed by nonspecific dimerization.  Freshly prepared recombinant 
MHC molecules have been found to release peptide, which can be re-presented by cell 
surface bound MHC molecules (Schott, Bertho et al. 2002).  A concern that pertains to 
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MHC heterodimers is that peptide from recombinant MHC complexes might be 
transferred between component MHC monomers within an MHC heterodimer and form 
undesired MHC “homo” dimers.  However, because staining is not observed from the 
“control” MHC heterodimers, we assume that peptide transfer is not an issue, perhaps 
due to the unstable nature of recombinant MHC Class I complexes, which dissociate in 
the absence of peptide (Garboczi, Hung et al. 1992).  In summary, the “control” MHC 
heterodimers served an important role in determining if any nonspecific “homo”-
dimerization was occurring. 
While the MHPH-MTFB cross-linking reaction is readily reproducible, the 
efficiency of this reaction was found to vary amongst different batches of either cross-
linker.  The reduced cross-linking efficiency jeopardizes the final yield of labeled MHC 
heterodimer, which complicates the use of the MHPH-MTFB cross-linking pair.  Ideally, 
a more efficient and bio-orthogonal reaction is more desirable.  A potential candidate is 
the alkyne-azide cross-linking pair, better known as a “click” reaction.  Recent studies 
have indicated that the “click” reaction is unprecedented in terms of specificity and bio-
orthogonality.   The rapid reaction rate combined with the absence of water hydrolysis 
greatly enhances the efficiency of the heterobifunctional cross-linking (Best 2009).  
Recently, iodoacetamide azide and iodoacetamide alkyne, two “click” cross-linkers 
became available commercially (Invitrogen), which can be readily conjugated onto MHC 
class I complexes through a free thiol at the C-terminus of the MHC class I heavy chain.   
In addition to the adaptation towards the “click” cross-linker reagents, which are 
currently underway, other systems of T cell cross-reactivity need to be evaluated.  For 
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example, humans infected with EBV-associated mononucleosis have T cells which cross-
react with influenza A virus (Clute, Watkin et al. 2005).  Additionally, T cells cross-
reactive between hepatitis C virus and influenza A virus have been found to influence the 
severity of HCV-induced liver pathology (Urbani, Amadei et al. 2005).  The adaptation 
of the bi-specific MHC heterodimer in these systems may help to better clarify the 
precise role of cross-reactive T cells.  A feasible experiment could be to use the MHC 
heterodimer to deplete cross-reactive T cells, in order to evaluate the effect of depletion 
on the immune response.  Similar work with the depletion of regulatory T cells has been 
done previously (Dietze, Zelinskyy et al. 2011).  Overall, the precise function of cross-
reactive T cells has been challenging to address, which is mostly attributed to the absence 
of viable reagents.   
 
IV.B. Generating T cell cross-reactivity 
For a conventional immune response, where T cells recognize foreign peptides 
presented by self-MHC molecules, there are three parameters that a useful T cell 
repertoire must fulfill in order to maximize reactivity towards foreign antigens.  An 
effective T cell repertoire must be able to recognize and respond towards a large variety 
of different peptide-MHC antigens so that pathogenic antigens will not go undetected; an 
effective T cell repertoire must be specifically geared towards foreign antigens; and the 
frequency of T cells reacting towards a foreign antigen must be sufficiently large in order 
to mount a rapid response (Wilson, Wilson et al. 2004).   In order to meet these criteria 
for an effective T cell repertoire, mathematical calculations estimate that a single T cell 
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should cross-react towards as many as 106 different peptide-MHC ligands (Mason 1998).  
It has been shown that only three to four different peptide residues are positioned to serve 
as TCR contact residues (Bjorkman, Saper et al. 1987; Fremont, Matsumura et al. 1992; 
Stern, Brown et al. 1994; Wilson, Wilson et al. 2004), which implies that any peptide 
containing these three to four residues might be cross-reactive.  Of the total possible 
nonamer peptides consisting of the 20 natural amino acids (209), upwards of 106 different 
peptides might contain such a sequence, which is in agreement with the mathematical 
estimates (Wilson, Wilson et al. 2004).    
The dynamics and the energetics of ligand-receptor interactions for T cells could 
further explain why T cell recognition is promiscuous.  The half life of TCR-MHC 
interactions are thought to be dictated by the off-rate, which has been reported to be 
largely dependent on TCR contact with the MHC alpha helices, without regard for the 
bound peptide (Wu, Tuot et al. 2002).  Furthermore, during selection, it has been found 
than an effective, but incomplete T cell repertoire can result from positive selection using 
a single thymic peptide (Ignatowicz, Kappler et al. 1996).  The resulting T cell repertoire 
is cross-reactive towards peptides that are unrelated in sequence to the single thymic 
peptide initially used during positive selection (Ignatowicz, Rees et al. 1997).    
On the structural level, it has been found that the overall peptide-MHC composite 
surface recognized by TCR encompasses almost 2500 square angstroms (Garcia 1999; 
Garcia, Teyton et al. 1999).  However, peptide-specific interactions comprise only 25% 
of this overall composite surface, whereas MHC-specific interactions comprise 75% 
(Garcia, Teyton et al. 1999).  Therefore, it’s likely that similar or perhaps even different 
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MHC alleles could adopt similar structures which might lead to promiscuous T cell 
recognition.   
In contrast to conventional T cell responses, there exist large subsets of T cells 
which recognize peptides in complex with MHC alleles that were not encountered during 
thymic development.  This mode of T cell recognition is commonly referred to as 
alloreactivity and is a clinical problem known as transplant rejection and graft versus host 
disease (Felix and Allen 2007).  Alloreactive T cells are found in 100-fold to 1,000-fold 
higher precursor frequencies as compared to the frequency of T cells specific for foreign 
antigens presented by self-MHC alleles (Suchin, Langmuir et al. 2001).   
While it may have been initially a surprise that alloreactive T cells are found in 
such high numbers, there is no process which selects against T cells from responding 
towards the hundreds of different MHC alleles that are not expressed by a given host.  
Furthermore, because 75% of the composite peptide-MHC surface recognized by TCR is 
based on interactions with MHC (Garcia, Teyton et al. 1999), structural similarities 
between different MHC molecules may lead to alloreactive T cell responses.  For 
example, it has been found that the specificity of alloreactive T cells is linked to 
polymorphisms in the MHC alpha helices which contact TCRs (Lombardi, Barber et al. 
1991).   
 
IV.C. Cross-reactive T cell responses toward LCMV-GP34-41 and VV-A11R198-205 
 The results in chapter III describe the molecular mechanism for the protective 
cross-reactive CD8+ T cell response between LCMV-GP34 and VV-A11R.  MHC 
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tetramer cross-competition experiments clearly indicate that the cross-reactive T cell 
response between LCMV-GP34 and VV-A11R is mediated by individually cross-reactive 
TCRs, capable of recognizing both ligands simultaneously (Figure III.1).  To address the 
mechanism for cross-reactive TCR engagement, the recognition determinants for LCMV-
GP34 and VV-A11R were compared by generating single site mutations in both epitopes, 
at the predicted TCR-contact residues.  The mutated peptides were tested in functional 
assays, which showed that the recognition determinants for LCMV-GP34 and VV-A11R 
differ both in the context of an acute LCMV infection (Figure III.5) and in GP34-A11R 
cross-reactive T cell lines (Figure III.6).  The cognate response towards LCMV-GP34 
was found to require both the P4 and P7 residues, while the cross-reactive T cell response 
towards VV-A11R largely required the P4N residue.  These results provide evidence that 
the shared P4N mediates the LCMV-cross-reactive T cell response towards VV-A11R.   
Given the sequence disparity between LCMV-GP34 and VV-A11R epitopes, 
which differ at 5 out of the 8 positions, structural mimicry was an unexpected explanation 
for the cross-reactive response.  However, analysis of the crystal structures of Kb-LCMV-
GP34 and Kb-VV-A11R revealed that the two complexes are structural mimics.  The 
residues which are most exposed in both structures were found at the P4 and the P7 
residues.  Not coincidentally, the P4N residue is identically placed in both structures with 
respect to MHC, such that the P4N from both structures can be overlaid on top of one 
another (Figure III.7).  Interestingly, the OVA peptide also contains a P4N (SIINFEKL), 
but cross-reactive T cell responses have never been observed towards OVA.  Other 
peptides sharing the P4N or the P7 residue from LCMV and VV were also tested and 
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found to be non-reactive in our system, suggesting that the cross-reactive T cell response 
between LCMV-GP34 and VV-A11R contains a unique recognition pattern that is not 
dependent on residues from the MHC molecule (Table III.4).   
Overlay of both Kb-LCMV-GP34 and Kb-VV-A11R structures with the previously 
reported Kb-OVA structure (Figure III.7) indicates that the P4N in OVA adopts a 
different rotamer as compared to our Kb-LCMV-GP34 and Kb-VV-A11R structures.  
Additionally, the overlay highlighted major structural differences at the P6 and P7 
residues, such that the OVA peptide contains a large glutamate residue followed by a 
lysine residue at P6 and P7, respectively.  In regard to cross-reactive TCR recognition, 
incorporation of a lysine at the P7 residue abrogated cross-reactive T cell responses 
(Figure III.5), which suggests that the bulky glutamate and lysine residues in OVA might 
inhibit binding of cross-reactive TCR.    
Interestingly, substitution of the P6 and P7 residues from LCMV-GP34 
(AVYNFATM) into a hybrid version of the OVA peptide (SIINFATL) generated cross-
reactive T cell responses in the context of a primary LCMV infection as well as in GP34-
A11R cross-reactive T cell lines.  The formation of cross-reactive T cell responses 
towards this hybrid OVA peptide suggests that the OVA peptide might share structural 
aspects necessary for cross-reactive TCR recognition.  Whether the P6 and P7 residues in 
the null OVA peptide inhibit LCMV-VV cross-reactive T cell responses towards the P4N 
or the P6 and P7 residues from LCMV- GP34 can sufficiently mediate LCMV-VV cross-
reactive T cell responses needs to be further examined.  Taken together, our results 
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highlight that shared structural features from two disparate peptide-MHC ligands from 
unrelated viruses can mediate heterologous immunity.     
The mode(s) by which a cross-reactive TCR can engage LCMV-GP34 and VV-
A11R is only speculative in the absence of the peptide-MHC-TCR co-crystal structures.  
Needless to say, the co-crystal structures of Kb-LCMV-GP34 and Kb-VV-A11R in 
complex with cross-reactive TCR is required and currently being pursued.  Nevertheless, 
our data clearly indicates that the P1, P6 and P7 residue requirements differ for TCR 
recognition of LCMV-GP34 and VV-A11R (Figure III.5), which reveals the manner by 
which cross-reactive TCRs might engage these ligands.     
If a co-crystal structure of cross-reactive TCR in complex with either Kb-LCMV-
GP34 or Kb-VV-A11R were available, I would expect two different possibilities for 
cross-reactive TCR engagement.  Cross-reactive TCR may bind the Kb-LCMV-GP34 and 
Kb-VV-A11R complexes using the same overall docking strategy as seen for 
conventional “diagonal” TCR engagement of peptide-MHC ligands (Garboczi, Ghosh et 
al. 1996; Garcia, Degano et al. 1996) or using two completely different binding modes, 
such that the TCR might be globally repositioned to engage one ligand as compared to 
the other.   
In the case where cross-reactive TCRs bind using the same overall docking 
strategy, cross-reactive TCR binding to LCMV-GP34 and VV-A11R may depend on the 
P4N and the P7T residues for recognition of LCMV-GP34 or the P4N and P1A residues 
for recognition of VV-A11R, with other peptide residues making less pronounced 
interactions contributing to TCR engagement.  In other words, specific interactions are 
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likely to occur at the residues, which have been found to be important TCR contacts, with 
other residues contributing minimally.  Alternatively, if cross-reactive TCRs utilize 
different binding modes for engaging Kb-LCMV-GP34 and Kb-VV-A11R, I would 
expect a repositioning of TCR in a manner that still allows TCR contact with the 
conserved P4N residue in both LCMV-GP34 and VV-A11R.  Cross-reactive TCRs might 
be seated over the p4N and the C-terminus of the LCMV-GP34 peptide, which correlates 
with the requirement of the P7T residue in recognition of LCMV-GP34 (Figure III.5).  
For VV-A11R, cross-reactive TCR might be seated over the N-terminus of VV-A11R in 
a manner that would contact the required P4N residue as well as the P1A residue, 
corresponding to the requirement of these residues for VV-A11R recognition (Figure 
III.5).   
In regard to isolating the cross-reactive TCR gene sequences, TCR Vβ repertoire 
analysis was performed on both TCL #1-A11R (Figure III.4) and TCL #1-GP34 (data not 
shown).  The results revealed that selecting for the LCMV-GP34 cross-reactive T cell 
population within the largely VV-A11R-reactive TCL enriched for the TCR Vβ 8.1 8.2+ 
population (data not shown).  The increase in LCMV-GP34 cross-reactivity following 
stimulation with LCMV-GP34 peptide correlated with an increase in the TCR Vβ 8.1 
8.2+ population (~80%) (data not shown).  It might be possible to isolate the TCR gene 
sequences from frozen vials of these GP34-A11R cross-reactive T cells (TCL #1-GP34), 
which could be clonal due to protracted expansion time in vitro (expresses >80% TCR 
Vβ 8.1 8.2).  An alternate approach to isolate the cross-reactive TCR is to expand GP34-
A11R cross-reactive T cells from either “newer” GP34-A11R cross-reactive T cell lines 
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or perhaps directly from LCMV-immune mice (~1% cross-reactive towards VV-A11R, 
Figure III.1A) and utilize single cell cloning by serial dilution.  Previous serial dilution 
attempts using cross-reactive T cells (from GP34-A11R cross-reactive TCLs) in the 
presence of peptide-pulsed B6 splenocytes as stimulators were unsuccessful, but recent 
attempts using RMA-S cells as stimulators showed more promise.   
In summary, the function(s) of cross-reactive T cells may be difficult to establish 
in vivo.  Hopefully, these issues will be addressed by selective depletion of cross-reactive 
T cell populations using bi-specific MHC heterodimers.  An intriguing approach to 
evaluating the role of cross-reactive T cells in vivo is through exclusion of the 
heterologous epitopes from viruses, which might inhibit cross-reactive T cell responses 
(Welsh and Fujinami 2007).  In the case of GP34-A11R cross-reactivity, exclusion of 
important contact residues (P4N) necessary for only cross-reactive T cell responses might 
be a better approach as cognate-epitope responses could be maintained.  The exclusion of 
these epitopes from vaccines has been suggested to avoid potential immunopathology 
generated by the elicited heterologous immune responses (Selin, Varga et al. 1998; Welsh 
and Fujinami 2007).   
 
IV.E. Immunopathology 
It has been known for almost 60 years that humans vaccinated against influenza 
produce antibodies against the immunizing virus, but in addition, produce antibodies of 
higher titer against a different strain of influenza, that was first encountered during 
childhood.  This phenomenon was named original antigenic sin because the immune 
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response is dominated by cross-reactive memory cells generated by the primary infection 
and are re-activated in the presence of the challenging pathogen (Fazekas de St and 
Webster 1966).  Original antigenic sin does not discriminate between beneficial versus 
detrimental immune responses.   
Despite the focus of this thesis being centered on protective immunity, 
immunopathology is also an important consequence, which has been documented in a 
variety of different human and mouse systems (Chen, Fraire et al. 2001; Urbani, Amadei 
et al. 2005; Rothman 2009).  Immunopathology is thought to be promoted by expansion 
of low affinity, cross-reactive T cells, which have greater affinity for the cross-reactive 
antigen as compared to the infectious antigen, leading to poor pathogen clearance 
(Mongkolsapaya, Dejnirattisai et al. 2003).  The expansion of these cross-reactive T cells 
can lead to cytokine release and immune-mediated tissue damage, which has been shown 
to occur via activation-induced cell death of CD4+ and CD8+ T cells (Aichele, Brduscha-
Riem et al. 1997).  In the case of subsequent dengue infections, where high antigenic load 
occurs, high-affinity T cells are thought to be preferentially driven into apoptosis, which 
could help to promote immunopathology by expanding the frequency of cross-reactive T 
cells with lower affinity for the infecting pathogen (Mongkolsapaya, Dejnirattisai et al. 
2003).   
Alternatively, failure to mount cytotoxic T cell responses by memory T cells 
towards infected target cells might be due to a shift in cytokine production (Rothman 
2009).  In the case of dengue, stimulation of memory T cells with heterologous dengue 
virus serotypes promotes greater relative production of a pro-inflammatory cytokine 
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TNFα, as compared to a potential antiviral cytokine IFNγ (Rothman 2009).  The shift in 
cytokine production from antiviral cytokine IFNγ, towards pro-inflammatory cytokine 
TNFα, has been found to hamper to ability of low affinity T cells to effectively clear 
virus (Von Herrath, Coon et al. 1997), which might further promote immunopathology 
for the reasons described earlier.  Taken together, these points illustrate how cross-
reactive memory T cells can promote immunopathology and be detrimental to the host.      
 
IV.F. Contribution of the CD8 co-receptor 
Compelling evidence has been found for the roles of the CD8 co-receptor, which 
includes the stabilization of the MHC-TCR complex (Garcia, Scott et al. 1996; Daniels 
and Jameson 2000; Wooldridge, van den Berg et al. 2005) and initiation of signaling 
cascades by the protein tyrosine kinase Lck during subsequent cell signaling (O'Rourke 
and Mescher 1993).  While numerous studies in human and mouse systems have been 
conducted to address the precise role of CD8 in T cell recognition, it still remains 
unclear.   
Whether CD8 is required or not during T cell recognition has remained a 
controversial issue.  T cells have been observed to engage high affinity peptide-MHC 
ligands in the absence of CD8 co-engagement (Kerry, Buslepp et al. 2003), which 
suggests that CD8 only serves to fine tune T cell recognition.  Meanwhile, other studies 
showed that CD8 co-engagement is required for T cell recognition (Delon, Gregoire et al. 
1998; Daniels and Jameson 2000; Dutoit, Guillaume et al. 2003; Gakamsky, Luescher et 
al. 2005).   
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In addition, if CD8 co-engagement is required for T cell recognition, some have 
argued over the precise timing for CD8 co-engagement of MHC-TCR complexes.  It is 
commonly believed that CD8 co-engagement recruits the protein tyrosine kinase Lck into 
the immunological synapse, which initiates downstream T cell activation pathways 
(Janeway 2001).  However, a recent report has shown that the association of the CD8 co-
receptor to the MHC-TCR complex occurs after initial TCR engagement and T cell 
triggering (Jiang, Huang et al. 2011).  Contrary to the norm, it was indicated in this study 
that the protein tyrosine kinase Lck recruits CD8 to the same peptide-MHC molecule, 
engaged by TCR.   
Despite the conflicting results surrounding the precise role or timing of CD8 co-
engagement, our observation that control peptide-MHC heterodimers (cognate peptide-
MHC monomer cross-linked to a noncognate peptide-MHC monomer) are not capable of 
binding to cross-reactive TCRs clearly indicates that the minimal requirements for 
dimeric TCR engagement is two CD8 co-receptor interactions combined with the two 
cognate peptide-MHC and TCR interactions (Figure II.9B).   
Recent work on thymocytes, using unlabeled peptide-MHC heterodimers, 
demonstrated that positive selection requires T cell interaction with two cognate peptide-
MHC complexes (Juang, Ebert et al. 2010).  Meanwhile, this same study revealed that 
negative selection proceeds with a self peptide-MHC molecule linked to a cognate 
peptide-MHC molecule (Juang, Ebert et al. 2010).  Given the differential ligand 
requirements for selection, it could be interesting to evaluate the precise number of CD8 
contacts required during selection or other processes such as reactivation of memory T 
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cells, which was found to require CD8 for only certain effector functions (Kerry, Maile et 
al. 2005).   
To address the requirements for CD8 co-engagement during immunological 
processes such as selection, a bi-specific MHC heterodimer could be assembled such that 
one peptide-MHC monomer, containing an intact CD8 binding site, could be cross-linked 
to another peptide-MHC monomer, containing a mutated CD8 binding site to either 
enhance or inhibit CD8 co-engagement (Wooldridge, van den Berg et al. 2005).  
Enhancing the CD8 co-engagement might increase the overall avidity of the CD8-MHC-
TCR interaction.  During selection, increasing the overall avidity of the MHC-TCR-CD8 
interaction of a developing T cell might promote apoptosis (Chidgey and Boyd 1997).   
Decreased CD8 binding on more mature T cells has been observed using MHC 
tetramers (Daniels, Devine et al. 2001).  However, a clear link between glycosylation and 
CD8 co-engagement is unclear using MHC tetramers, where glycosylation could also 
affect TCR clustering (Demetriou, Granovsky et al. 2001).  The results in Chapter V.C 
(in appendices) highlights that glycosylation modulates the ability of naïve T cells to bind 
to MHC monomers, likely through altering CD8 co-engagement.  The reduced CD8 co-
engagement on naïve CD8+ T cells in the presence of glycan adducts provides a 
mechanistic explanation for how glycosylation affects T cell engagement of peptide-
MHC ligands and highlights that glycosylation provides an additional level of control 
over T cell recognition.   
In addressing the role of CD8, I found that the widely used mutation of the 
conserved CD8 binding site (D227K) on the MHC class I α3 domain, compromises the 
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integrity of the MHC class I complex (Figure V.C.2B).  If the D227K mutation 
compromises the stability of all MHC class I alleles, those studies need to be re-
evaluated.  In the future, a different or stable Kb complex containing a mutated CD8 
binding site needs to be generated to further evaluate the role of CD8 co-engagement.  
Our monomer binding assay using WT and CD8-null MHC monomers could be then 
repeated using the same desialylation and resialylation protocols to specifically address 
whether T cell engagement altered by glycosylation pattern changes can be attributed to 
glycan moieties on CD8.   
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V.A.1. AGAROSE GEL ELECTROPHORESIS                                                    
Protocol modified from Jennifer Stone 
 
Procedure: 
 
1. Prepare 100 ml of a 1% agarose solution.  (Measure 1 g agarose into a glass 
beaker or flask and add 100 ml 1X TBE or TAE.) 
2. Microwave or stir on a hot plate until agarose is dissolved and solution is clear.  
Note: the solution may boil rapidly after microwaving, so be careful handling it.  
3. Allow solution to cool to about 55˚C before pouring. (Ethidium bromide can be 
added at this point to a concentration of 0.5 µg/ml.)  
4. Prepare clean gel tray by sealing ends with tape or other custom-made dam.  
5. Place comb in gel tray about 1 inch from one end of the tray and position the 
comb vertically such that the teeth are about 1-2 mm above the surface of the tray.  
6. Pour 50˚C gel solution into tray to a depth of about 5 mm. Allow gel to solidify 
about 20 minutes at room temperature.  Excess agarose can be stored at room 
temperature and re-melted in a microwave.  
7. To run, gently remove the comb, place tray in electrophoresis chamber, and cover 
(just until wells are submerged) with electrophoresis buffer (the same buffer used 
to prepare the agarose).  
8. To prepare samples for electrophoresis, add 1 µl of 6x gel loading dye for every 5 
µl of DNA solution. Mix well. Load 5-12 µl of DNA per well (for minigel).  
9. Electrophorese at 50-150 volts until dye markers have migrated an appropriate 
distance, depending on the size of DNA to be visualized.  
10. If the gel was not stained with ethidium during the run, stain the gel in 0.5 µg/ml 
ethidium bromide until the DNA has taken up the dye and is visible under short-
wave UV light, if the DNA will not be used further, or with a hand-held long-
wave light if the DNA is to be cloned. 
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Materials: 
 
Agarose Gel Solution 
Agarose in TBE or TAE (1%)  
1x TBE or TAE Buffer 
 
Gel loading dye  
10 mg/ml Ethidium Bromide  
 
50x TAE Buffer 
242 g Tris Base 
57.1 g Glacial Acetic Acid 
100 mL 0.5M EDTA, pH 8 
Fill to 1L with ddH2O 
 
10x TBE  
108 g Tris Base 
55 g Boric Acid 
40 mL 0.5 M EDTA, pH 8 
6x Gel Loading Buffer 
0.25% Bromophenol Blue 
0.25% Xylene Cyanol FF 
33% Glycerol 
18% 50x TAE Buffer 
49% ddH2O 
 
 
      
  
139 
 
 
 
V.A.2.BIOTINYLATION YIELD TEST FOR MHC CLASS I COMPLEXES 
Protocol modified from Jennifer Stone 
 
Procedure: 
 
1. Set up reducing SDS-PAGE using a 12% polyacrylamide gel. 
2. Assemble the following samples in reducing SDS loading buffer and boil your 
samples.  Make sure to add enough reducing SDS loading buffer to account for 
the addition of streptavidin or PBS in step 3.  Samples b-d should be brought to 
the same final volume. 
a. Protein MW standards 
b. 2 g Biotinylated MHC class I + PBS or other buffer 
c. 2 g Biotinylated MHC class I + 2 g Streptavidin 
d. 2 g Streptavidin 
3. Cool all boiled samples to at least room temperature. Then add an excess of 
streptavidin (2 g) to the samples and an equivalent volume of PBS or similar 
buffer to the unbiotinylated monomer sample.  Allow all samples to sit at least 10-
15 minutes to allow for the streptavidin-biotin interaction to occur. 
4. Run samples on gel (140V for 1 hour), then stain with coomassie. I usually rinse 
the gel after coomassie staining with deionized water and then add the destain. 
a. Note, when destaining, tie two kimwipes (single knot) and immerse in the 
destaining solution. The kimwipes will bind up the coomassie.   
5. The band corresponding to the biotinylated heavy chain of your MHC class I 
should disappear in sample C, and larger bands will appear indicating the 
presence of streptavidin-MHC oligomers.   
6. The yield of biotinylation can be determined by determining the fraction of MHC 
class I heavy chain remaining after streptavidin was added. 
7. Sample of biotinylated yield test for an MHC class I complex can be found in 
Figure II.3 
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V.A.3. BRADFORD ASSAY 
Protocol modified from Jennifer Stone 
Materials: 
 
Dye stock: Coomassie Blue G (Cat# 42655) (100 mg) is dissolved in 50 mL of methanol. 
(If turbid, the solution is treated with Norit (100 mg) and filtered through a glass-fiber 
filter.)  The solution is added to 100 mL of 85% H3PO4, and diluted to 200 mL with 
water.  The solution should be dark red.  The final reagent concentrations are 0.5 mg/mL 
Coomassie Blue G, 25% methanol, and 42.5% H 3PO4.  The solution is stable indefinitely 
in a dark bottle at 4°C.  
Assay reagent: The assay reagent is prepared by diluting 1 volume of the dye stock with 4 
volumes of distilled H2O.  The solution should appear brown, and have a pH of 1.1.  It is 
stable for weeks in a dark bottle at 4°C.  
Protein Standards: Protein standards should be prepared in the same buffer as the samples 
to be assayed.  A convenient standard curve can be made using bovine serum albumin 
(BSA) with concentrations of 0, 250, 500, 1000, 1500, 2000 µg/mL for the standard 
assay, and 0, 10, 20, 30, 40, 50 µg/mL for the microassay.  
Standard Protein Assay Procedure (For 200 - 2000 µg/mL protein): 
 
1. Prepare six standard solutions (1 mL each) containing 0, 250, 500, 1000, 1500 
and 2000 µg/mL BSA.  
2. Set the spectrophotometer to collect the spectra over a wavelength range from 400 
to 700 nm and over an absorbance range of 0 to 2 Absorbance units, and overlay 
the collected spectra.  
a. Use a 4 mL plastic cuvette filled with distilled water to blank the 
spectrophotometer over this wavelength range. 
b. Empty the plastic cuvette into a test tube and shake out any remaining 
liquid.  Then add 2.0 mL Assay reagent and 0.04 mL of protein standard 
solution, starting with the lowest protein concentration and working up, or 
one of the samples to be assayed. 
3. Cover with Parafilm and gently invert several times to mix.  
4. Record the absorbance spectrum of the sample from 400 to 700 nm, and note the 
absorbance at 595 nm.  
5. Repeat the steps above for each of the protein standards and for the samples to be 
assayed.  
6. Examine the spectra of the standards and samples. If any spectrum has an 
absorbance at 595 nm greater than 2, or if any sample has an absorbance greater 
than the greatest absorbance for any of the standards, dilute the sample by a 
known amount and repeat the assay.   
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7. At one wavelength, approximately 575 nm, all of the spectra should have the 
same absorbance.  (Such an intersection is called an isosbestic point and is a 
defining characteristic of solutions containing the same total concentration of an 
absorbing species with two possible forms.  If any spectrum does not intersect the 
other spectra at or near the isosbestic point, it should be adjusted or rejected and 
repeated.    
8. Prepare a graph of Absorbance at 595 nm vs [Protein] for the protein standards. 
9. Examine the graphed points and decide if any should be rejected.   
a. Often a single point can be rejected without invalidating the standard 
curve, but if more than one point appears questionable the assay should be 
repeated.   
b. The Bradford assay gives a hyperbolic plot for absorbance versus protein 
concentration, but within a range of relatively low protein concentrations, 
the hyperbolic curve can be approximated reasonably well by a straight 
line.  
10. To determine the protein concentration of a sample from it absorbance, use the 
standard curve to find the concentration of standard that would have the same 
absorbance as the sample.  
Microassay Procedure (For <50 µg/mL protein): 
 
1. Prepare five standard solutions (1 mL each) containing 0, 10, 20, 30,  40 and 50 
µg/mL BSA  
2. To a 1.4 mL plastic cuvette, add 
a. 0.2 mL Dye stock 
b. 0.8 mL of one of the protein standard solutions or  samples to be assayed 
(containing <100 µg of protein for <50 µg/mL standards)  
3. Cover with Parafilm and gently invert several times to mix.  
4.  Follow the procedure described above for the standard assay procedure. 
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V.A.4. BUFFER EXCHANGE OF REFOLDED PEPTIDE-MHC CLASS I 
COMPLEXES  
Protocol developed with Keith Daniels 
 
Materials: 
 
 6L of 20 mM Tris, pH 8.0  
 2L 1M NaOH 
 20L distilled water 
 
Procedure: 
 
1. Prior to HQ chromatography, you need to get rid of excess arginine.  Typically, 
we buffer exchange out the refolding mixture into Buffer A (20 mM Tris pH 8.0) 
for HQ chromatography.   
2. Basic operations of the concentrator: 
a. FLOW SWITCH – controls whether the pump is in FORWARD or 
REVERSE.   
b. FLOW DIRECTION – controls whether the contents from the 
RESERVOIR are recirculated and pumped into the filter OR pumped 
through the COLLECTION line which is used for recovery or waste.   
c. PRESSURE KNOB – controls how much pressure is generated, which 
determines how much “flow through” is forced through the 10k MWCO 
cartridge, which retains your protein on the membrane.  Pressure can be 
adjusted by turning clockwise for more pressure and counterclockwise for 
less pressure.   Try to keep the pressure under 10 PSI as indicated on the 
lower pressure gauge.   
3. Set up your CARTRIDGE in the concentrator.  We use the Prep/ScaleTM-TFF 1ft2 
cartridge (PLGC 10k regenerated cellulose, Millipore CDUF001LG).   
4. As a general rule, before and after concentrating, clean the CARTRIDGE (and the 
system) by recirculating 1L 1M NaOH for 30 minutes or more without any 
pressure.  Set the FLOW SWITCH to FORWARD and make sure the FLOW 
DIRECTION is for recirculating.   
5. After cleaning, rinse the concentrator out thoroughly with at least 2L of distilled 
water (repeat a few times) under 10 PSI pressure (bottom pressure gauge).  In a 
pinch, you can simply rinse and discard 3-4 times.  Just make sure to pH the 
liquid that exits through the OUTLET to ensure that excess NaOH has been 
flushed out of the system.   
6. For buffer exchange, I prefer to use diafiltration, which is a convenient “hands-
free” technique.  Seven diafiltration volumes will remove 99.9% of salt.  (i.e. 300 
mL of MHC class I refolding and 2100 mL of buffer A) 
7. Filter your refolding mixture through a 0.2 µM filter and pour contents into the 
RESERVOIR.  Set the FLOW SWITCH to FORWARD and make sure the 
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FLOW DIRECTION is set to recirculation.  Pressurize the system to 10 psi 
(bottom pressure gauge) by turning the PRESSURE KNOB clockwise.   
8. For diafiltration, you need to set up a closed system on the concentrator, meaning 
the same volume of liquid leaving the system through the OUTLET will need to 
be replaced by new buffer entering the RESERVOIR, via tubing through the 
INLET at the top of the RESERVOIR (see picture below).  
a. Prepare 3L of 20 mM Tris pH 8.0 for the BUFFER RESERVOIR. 
b. The tubing needed to run this “closed system” is 0.25 inch I.D., 0.5 inch 
O.D., 0.125 inch wall PVC tubing. (Fisher Scientific 14-169-7E).   
9. Concentrate your protein in the RESERVOIR to about 300 mL so that you can set 
up diafiltration with 3L (10x diafiltration volumes).  Thread in the tubing from 
your BUFFER RESERVOIR into the INLET at the top of the RESERVOIR and 
close off the system by turning the TOP KNOB clockwise to open the O-ring 
which makes a seal inside of the RESERVOIR.  
10. Wait until the liquid from the BUFFER RESERVOIR is being drawn into the 
RESERVOIR via the INLET tube at an approximate rate at which liquid exits the 
RESERVOIR through the OUTLET before walking away.   
11. Allow all of the 3L of the BUFFER RESERVOIR to circulate through the system 
(~1.5L/hour at 10 psi).   
12. To recover the concentrated protein, pump contents off of the membrane and back 
into the RESERVOIR by pumping in REVERSE.  Change the FLOW 
DIRECTION from recirculating into the RESERVOIR to the COLLECTION line 
to recover final product.  I typically collect my protein right into 0.2 µM filter and 
filter the refolding in preparation for HQ chromatography.   
13. After you are done, clean out the concentrator as described earlier using 1M 
NaOH, followed by rinses with water and remove your CARTRIDGE.   
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Figure V.A.1.  Concentrator Setup for Diafiltration.  
1-CARTRIDGE 
2-FLOW SWITCH 
3-FLOW DIRECTION 
4-PRESSURE KNOB 
5-RESERVOIR 
6-OUTLET 
7-INLET 
8-BUFFER RESERVOIR 
9-TOP KNOB 
10-COLLECTION LINE 
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V.A.5. COUNTING TISSUE CULTURE CELLS 
Protocol from Jennifer Stone 
 
 
 
Note:  Make sure you have enough cells in each of the squares (typically 20-40 cells/red 
square).  I usually count four squares and take the average to get better counts.   
Count cells 
touching top 
or left line
Do NOT count cells touching 
right or bottom line
Volume 
= 0.1 L
**Dilute cells 1:2 with trypan
blue, e.g. add 10 L cell 
suspension to 10 L trypan
blue.
**Add mixture to 
hematocytometer under the 
coverslip (takes about 10 L)
**Count cells in 2 squares the 
size of the red outlined 
portion—add numbers 
together
**Multiply result by 104 to get 
# cells/mL
EXAMPLE:
square 1: 31 cells
square 2: 34 cells
TOTAL= 65 cells in 0.1 mL
Density=0.65x106cells/mL
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V.A.6. DNA SEQUENCING 
Protocol modified from Walter Kim 
 
Note: Before Genewiz offered their DNA sequencing services, we used to run our 
own PCR reactions and dye cleanup.  
 
Reaction procedure: 
 
1. Do forward and reverse sequencing reactions separately 
2. For the reaction mixture 
a. Add 4 μL ultrapure water 
b. Add 2 μL plasmid DNA (stock [] from mini prep) 
c. Add 2 μL of primer  
i. 10 μM primer concentration, stock [100 uM] 
d. Add 2 μL BigDye V3.0 or V3.1 
3. On PCR machine, run SEQ program 
a. Runs for 4-6 hours 
4. Add 1 μL 2% SDS to each reaction and incubate for 5 minutes at 95 degrees 
(plate method) 
 
DyeEx cleanup Procedure: 
 
1. Vortex DyeEx column gently 
2. Twist ¼ turn and snap off bottom and place spin column in 2 mL collection 
column for 3 minutes @ 3000 rpm 
a. Remove foil from both sides of plate, spin for 3 minutes at 750-1000xg 
3. Snap off bottom of column and spin for 3 minutes @ 3000 rpm 
4. Transfer column to centrifuge tube 
5. Add 10 μL of DNA mixture directly to gel (slanted) without touching sides of 
tube 
6. Spin column in centrifuge tube for 3 minutes @ 3000 rpm 
a. Transfer contents to microcentrifuge tube and use a speed vac to evaporate 
liquid 
7. Bring to CFAR facility for sequencing 
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V.A.7. FREEZING T CELL LINES 
Protocol modified from Keith Daniels and Michael Brehm 
 
Materials: 
 
Freezing Media: 
90% Fetal Calf Serum 
10% Dimethyl Sulfoxide 
 
Procedure: 
 
1. Critical note:  before freezing down your antigen-specific T cell lines, realize that 
the specificity may be different upon thawing. 
2. Prepare fresh freezing media as specified above. 
3. Spin cells down at 1500 x g for 5 minutes and aspirate the supernatant.   
4. Suspend cells to 1e7 cells/ml in freezing media.   
5. Aliquot into cryovials kept on ice (~1 ml/vial).   
6. Place in Nalgene Cryo 1°C Freezing Container (Cat# 5100-0001) and make sure 
there’s alcohol in the freezing container to allow for a -1°C/minute decrease in 
temperature.  Store in –80C freezer overnight.   
7. Move into liquid nitrogen cell dewar within 24 hours. 
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V.A.8. GENERATION AND MAINTENANCE OF ANTIGEN-SPECIFIC T 
CELL LINES  
Protocol modified from Michael Brehm 
 
Materials: 
 
o RMA cells (Roche virus transformed lymphocyte derived from B6 mice), 
expressing KbDb 
o T cell media 
o RPMI, 10% FCS, 1% P/S, 5 mL HEPES, 5 mL L-Glut, 5 mL nonessential 
amino acids, 5 mL sodium pyruvate, 2.5 mL 0.01M BME 
 All purchased from Invitrogen (except BME) 
o RP10 
o RPMI, 10% FCS, 1% P/S, 5 mL HEPES, 5 mL L-Glut 
o 1 uM peptide (VV-A11R198-205, LCMV-GP34-41) 
o Filtered tips to prevent cross contamination of peptide 
o 0.8% Sterile Ammonium Chloride or Sigma RBC lysis buffer (Cat #R7757) 
o 12 well plates (4 mL well volume ideal) 
o BD T-Cell Culture Supplement without conA (IL-2 culture supplement), rat (BD 
Cat# 354115) 
 
Procedure: 
 
1. Spin down RMA cells for 5 minutes 1200 rpm and resuspend in T cell media to 
10 million cells/mL 
2. Pulse cells with peptide by adding 5 uL (200 ug/mL stock) peptide for every 10 
million cells/mL 
3. Incubate for 1 hour in CO2 incubator, leaving 50 mL conical caps loosened 
4. Irradiate pulsed cells for 3000 rads 
a. Wash irradiated cells with 25 mL T cell media and resuspend in 1 
million/mL 
5. Mash up spleens with 3 mL syringe top (inside of mesh) and add 5 mL of 0.8% 
Ammonium Chloride OR Sigma Lysis buffer for 5 minutes 
a. Add 25 mL of media to stop the lysis and spin down 1200 rpm for 5 
minutes, discard supernatant 
6. Count and resuspend splenocytes in 3.33 million/mL 
7. Want a 10:1 ratio of splenocytes:stimulator RMA cells 
8. Add 1 million cells (1 mL) of pulsed, irradiated cells to culture and 10 million (3 
mL) of splenocytes to the culture 
9. Check culture every 3-4 days, add 1 mL of T cell media if necessary 
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Restimulation procedure: 
 
1. Spin down stimulator RMA for 5 minutes 1200 rpm and resuspend in T cell 
media to 10 million cells/mL 
2. Pulse cells with peptide by adding 5 uL (200 ug/mL stock) peptide for every 10 
million cells/mL 
3. Incubate for 1 hour in CO2 incubator, leaving 50 mL conical caps loosened 
4. Irradiate pulsed cells for 3000 rads  
a. Tighten cap on conical tube and place tube in irradiator 
i. To operate irradiator, turn on, put samples in and set time and 
make sure the timer starts counting upwards 
ii. Set to automatic  
iii. When completed, follow procedure to exit (COMMAND, ARM, 
YES) 
b. Wash irradiated cells with 25 mL T cell media and resuspend in 1 
million/mL 
i. Can use between 500,000 and 1 million stimulator cells per well 
5. Harvest the cells by taking up the full 4 mLs in each well, and then pipet down in 
a circular motion to get all of the cells, do this twice for each well and then add to 
a 50 mL conical 
6. After harvest, add 1 mL PBS and put back into incubator for 5-10 minutes while 
harvesting other plate(s) 
a. Take 4 mLs of the harvested cell mixture and use that to harvest the 1 mL 
of PBS added + cells and add to 50 mL conical 
b. Adding PBS will help remove the cells that are stuck to the bottom of the 
well, this is more important for latter passages 
7. Spin down harvested cells for 5 minutes at 1200 rpm 
8. Reseed cell lines based on density, which is determined visually (seed 1:2 or 2:3 
for the first 3 passages and 1:3 or 1:4 for later passages) 
9. Resuspend pelleted cells using T cell media containing 10% T stim without ConA 
a. Make cocktail with T cell media so that cells can be resuspended into 3 
mLs each well  
10. Add 1 mL of pulsed RMA stimulators (between 500,000-1 million) with reseeded 
T cells and incubate for 3-4 days 
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V.A.9. GROWING BL21 EXPRESSING MHC CLASS I IN A 10 L FERMENTOR 
Protocol modified from Jennifer Stone and Guoqi Li 
 
Procedure: 
 
Day 1: 
1. Streak an LB-amp (chloramphenicol also if cells are pLyss or chloramphenicol if 
cotransforming with BirA) plate in the evening using a glycerol stock containing 
the transformed BL21 cells of interest.     
2. Incubate at 37˚C overnight. 
 
Day 2: 
1. Put streaked plate at 4˚C in morning, sealed with parafilm. 
2. Autoclave the following items:  Assembled fermentor filled with 8 L of distilled 
water, 1 L 1x LB broth, 1 L 10x LB broth, 1 L of distilled H2O and least 150 mL 
20 % glucose. 
3. Inoculate autoclaved, 1 L 1x LB broth with a colony from your plate and grow 
overnight. 
 
Day 3: 
1. Set up the fermentor:  For 10L: 1L 10x LB broth, 10 mL of 1000x Ampicillin, 100 
mL 20 % glucose and 1-2 mLs antifoam.  If  the cells are pLyss or if 
cotransforming with BirA, also add 10 mL 35 mg/mL chloramphenicol.  Mix well.  
Remove 1 mL as a blank and store in a plastic cuvette with 1 L 20 % NaN3 to 
prevent growth.   
2. Run the mixer on the fermentor at ~700 rpm, and run the air at 15 psi and 5 LPM.  
Watch for excessive foaming and add antifoam if more is needed.   
3. Seed the fermentor with 1L of the overnight flask and allow the bacteria to grow 
depending on temperature (should take about 4-5 hours at room temperature to 
reach OD600 = 0.7) 
4. Take samples and check the OD600 every hour or so until you get close to 0.7, and 
then check more frequently.  Do not overgrow! 
5. When the OD600 reaches 0.7, take a 1 mL sample “not induced or N.I.”  Spin down 
and re-suspend in 1x urea-SDS loading buffer. Freeze at –20˚C. 
6. Add IPTG to 0.75 mM final concentration.  If performing in vivo biotinylation (i.e. 
co-transformed BirA + MHC class I plasmids), also add biotin to 50 μM.  For a 
10L fermentor, I add 10 mL of 0.75M IPTG stock (1000x) and 10 mL of 50 mM 
Biotin (1000x).   
7. Grow for another 2-6 hours depending on the temperature. I induce MHC class I at 
room temperature for 4 hours.   
8. Take a 1 mL sample for “induced.”  If you want, you can take an “induced” sample 
every hour during induction as in the gel below.  Spin down and re-suspend in 1x 
urea-SDS loading buffer.  Freeze at –20 ˚C until you are ready to check the “not 
induced” and “induced” samples on a gel by SDS-PAGE. 
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9. Spin down all the cells at 8000 x g and discard the supernatant.  For inclusion 
bodies, you may freeze the pellet at –20˚C, or proceed with the inclusion body prep 
through the DNAse step and freeze at –20˚C. 
 
Figure V.A.2. MHC 
Class I Heavy Chain 
Expression.  MHC Class 
I HC expression was 
monitored during the 
growth of a 10 L 
fermentor at room 
temperature.  12% SDS-
PAGE gel of non-induced 
versus 0.75 mM iPTG-
induced samples are 
shown.  Molecular weight 
markers are labeled on the 
left.   
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V.A.10. HQ ON THE BIOCAD SPRINT HPLC 
Protocol modified from Jennifer Stone 
 
Setting up the biocad: 
 
1. Start Biocad program (icon on desktop) 
2. In the CONTROL PANEL window, select CONFIG, select EDIT CONFIG 
3. To change values, double-click on the current value 
a. Buffer A = 20 mM Tris pH 8.0 
Buffer B = 20 mM Tris pH 8.0 + 1 M NaCl 
b. Column type = ZS MHC class I, max flow rate 15 mL/minute, set high 
pressure to 1000 psi (if you don’t know the pressure, ask someone who 
does know).   
c. Only change pressure and column type 
d. Make sure under DETECTOR that lamp is on 
Equilibrating Buffer Lines:  
 
1. Set the wavelength at 214nM to detect for the disappearance of azide (water 
azide) 
2. Set to 10 mL/minute and pump 100% Buffer A until leveled  
3. Set to 10 mL/minute and pump 100% Buffer B until leveled 
4. If there are bubbles in the lines, they must be purged  
a. Fix tubing onto a large 60 mL syringe from the PURGE KNOB 
b. Loosen the PURGE KNOB on the biocad 
c. Remove the bubbles with the 60 mL syringe 
d. Re-tighten the PURGE KNOB on the biocad 
Equilibrating Column: 
1. Hook up column by twisting off bottom and top screw nubs gently 
2. Using the flow rate (5 mL/minute), equilibrate using 100% Buffer A and 100% 
Buffer B independently 
3. To equilibrate your column, you have to run a gradient wash.  To open up any 
method, go to the Control Panel window, select WINDOW and METHOD 
EDITOR. 
4. To run a method, go to FILE, OPEN and locate your method.  My methods can be 
found in Biocad, People, Zu, Methods, “gradientwash” and choose RUN 
METHOD.  It’s not necessary to save the profile from the wash.     
5. Select UPDATE METHOD WITH SYSTEM CONFIG when the biocad asks you 
as long as system config is correct.   
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Loading Buffer Exchanged Refolding Mix onto HQ column: 
 
1. Before or after equilibrating your HQ column (I prefer before so that the contents 
of the F line don’t enter the column), make sure to flush out the F line with Buffer 
B followed by Buffer A.   
a. The F line is where you can load large volumes of protein.  You can also 
inject into the biocad, but your method must have the injection step built 
in.   
2. Load your buffer exchanged refolding mixture onto the column by selecting 
100% and F and make sure you hit SET.  You can then choose your FLOW 
RATE and hit START.  I prefer to load at a slower flow rate such as 5 mL/minute 
as compared to the flow rate in the actual method (8 mL/minute).   
a. I prefer to collect the flow through just in case something happens during 
the run.   
3. Make sure the fraction collector is positioned properly.  If you don’t know what 
this means, ask someone.  A note about the fraction collector, it’s old.  I typically 
reset the fraction collector before each run to prevent errors from occurring mid-
run.  I’ve had the fraction collector stop mid-run or not start at all, so beware.   
4. After your refolding mixture is loaded, go to the METHOD EDITOR window.  
Select FILE, OPEN and my HQ method is located in Biocad, People, Zu, 
Methods, “KbFinject” and choose a location to save your results and hit RUN 
METHOD.  A typical MHC Class I anion exchange profile can be found in Figure 
V.D.1A.   
a. A 1 L refolding mixture should yield approximately between 15-25 mgs of 
refolded MHC Class I monomer  
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5. V.A.11. INCLUSION BODY PREPARATION FOR MHC CLASS I 
SUBUNITS 
Protocol modified from Mia Rushe 
 
Procedure (for pellet from 10 L culture): 
 
1. Spin down cells at 5000 x g—collect supernatant into a container, sterilize with 
1% Wescodyne for 10-20 minutes, and then dump down the sink. 
2. With a rubber spatula, re-suspend fresh bacteria into a single plastic container 
with ~200 mL Sucrose Solution. 
3. Chop the solution briefly in a homogenizer or polytron. **Do not sonicate! 
4. Most of our cells are not pLyss, so add 1 mg dry lysozyme per mL suspension (0.2 
g) and stir for 10 minutes.  If cells are pLyss, just stir for 10 minutes. 
5. While stirring, add 500 mL Deoxycholate-Triton Solution.  Solution will become 
very viscous due to cell lysis and DNA release. 
6. Add 1 mL of 4 M MgCl2 Solution to make 5 mM final concentration. 
7. Add 2 mL DNAse Solution.  Stir until the solution is the viscosity of water. 
8. Freeze overnight at –20˚C.   
9. Thaw solution in warm water bath. 
10. Stir an additional 10 minutes after thawing to allow the DNAse to work again. 
11. Spin down in 2 centrifuge bottles at 8000 x g for 20 minutes. Discard supernatant. 
12. Re-suspend pellets in 300 mL or more each Triton Solution.  Chop briefly, 
keeping the pellets on ice as much as possible.  Spin down at 8000 x g for 20 
minutes and discard supernatant. 
13. Repeat step 12 three or more times. 
14. Re-suspend pellets into 300 mL or more each Tris Solution.  Chop briefly, 
keeping the pellets on ice as much as possible. Spin down at 8000 x g for 20 
minutes and discard supernatant. 
15. Repeat step 14 two or more times. 
16. Re-suspend/dissolve the pellets and chop in ~ 200 mL Urea Solution. 
17. Spin down at 20˚C, 15,000 x g for 30 minutes.  Filter through a 0.2 m filter. 
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Solutions (**Note: Do not add DTT until just before use!): 
 
Solution Name Stock For 1 L, 1x For 1 L 10x 
Sucrose     
50 mM Tris, pH 8.0 
25% Sucrose 
1 mM EDTA 
0.1% NaN3 
10 mM DTT 
1 M Tris, pH 8.0 
Dry, FW = 342.3 
0.5 M EDTA 
20 % NaN3 
Dry, FW = 154.04 
50 mL 
250 g 
2 mL 
5 mL 
1.54 g 
 
N/A 
Deoxycholate-Triton    
1 % Deoxycholic Acid 
1 % Triton X-100 
20 mM Tris, pH 7.5 
100 mM NaCl 
0.1% NaN3 
10 mM DTT 
Dry, FW = 414.6 
100% solution 
1 M Tris, pH 7.5 
5 M NaCl 
20 % NaN3 
Dry, FW = 154.04 
10 g 
10 mL 
20 mL 
20 mL 
5 mL 
1.54 g 
100 g 
100 mL 
200 mL 
200 mL 
50 mL 
N/A 
Triton     
0.5 % Triton X-100 
50 mM Tris, pH 8.0 
100 mM NaCl 
1 mM EDTA 
0.1% NaN3 
1 mM DTT 
100% solution 
1 M Tris, pH 8.0 
5 M NaCl 
0.5 M EDTA 
20 % NaN3 
Dry, FW = 154.04 
5 mL 
50 mL 
20 mL 
2 mL 
5 mL 
0.154 g 
50 mL 
500 mL 
200 mL 
20 mL 
50 mL 
N/A 
Tris     
50 mM Tris, pH 8.0 
1 mM EDTA 
0.1% NaN3 
1 mM DTT 
1 M Tris, pH 8.0 
0.5 M EDTA 
20 % NaN3 
Dry, FW = 154.04 
50 mL 
2 mL 
5 mL 
0.154 g 
500 mL 
20 mL 
50 mL 
N/A 
Urea     
8 M Urea 
25 mM MES, pH 6.0 
10 mM EDTA  
0.1 mM DTT 
Dry, FW = 60.06 
Dry, FW = 213.3 
0.5 M EDTA 
Dry, FW = 154.04 
480.48 g 
5.33 g 
20 mL 
15.4 mg 
N/A 
DNAse   *Make 50 mL, not 1 L  
75 mM NaCl 
50% Glycerol 
2 mg/mL DNAse 
Sigma Cat# D25 
5 M NaCl 
100% Glycerol 
Dry 
0.75 mL 
25 mL 
100 mg 
N/A 
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V.A.12. INTRACELLULAR CYTOKINE STAINING 
Protocol modified from Keith Daniels 
 
1. Prepare the cells normally and lyse Red Blood Cells using 0.84% NH4Cl or Red 
Blood Cell lysis buffer (Sigma Cat# R7757). 
2. Add 2e6 cells per culture well. 
3a. For Spontaneous and Non-Specific Stimulation 
 
 Plate (Volume/well) 
Total Volume 200 µl 
GolgiPlug 0.2 µl neat 
CD3 0.1 µl of 0.5mg/ml stock 
  
PMA 0.5 ul of a 20 µg/ml stock (50 ng/ml) 
Ionomycin 1ul of a 100 µg/ml stock (500 ng/ml) 
 
3b. For Specific Peptide Stimulation add 1ul of a 200ug/ml peptide solution per well 
 
 Plate 
Total Volume 200 µl 
GolgiPlug 0.2 µl neat 
IL-2 (neat) 0.004 l of 1µg/ml (10U/ml) Stock 
IL-2 (Diluted) 0.4 µl 
 
 
4. Incubate at 37°C for 4 hours (PMA & Ionomycin or CD3) or 5 hours (Peptide 
Stimulation). 
5. Wash 1x using Staining Buffer (PBS without Mg2+ of Ca2+; 1% FCS; 0.09% Sodium 
Azide) 200ul/well - Centrifuge for 5 min at 1200-1500 rpm. 
6. Block Fc receptors using 2.4G2 antibody for 5 min at 4°C in 100ul of Staining 
Buffer. 
7. Wash 1x - Add 100µl Staining Buffer and Centrifuge for 5 min at 1200-1500 rpm. 
8. Stain cells for surface antigens using appropriate antibodies in 100ul of Staining 
Buffer for 20 min at 4°C. 
9. Wash cells 2x with Staining Buffer. 
10. Resuspend cells using 100ul per well of CytoFix/CytoPerm Solution for 20 min at 
4°C. 
11. Wash cells 2x in 1X Perm/Wash solution (Dilute 10X stock in dH2O) 
12. Resuspend cells in 100ul of Perm/Wash solution containing anti-cytokine antibodies. 
13. Incubate for 25 min at 4°C in the dark. 
14. Wash cells 2x with 1X Perm/Wash. 
15. Wash cells 1x using Staining Buffer. 
16. Put in a final Volume of 300ul of Staining Buffer for Analysis. 
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V.A.13. MHC CLASS I HETEROGENOUS CROSS-LINKING  
USING MHPH AND MTFB 
Protocol modified from Solulink 
 
Procedure: 
 
1. Store small aliquots (~50 uL) stock solutions of cross-linker reagents 3-N-
Maleimido-6-hydraziniumpyridine hydrochloride (MHPH, Solulink Cat# S-1009-
010) and Maleimido Trioxa Formylbenzaldehyde (MTFB, Solulink Cat# S-1035-
105) at 20 mM in DMF at -80° C. 
2. Reduce cysteine containing proteins (A and B) in 5 mM DTT overnight 
3. Calculate the amount of MHPH and MTFB cross-linker to add to the proteins 
using a 5:1 molar excess of cross-linker.  Do not allow the final volume of DMF 
to exceed 5% of the total volume. 
4. Right before adding the cross-linker, remove DTT using NAP-5 drip column (GE 
Healthcare Cat# 17-0853-02) and equilibrate protein into 100mM phosphate, pH 
6.0, 150mM NaCl. 
5. Add the appropriate amount of MHPH to protein A and MTFB to protein B, 
keeping them separated.  Allow the reaction to proceed at room temperature for 2 
hours. 
6. Set up and equilibrate Superdex 200 column on biocad (GE Healthcare Cat#17-
5175-01) using 100mM phosphate, pH 6.0, 150mM NaCl.   
7. Purify away the free cross-linker from modified proteins over HPLC 
o Make sure to perform a blank run in between as I’ve observed the free 
cross-linker eluting much later off of the Superdex 200 column 
8. Check the peak fractions for protein concentration and pool and concentrate the 
peak fractions. 
o Save a small sample for SDS-PAGE 
9. Make sure that the concentration of protein A and protein B are MATCHED and 
range between 10 – 30 μM. 
10. Mix equal molar amounts of protein A-MHPH and protein B-MTFB in the same 
tube and add aniline catalyst (Acros Organics Cat#158190050) to 5mM.  Allow 
the reaction to proceed for at least 2 hours at room temperature.   
o Save a small sample for SDS-PAGE.   
11. Purify the reaction mixture using a Superdex 200 column.  Pool and concentrate 
the peak fractions.   
o Save a small sample for SDS-PAGE.   
12. Label the MHC (hetero/homo) dimers using the primary amines (see protocol for 
labeling primary amines).   
13. Run the saved samples on an SDS-PAGE.  See Figure II.5 for an example.   
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V.A.14. MODIFYING FREE CYSTEINES ON PROTEINS USING MALEIMIDES 
Protocol modified from Jennifer Stone 
 
Procedure: 
 
11. If the protein is not freshly reduced, add DTT to 5 mM and incubate the protein 
overnight at room temperature.  
a. If the protein has been stored in DTT and is freshly purified by anion 
exchange, there is no need to re-reduce. Skip to step 2. 
12. Either column-purify, dialyze, or concentrate/switch buffers to remove DTT and 
put protein in reaction buffer (I’ve tested PBS, Tris and Phosphate pH 6-8.  If the 
pH is too high, the maleimide reagent will also modify primary amines such as 
lysine residues).  
a. I prefer to use the NAP5 drip columns (GE Healthcare cat# 17-0853-01) 
because the procedure is quick and easys.   
b. The MHC class I complexes elute between 0.75 mL to 1.5 mL.   
13. Immediately check the concentration of the protein, which should be no lower 
than 10 M, otherwise hydrolysis of maleimide will occur  
14. Add the maleimide reagent to a final concentration so that you get between a 5-10 
fold molar excess of maleimide to your freshly reduced protein.   
a. Your maleimide stock solution should be made in DMSO at a 
concentration greater than 5-10 mM.  The reason being is that you want to 
be able to dilute your DMSO and still have a high enough concentration to 
prevent hydrolysis.  I typically do at least a 1:20 dilution into the protein 
solution.   
15. Mix well and store the solution at room temperature for 1-2 hours. If the probe is 
fluorescent, store the solution in the dark to prevent fluorescence quenching. 
16. After the incubation, you might consider adding DTT to a final concentration of 5 
mM to quench any remaining unreacted maleimide, although I’ve found that this 
isn’t necessary.   
17. HPLC purify away the excess maleimide and DTT (if added in step 6) using a 
Superdex 200 column (GE Healthcare Cat# 17-5175-01) set up on the Biocad.   
18. Pool and concentrate the peak fractions.   
19. Measure the final concentration and, if applicable, the degree of labeling. 
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V.A.15. MODIFYING PRIMARY AMINES ON PROTEINS USING NHS ESTERS                         
Protocol modified from Pierce 
 
Procedure: 
 
20. Make sure your protein is stored in an amine-free buffer at pH 7.25-8.0.  
Basically, avoid Tris or glycine buffers.  I typically use phosphate or PBS at pH 
8.0.   
21. Check the concentration of the protein, which should be no lower than 10 M, 
otherwise the reaction will not go efficiently.   
22. Add the NHS ester reagent to a final concentration of so that you get a 10-20-fold 
molar excess of NHS ester to your protein.  Your NHS ester stock solution should 
be made using DMSO at a concentration around 4 mM.  The reason being is that 
you want to be able to dilute your DMSO and still have a high enough 
concentration to prevent hydrolysis of the succinimidyl ester.  I typically do at 
least a 1:20 dilution into the protein solution.   
23. Mix well and store the solution at room temperature for 1-2 hours. If the probe is 
fluorescent, store the solution in the dark to prevent fluorescence quenching. 
24. After the incubation, add a 50-fold molar excess of ethanolamine relative to the 
amount of NHS ester added, to quench any remaining unreacted NHS ester. 
a. I’ve found that quenching with Tris, followed by multiple rounds of 
dialysis is insufficient to quench the NHS ester.   
25. HPLC purify away the excess NHS ester using a Superdex 200 (GE Healthcare 
Cat# 17-5175-01) column set up on the biocad.   
26. Pool and concentrate the peak fractions.   
27. Measure the final concentration and, if applicable, the degree of labeling. 
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V.A.16. POURING LB-AMP PLATES 
Protocol modified from Jennifer Stone 
 
Procedure: 
 
1. Dissolve 25 grams of LB mix in a final volume of 1 liter.  Add 15 grams of 
Bacto-agar (not agarose). Cover top with foil and autoclave for 20-30 minutes. 
2. After autoclaving, swirl vigorously in the flask to mix the molten agar.  Cool the 
solution to 50C.  This is approximately when you can stand to hold the bottom of 
the flask for 10-20 seconds. 
3. For ampicillin, add 100 mg of Ampicillin and swirl until it dissolves. 
4. Make space to accommodate ~40 plates, unstacked, per liter of agar mix.  Pour 
plates to a depth of approximately 3 mm.  You can measure 20-25 mL per plate, 
but I prefer to pour.   
a. If there are bubbles on the surface of the agar, these can be removed by 
briefly flaming the surface with a Bunsen burner. 
5. Leave the plates out at room temperature and unstacked.  Wait at least a few hours 
before stacking and putting the plates in the fridge. 
6. Label the plates with the date and note the antibiotic.   
7. Store the plates in a plastic sleeve at 4C. 
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V.A.17. PREPARING MHC CLASS I TETRAMERS 
Protocol modified from Jennifer Stone 
 
Materials: 
 
 Kb-pep: Biotinylated MHC class I complex of choice in PBS or Tris. 
 SA-PE: Choice of fluorochome conjugated streptavidin, I frequently use premium 
grade R-phycoerythrin conjugated streptavidin (Invitrogen Cat# XXX 
 PBS, 1x 
 FACS buffer: 1x PBS, 2% FCS 
 BD cytofix (Cat# XXXX) 
 Fluorescent antibodies to cell-surface markers: 
o -CD8β PerCP Cy 5.5 
o -CD44-FITC 
 
Procedure for 50 l:  This procedure is generally completed on ice and the reagent 
should be made up fresh for each stain.  I typically use 300-500 nM of MHC tetramer for 
most tetramer stains.   
 
1. Aliquot 1.5 g Kb-pep into an eppendorf tube. 
2. In a separate tube, dilute 2 L R-phycoerythrin conjugated Streptavidin (SA-PE) 
with 4 L PBS 
3. Add 2 L of diluted SA-PE mixture to the tube with Kb-pep and pipet-mix well 
4. Wait 2 minutes 
5. Add 2 L of diluted SA-PE mixture to the tube with Kb-pep and pipet-mix well 
6. Wait 2 minutes  
7. Add the rest of the diluted SA-PE mixture to the tube with Kb-pep and pipet-mix 
well 
8. Wait 2 minutes and the complex should form between biotinylated Kb-pep and 
SA-PE: Kb-SAPE oligomer 
9. Dilute Kb-SAPE oligomer with FACs buffer to a final volume of 50 L. 
10. I’ve made an excel spreadsheet to expedite these calculations.  It should be 
located in my protocol folder on the “S drive”, named “MHC Class I calc”.   
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V.A.18. REFOLDING OF MHC CLASS I COMPLEXES 
Protocol modified from NIH Tetramer Facility 
 
Procedure: 
 
8. Pre-chill 1 L of Folding Buffer in a 1.5 L beaker to 4C.  
9. Add 5 mM reduced glutathione, 0.5 mM oxidized glutathione, and 0.2 mM PMSF 
to cold Folding Buffer, stirring quickly and try to avoid foaming! 
10. Calculate 1 M heavy chain urea-solubilized subunit and add to 4 mL of Injection 
Buffer. 
11. Calculate 2 M 2M urea-solubilized subunit and add to the same 4 mL Injection 
Buffer. 
12. Weigh out 10-20 mg of peptide and dissolve in 0.5 mL DMSO. 
13. Add peptide solution dropwise to rapidly stirring Folding Buffer. 
14. Forcefully inject heavy chain and 2M to the stirring reaction through a 26-gauge 
needle as close to the stir-bar as you can.  There may be some precipitation or 
light foaming. 
15. Replace the mixture at 4C and incubate overnight. 
16. The following morning, inject heavy chain and 2M in Injection Buffer into the 
cold, quickly-stirring mixture as above.  Replace at 4C. 
17. In the evening, once again inject heavy chain and 2M in Injection Buffer into 
the cold, quickly-stirring mixture as above.  Replace at 4C and incubate 
overnight 
 
Solutions: 
  
Folding Buffer (pH 8.0)    Injection Buffer (pH 4.2) 
400 mM L-Arginine (Sigma A5949)   3 M Guanidine-HCL 
100 mM Tris, pH 8.0     10 mM Sodium Acetate 
2 mM EDTA      10 mM EDTA 
 
Other Materials 
Urea-solubilized heavy chain and light chain (β2M) 
Peptide of choice 
Reduced glutathione (Sigma G4705) 
Oxidized glutathione (Sigma G4501) 
100 mM Phenylmethylsulfonyl fluoride (PMSF - Sigma P7626) 
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V.A.19. SDS-PAGE 
Protocol modified from Mia Rushe 
 
Procedure: 
 
1. Assemble the gel apparatus, being careful to avoid leakage. 
2. Select the percentage of Separating Gel you would like to pour. (Lower 
percentage gels allow higher molecular weight proteins to separate further.) 
3. Add the ingredients in the order listed - mix well between each step. 
4. After the temed and APS, move quickly, since the acrylamide will try to begin 
polymerizing.  
5. Pour about 2.5-3 mL of acrylamide mixture into the space between the gel plates. 
6. Slowly layer a small amount of water on top of the acrylamide mixture using a 
syringe.  The acrylamide polymerizes faster in anaerobic conditions. 
7. Allow the Separating Gel to polymerize for about 45 minutes. 
8. Remove the water layer from the top of the gel by tilting and using a paper towel.  
9. Mix the ingredients for the Stacking Gel (shown below) in order, mixing after 
each one. 
10. Layer the Stacking Gel mixture on top of the Separating Gel. Fill all the way to 
the top. 
11. Insert a comb into the stacking gel to create lanes for loading your samples. 
12. Allow the Stacking Gel to polymerize for about 45 minutes.  
13. Remove the comb. 
14. At this point, you can either place the gel into the electrophoresis chamber 
covered with SDS Running Buffer, load samples in 1x SDS Loading Buffer, and 
run the gel, or you can store the gel at 4˚C by wrapping in several soaked paper 
towels and then surrounding it with Saran Wrap. The gel should keep stored this 
way for a week or two. 
15. After running your samples, disassemble the apparatus and place the gel into 
Coomassie Stain (or use other stain protocol). Allow to shake for >1 hour at room 
temperature.   
16. Remove the stain and rinse with deionized water.  Place gel into Destain on 
shaker with two knotted kimwipes. Observe on light box. 
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SDS-PAGE Gel Recipes: 
Stacking Gel 
Component  
30% Acrylamide 0.3 mL
ddH2O  1.2 mL
4x Lower Buffer 0.5 mL
TEMED 5 µL 
10% APS 20 µL 
 
Separating Gel 
Component 7.5% 10% 12.5% 15% 
30% Acrylamide 1 mL 1.3 mL 1.7 mL 2 mL 
ddH2O  2 mL 1.7 mL 1.3 mL 1 mL 
4x Lower Buffer 1 mL 1 mL 1 mL 1 mL 
TEMED 10 µL 10 µL 10 µL 10 µL 
10% APS 20 µL 20 µL 20 µL 20 µL 
 
 
Solutions: 
 
4x Lower Buffer 
181.7 g Tris Base 
4.0 g SDS 
Fill to 1L with ddH2O 
Adjust pH to 8.8 
4x Upper Buffer 
60.6 Tris Base 
4.0 g SDS 
Fill to 1L with ddH2O 
Adjust pH to 6.8 
10x Running Buffer 
30.3 g Tris Base 
10.0 g SDS 
144.0 g glycine 
Fill to 1L with ddH2O 
Do not pH 
 
5x Laemlli Loading Buffer 
60 mM Tris, pH 6.8 
100 mM DTT (for reducing) 
1% SDS 
10% Glycerol 
0.001% Bromophenol Blue 
in ddH2O 
 
Coomassie Blue Stain 
0.25% CBBR-250 
15% Methanol 
10% Acetic Acid in ddH2O 
Note: Dissolve CBBR in 
Methanol first, add Acetic 
Acid in water and filter. 
Destain 
15% Methanol 
10% Acetic Acid in ddH2O 
2x SDS Sample Buffer 
6.67 g SDS 
20 g Sucrose 
0.3 g Tris Base 
1.03 g DTT 
Note: pH to 7.5 with HCl, 
 Add to 100 mL ddH2O 
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V.A.20. SINGLE CELL SUSPENSIONS FROM MOUSE ORGANS 
Protocol from Keith Daniels and Jennifer Stone 
 
Materials: 
 
RP10 
RPMI media 
10% FCS 
1% P/S 
1% HEPES 
1% L-Glut (even if it’s already included in RPMI) 
 
Procedure: 
 
1. Collect the mouse organs (lymph nodes, spleen, etc) in a Petri dish with 3-5 
mL RP10 medium. 
2. Crush the organs between the frosted handles of two glass slides (sterilized).  
Start with the smallest organs, as the solution will become cloudy and the 
small organs will be difficult to see later. 
3. Spin down cells at 1500 rpm, 10 minutes. Ensure that a pellet has formed! 
Remove supernatant and retain in a separate tube. 
4. Resuspend cells in 2-3 mL room temperature RBC lysis buffer (Sigma Cat# 
R7757) per mouse. Allow to sit 5 minutes and no longer.  NOTE: If you have 
trouble with losing cells in this step, try a Ficoll gradient to isolate the white 
blood cells instead of lysing the RBC’s. 
5. Dilute with 10 mL/mouse RP10 medium and spin down at 1500 rpm, 10 
minutes. Ensure that a pellet has formed.  Remove supernatant and 
immediately resuspend pelleted cells in RP10 medium and count total 
number.  
 
166 
 
 
 
V.A.21. SITE DIRECTED MUTAGENESIS 
Modified from Walter Kim 
 
Procedure: 
 
1. In a PCR tube, add the following: 
a. 3 μL 100% DMSO (quiksolution), final in 50 μL is 6% 
b. 0.5 μL plasmid DNA (miniprep) 
c. Primer 
i. I test 1 μL, 2 μL and 5 μL [10 μM] of both forward and reverse 
primers 
d. 5 μL 10x PFU buffer 
e. 2.5 μL 4 mM (20x) dNTP mix or 1 μL 10 mM (50x) dNTP mix (New 
England Biolabs Cat# N0447s) 
f. Ultra pure ddH2O to 49 μL 
g. 1 μL PFUultra (2.5 Units/μL) last to 50 uL 
i. PFU ultra has exonucleases which can cleave ssDNA primers 
2. Run QUIKC2 program on PCR 
3. After program is run, add 1 μL Dpn I restriction enzyme (10 U/uL)  
a. Mix reaction by vortexing 
b. Incubate for 1 hour at 37° to digest parental DNA 
4. Transform 5 μL of DNA in 45 μL supercompetent XL1-blue E. coli 
5. Incubate on ice for 5 minutes 
6. Heat shock in 42°C water bath for 45 seconds 
7. Incubate on ice for 5 minutes  
8. Add 100 µL of S.O.C. (warmed to 42°C) 
9. Place in 37°C rotator for 1 hour  
10. Plate all (150 µL) of reaction mixture onto Amp plates around noon and grow 
plate overnight. Note that XL1-blue colonies are really small.   
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V.A.22. STAINING CD8+ T CELLS WITH MHC CLASS I TETRAMERS 
Protocol modified from Jennifer Stone and Keith Daniels 
 
 
Procedure: 
 
1. Prepare the cells normally and lyse Red Blood Cells using 0.84% NH4Cl or Red 
Blood Cell lysis buffer (Sigma Cat# R7757). 
2. Block Fc receptors using 2.4G2 antibody for 5 min at 4°C in 100 l of FACs 
buffer.   
3. Wash once using 200 l FACs buffer and centrifuge for 5 minutes at 1500 rpm. 
a. You will want to have a final volume such that you use 40 L cell 
suspension and add 10 L of each tetramer. 
4. Aliquot 40 l cell suspension into one well of a 96-well round-bottom plate for 
each staining experiment. 
5. Add 10 l of MHC class I tetramer to the cell suspension in appropriate wells 
6. Incubate the plate at 4°C for 40 minutes. 
7. Prepare a cocktail of desired fluorescent antibodies.  Typically use 1 l or less of 
each antibody per sample and dilute with FACS Buffer so that you will add 50 L 
cocktail per sample. 
8. Add 50 l of fluorescent antibody cocktail to each sample. Pipet mix well. 
9. Incubate on ice for 20 minutes. 
10. Add 100 l cold FACS buffer to each sample.  Spin plate at 4°C for 5 minutes, 
1500 rpm.   
11. Flick plate into sink.  Look at the bottom of the plate to make sure cell pellets 
have are still present after plate flick.   
12. Wash with 150 l cold FACS buffer and pipet mix well.  Spin plate at 4°C for 5 
minutes, 1500 rpm. 
13. Flick supernatant 
14. Add 100 l of BD cytofix to each sample to fix the samples 
15. Wash with 150 l cold FACS buffer and pipet mix well.  Spin plate at 4°C for 5 
minutes, 1500 rpm. 
16. Flick supernatant. 
17. Resuspend samples in 150 l cold FACs buffer. 
18. Analyze by flow cytometry immediately or the next day. 
 
NOTE: Remember to include plenty of controls including single-stained cells for 
compensation adjustment, control tetramers, control cells if available 
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V.A.23. STOCK SOLUTIONS 
 
 
Solution 1000x stock grams Final Volume Solvent 
Biotin 50 mM 0.12212 10 mL ddH2O with 1M NaOH 
iPTG 0.75 M 1.7871 10 mL ddH2O 
Ampicillin 100 mg/mL 1 10 mL ddH2O 
Chloramphenicol 35 mg/mL 0.35 10 mL 100% Ethanol 
Kanamycin 50 mg/mL 0.5 10 mL ddH2O 
PMSF 0.2 M 34.84 mg 1 mL 100% ethanol 
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V.A.24. TRANSFORMING COMPETENT BACTERIA 
Modified from Jennifer Stone and Walter Kim 
 
Procedure: 
 
1. Before starting, determine the fate for your transformed bacteria.  If the 
transformation is being done to express plasmid DNA, I use XL1-blue E. coli.  
However, for protein expression, I always use BL21 E. coli.   
2. For transformation, I prefer the “5-45-5” method as coined by Walter Kim.  
Briefly, it’s 5 minutes on ice, 45 seconds at 42°C followed by 5 minutes on ice.   
3. Prepare enough LB-agar plates for all of your samples, containing the antibiotic 
you will be selecting for.  You will also need sterile eppendorf tubes, pipet tips, 
and a spreader. 
4. Thaw an aliquot of competent cells on ice.  For co-transformation (i.e. BirA + 
MHC class I), use supercompetent cells.   
5. Pre-heat a water bath to 42C. 
6. For each sample, add 1L of miniprepped DNA (approximately 1-50ng) to 50L 
of competent cells in a sterile eppendorf tube.  Ideally, you should perform at least 
two controls: a known plasmid with the antibiotic resistance tag you will be using 
(such as pLM1 for ampicillin resistance), and cells with no DNA added. 
7. Incubate on ice 5 minutes.   
8. Place tubes in the water bath at 42C for 45 seconds.  
9. Return the tubes to ice for another 5 minutes.   
10. For co-transformation, add a 10x volume of S.O.C. recovery media (Invitrogen 
Cat# 15544-034), mix gently and incubate the transformed cells at 37C for 1 
hour.  This allows recovery from the heat shock in the water bath.  For 
transformation of a single plasmid, skip to step 11.   
a. S.O.C. media can also be prepared using the ingredients below.    
i. S.O.C. formulation per one liter (from Invitrogen) 
2% tryptone 
0.5% yeast extract 
10 mM sodium chloride 
2.5 mM potassium chloride 
10 mM magnesium chloride 
10 mM magnesium sulfate 
20 mM glucose  
11. Plate the cells onto LB plates containing the antibiotic you are using to screen (for 
example, ampicillin).  Use a disposable spreader.   
12. Incubate plate overnight at 37C.  You should have colonies on your positive 
control plasmid plate (such as pLM1), and no colonies on your “no DNA” plate.   
a. Note: If you get too many colonies or a “lawn” on your transformation 
plates, use a smaller volume of the transformation mixture to spread onto 
your plates. 
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13. To test protein induction in BL21 or other production strain, grow several 
colonies from the transformed plate in 5 mL of 1x LB medium, 100 g/mL 
ampicillin (or other selecting antibiotic), 0.2-0.5% glucose until the cultures reach 
an OD600 of ~0.7.  Take a “Not Induced” sample from each culture.  Add IPTG to 
0.75 mM final concentration and grow for another 1-3 hours at 37C.  Take an 
“Induced” sample of the same volume from each culture.  Run an SDS gel of the 
samples against molecular weight markers to test protein induction in each 
culture.   
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V.B. Gene Constructs used in this Thesis 
Modified from Jennifer Stone 
 
Gene 
Construct 
H-2Kbbsp  
Mouse heavy chain with biotin signal peptide (bsp) tag 
Plasmid pLM1 
Promoter T7 
Antibiotic 
Resistance 
Ampicillin 
Made by NIH tetramer facility 
Gene 
Sequence 
ATGGGACCACATTCGCTGAGGTATTTCGTCACCGCCGTGTCCCGGCCCGGCCTCGGGGA 
GCCCCGGTACATGGAAGTCGGCTACGTGGACGACACGGAGTTCGTGCGCTTCGACAGCG 
ACGCGGAGAATCCGAGATATGAGCCGCGGGCGCGGTGGATGGAGCAGGAGGGGCCCGAG 
TATTGGGAGCGGGAGACACAGAAAGCCAAGGGCAATGAGCAGAGTTTCCGAGTGGACCT 
GAGGACCCTGCTCGGCTACTACAACCAGAGCAAGGGCGGCTCTCACACTATTCAGGTGA 
TCTCTGGCTGTGAAGTGGGGTCCGACGGGCGACTCCTCCGCGGGTACCAGCAGTACGCC 
TACGACGGCTGCGATTACATCGCCCTGAACGAAGACCTGAAAACGTGGACGGCGGCGGA 
CATGGCGGCGCTGATCACCAAACACAAGTGGGAGCAGGCTGGTGAAGCAGAGAGACTCA 
GGGCCTACCTGGAGGGCACGTGCGTGGAGTGGCTCCGCAGATACCTGAAGAACGGGAAC 
GCGACGCTGCTGCGCACAGATTCCCCAAAGGCCCATGTGACCCATCACAGCAGACCTGA 
AGATAAAGTCACCCTGAGGTGCTGGGCCCTGGGCTTCTACCCTGCTGACATCACCCTGA 
CCTGGCAGTTGAATGGGGAGGAGCTGATCCAGGACATGGAGCTTGTGGAGACCAGGCCT 
GCAGGGGATGGAACCTTCCAGAAGTGGGCATCTGTGGTGGTGCCTCTTGGGAAGGAGCA 
GTATTACACATGCCATGTGTACCATCAGGGGCTGCCTGAGCCCCTCACCCTGAGATGGG 
AGCCTCCTCCATCCGGATCCCTGCATCATATTCTGGATGCACAGAAAATGGTGTGGAAT 
CATCGTTAA 
Protein 
Sequence 
MGPHSLRYFVTAVSRPGLGEPRYMEVGYVDDTEFVRFDSDAENPRYEPRARWMEQEGPE 
YWERETQKAKGNEQSFRVDLRTLLGYYNQSKGGSHTIQVISGCEVGSDGRLLRGYQQYA 
YDGCDYIALNEDLKTWTAADMAALITKHKWEQAGEAERLRAYLEGTCVEWLRRYLKNGN 
ATLLRTDSPKAHVTHHSRPEDKVTLRCWALGFYPADITLTWQLNGEELIQDMELVETRP 
AGDGTFQKWASVVVPLGKEQYYTCHVYHQGLPEPLTLRWEPPPSGSLHHILDAQKMVWN 
HRSTOP 
Protein 
MW 
34,271.4 Da 
Protein 
extinction 
coefficient 
78,900 at 280nm (unfolded) 
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Gene 
Construct 
H-2Kbcs 
Mouse heavy chain with uniquely reactive cysteine at the C-terminus 
Plasmid pLM1 
Promoter T7 
Antibiotic 
Resistance 
Ampicillin 
Made by Mia Rushe 
Insert size ~860bp 
Gene 
Sequence 
ATGGGACCACATTCGCTGAGGTATTTCGTCACCGCCGTGTCCCGGCCCGGCCTCGGGGA 
GCCCCGGTACATGGAAGTCGGCTACGTGGACGACACGGAGTTCGTGCGCTTCGACAGCG 
ACGCGGAGAATCCGAGATATGAGCCGCGGGCGCGGTGGATGGAGCAGGAGGGGCCCGAG 
TATTGGGAGCGGGAGACACAGAAAGCCAAGGGCAATGAGCAGAGTTTCCGAGTGGACCT 
GAGGACCCTGCTCGCTACTACAACCAGAGCAAGGGCGGCTCTCACACTATTCAGGTGAT 
CTCTGGCTGTGAAGTGGGGTCCGACGGGCGACTCCTCCGCGGGTACCAGCAGTACGCCT 
ACGACGGCcGtGATTACATCGCCCTGAACGAAGACCTGAAAACGTGGACGGCGGCGGAC 
ATGGCGGCGCTGATCACCAAACACAAGTGGGAGCAGGCTGGTGAAGCAGAGAGACTCAG 
GGCCTACCTGGAGGGCACGTGCGTGGAGTGGCTCCGCAGATACCTGAAGAACGGGAACG 
CGACGCTGCTGCGCACAGATTCCCCAAAGGCCCATGTGACCCATCACAGCAGACCTGAA 
GATAAAGTCACCCTGAGGTGCTGGGCCCTGGGCTTCTACCCTGCTGACATCACCCTGAC 
CTGGCAGTTGAATGGGGAGGAGCTGATCCAGGACATGGAGCTTGTGGAGACCAGGCCTG 
CAGGGGATGGAACCTTCCAGAAGTGGGCATCTGTGGTGGTGCCTCTTGGGAAGGAGCAG 
TATTACACATGCCATGTGTACCATCAGGGGCTGCCTGAGCCCCTCACCCTGAGATGGGA 
GCCTtgctaa 
Protein 
Sequence 
MGPHSLRYFVTAVSRPGLGEPRYMEVGYVDDTEFVRFDSDAENPRYEPRARWMEQEGPE 
YWERETQKAKGNEQSFRVDLRTLLGYYNQSKGGSHTIQVISGCEVGSDGRLLRGYQQYA 
YDGRDYIALNEDLKTWTAADMAALITKHKWEQAGEAERLRAYLEGTCVEWLRRYLKNGN 
ATLLRTDSPKAHVTHHSRPEDKVTLRCWALGFYPADITLTWQLNGEELIQDMELVETRP 
AGDGTFQKWASVVVPLGKEQYYTCHVYHQGLPEPLTLRWEPCSTOP 
Protein 
MW 
32,122 Da 
Protein 
extinction 
coefficient 
73,210 at 280nm (unfolded) 
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Gene 
Construct 
Beta-2-Microglobulin  
Human light chain 
Plasmid pLM1 
Promoter T7 
Antibiotic 
Resistance 
Chloramphenicol 
Made by NIH tetramer facility 
Gene 
Sequence 
ATGATCCAGCGTACACCAAAGATTCAGGTTTACTCACGTCATCCAGCAGAGAATGGAAA 
GTCAAATTTCCTGAATTGCTATGTGTCTGGGTTTCATCCATCCGACATTGAAGTTGACT 
TACTGAAGAATGGAGAGAGAATTGAAAAAGTGGAGCATTCAGACTTGTCTTTCAGCAAG 
GACTGGTCTTTCTATCTCTTGTACTACACTGAATTCACCCCCACTGAAAAAGATGAGTA 
TGCCTGCCGTGTGAACCATGTGACTTTGTCACAGCCCAAGATAGTTAAGTGGGATCGAG 
ACATGTAA 
Protein 
Sequence 
MIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSK 
DWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDMSTOP 
Protein MW 12,148 Da 
Protein 
extinction 
coefficient 
20,003 at 280nm (unfolded) 
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V.C. Glycosylation Modulates Binding of MHC Class I Monomers onto Naïve CD8+ 
T cells 
 
MHC class I tetramer binding is affected by glycosylation, which has been 
attributed to glycan moieties presented on cell surface glycoproteins such as TCR or CD8 
co-receptor.  These glycan adducts are thought to either restrict receptor (TCR/CD8) 
clustering (Demetriou, Granovsky et al. 2001) or alter CD8 co-engagement (Daniels and 
Jameson 2000; Daniels, Devine et al. 2001; Moody, Chui et al. 2001).  However, due to 
the multivalent nature of MHC tetramers, reduced MHC tetramer staining after de-
glycosylation might be due to either reduced TCR clustering or CD8 co-engagement.  As 
part of a collaborative project with Dr. Jonathan Schneck, the effect of glycosylation was 
investigated using differentially sialylated CD8+ T cells from naïve 2C-TCR transgenic 
mice.   
To generate a desialylated T cell population, a broad range neuraminidase from 
vibrio cholera (Sigma N-6514) was utilized, which removes both N- and O-linked 
glycans.  Briefly, naïve CD8+ T cells from 2C TCR-transgenic mice were kept at a 
density of 2e6/mL and incubated with 8 μL/mL neuraminidase for 30 minutes at 37°C 
degrees.  The extent of desialylation was determined by a reduction in anti-CD43 staining 
(data not shown).  To generate a resialylated T cell population, a sialylatransferase 
(Calbiotech Cat# 566227) was utilized to add back the O-linked glycans.  Briefly, 1.5mM 
CMP-Sialic Acid (EMD Cat# 233264) was added with 0.2 Units of sialyltransferase to 
the desialylated T cells and incubated for 40 minutes at 37°C degrees.  The extent of 
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resialylation was determined by an increase in anti-CD43 staining (data not shown).  The 
differentially sialylated T cell sub-populations were stained with labeled peptide-Kb 
monomers for one hour at 4°C degrees.  T cells were fixed for 5 minutes using 1% 
paraformaldehyde and then washed once with staining buffer to get rid of any 
nonspecifically bound monomer.   
Unlike MHC tetramer binding, where glycosylation could affect either TCR 
clustering or CD8 co-engagement (Demetriou, Granovsky et al. 2001), MHC monomers 
can engage only a single TCR, which would not be affected by TCR clustering.  For this 
reason, we hypothesized that any effect of glycosylation on MHC monomer binding 
might be attributable to altered CD8 co-engagement.     
We observed that naïve desialylated CD8+ T cells bind MHC monomers more 
cooperatively as compared to naïve untreated CD8+ T cells (Figure V.C.1A, B).  The 
monomer binding data for the desialylated CD8+ T cells fit a two-site binding equation, 
which indicates the simultaneous engagement of TCR and CD8 onto MHC monomers.  
Additionally, a curvilinear scatchard plot for the MHC monomer binding was observed 
for the naïve desialylated T cells, which indicates more cooperative binding following 
desialylation (Figure V.C.1B).  Interestingly, adding back O-linked glycans onto the 
naive desialylated T cells resulted in less cooperative MHC monomer binding (Figure 
V.C.1C), similar to what was observed for the naïve untreated CD8+T cells (Figure 
V.C.1A).   
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Figure V.C.1. Glycosylation Modulates MHC Class I Monomer Binding.  CD8+ T 
cells from 2C TCR-transgenic mice were differentially glycosylated and tested for 
binding to Alexa 647-labeled peptide-Kb monomers.  Specific MHC monomer binding to 
A. Naïve T cells (Untreated), B. naïve desialylated (Desialylated) and C. naïve 
resialylated after desialylation (Resialylated) T cells was calculated for each 
concentration by subtracting the observed binding (MFI) of the noncognate KbOVA 
monomer from that of the cognate KbSIY monomer.  The specific binding data was fit 
using Graphpad to a one-site or two-site binding equation and plotted against 
concentration on a logarithmic scale.  Scatchard analysis was performed and displayed as 
an inset.    
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To confirm that the effect of glycosylation on MHC monomer binding is due to 
altered CD8 co-engagement, we generated the widely used D227K mutation in the 
conserved MHC class I HC α3 domain (Daniels and Jameson 2000; Dutoit, Guillaume et 
al. 2003).  Most studies have addressed the role of this CD8 mutation using MHC 
tetramers.  However, binding of multivalent MHC tetramers may depend more on the 
higher affinity MHC-TCR interaction (~10 μM)  (Cole, Pumphrey et al. 2007) as 
compared to the CD8-MHC interaction (~100 μM) (Moody, Xiong et al. 2001), which 
makes tetramer binding a complicated method to analyze CD8 co-engagement.  For this 
reason, we performed MHC monomer binding assays on the high affinity OT-1 TCR 
system (Alam, Davies et al. 1999), which might tolerate the absence of CD8 co-
engagement for MHC monomer binding.    
Our results show that cognate KbOVA monomers bind to naïve OT-1 T cells, with 
binding not observed for the noncognate KbSIY monomer (Figure V.C.2A).  However, 
we found that KbOVA binding was abrogated in the absence of CD8 co-engagement, 
which initially appeared to be an interesting result.  Upon reagent analysis, I observed 
that the Kb D227K monomers were more susceptible to protein aggregation under storage 
conditions that have been routinely used for the WT Kb monomers.  For this reason, I 
analyzed the Alexa 647-labeled peptide-Kb complexes by size exclusion chromatography 
(data not shown) and 12% SDS-PAGE (Figure V.C.2B).  The SDS-PAGE analysis 
revealed that the Alexa 647-labeled peptide-Kb complexes contain cleavage products, as 
indicated by protein bands appearing around 26 kDa and ~30 kDa.  The cleavage 
products are most likely derived from the MHC Class I heavy chain, as the same relative 
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amount of β2M is detected for both the WT and D227K complexes.   This finding 
indicates that the D227K mutation compromises the stability of the MHC class I HC or 
alternatively, makes it susceptible to proteolysis.   
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Figure V.C.2.  Mutation of the Conserved CD8 Binding Site Compromises the 
Stability of the MHC Class I Complex.  A. Naïve CD8+ T cells from OT-1 transgenic-
mice were tested for binding to Alexa 657-labeled peptide-Kb monomers, which contain 
either an intact or mutated (D227K) CD8 binding site.   The monomer binding (MFI) was 
plotted against concentration.  B. Alexa 647-labeled peptide-Kb monomers were analyzed 
by 12% SDS-PAGE.  The bands corresponding to MHC class I heavy chain and β2M are 
indicated on the right hand side.  Molecular weight markers are labeled on the left hand 
side.  
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V.D. In Cellular Assays the 9mer LCMV-GP33-41 Peptide binds to H-2Kb as the 8mer 
LCMV-GP34-41 Peptide 
 
Canonically, the termini of MHC class I bound peptides associate with the MHC 
Class I heavy chain through hydrogen bonding at the amino terminus and hydrophobic 
interactions at the carboxyl terminus (Matsumura, Fremont et al. 1992; Rammensee 
1995).  However, a recent report has contradicted this view, and instead, has reported that 
the 9mer LCMV-GP33-41 (KAVYNFATM) peptide can bind to the MHC Class I H-2Kb 
without hydrogen bonding interactions with the MHC class I molecule at the amino 
terminus (Achour, Michaelsson et al. 2002).  In addition, this report indicated that the 
9mer LCMV-GP33-41 peptide binds to H-2Kb in a manner that allows for the P1K residue 
to be extended out of the amino terminal pocket on the MHC class I molecule.  However, 
the crystallographic data which accompanies this report does not contain electron density 
for the P1K residue, which was attributed to the flexibility of this residue in the absence 
of an interaction with the MHC class I heavy chain (Achour, Michaelsson et al. 2002).   
The cellular results that I have indicate that the 9mer LCMV-GP33-41 peptide 
(KAVYNFATM) binds as the 8mer LCMV-GP34-41 (AVYNFATM) peptide to the H-2Kb 
molecule.  To determine if the 9mer LCMV-GP33-41 peptide is presented by H-2Kb 
molecules, we first tested the refolding efficiency of the 8mer LCMV-GP33-41 and the 
9mer LCMV-GP34-41 peptides onto H-2Kb molecules.   We observe that the refolding 
efficiency of the 9mer KbGP33-41 complex is tenfold lower as compared to the native 
8mer KbGP34-41 complex, as indicated by the anion exchange chromatography traces 
(Figure V.D.1).  SDS-PAGE analysis of the labeled fractions from the anion exchange 
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chromatography show trace amounts of the Kb heavy chain and β2M light chain detected 
for the KbGP33-41 complex, whereas both subunits were readily observed for the KbGP34-41 
complex (Figure V.D.1B).   These results clearly demonstrate that the KbGP33-41 complex 
is refolded much less efficiently as compared to the KbGP34-41 complex.   
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Figure V.D.1. The 9mer LCMV-GP33-41 Peptide Refolds Inefficiently with H-2Kb.  
MHC Class I refolding was conducted as previously described using 95% pure peptide 
preparations (21st Century Biochemicals).  A.  Folded H-2Kb complexes were buffer 
exchanged into 20 mM Tris pH 8.0 and purified by anion exchange chromatography.  
The 280 nm and 214 nm wavelengths are displayed for both KbGP33-41 and KbGP34-41.  B.  
Fractions from the anion exchange purification of both H-2Kb complexes were analyzed 
by 12% SDS-PAGE.  The band corresponding to MHC Class I HC and β2M light chain 
are indicated on the right hand side.  The molecular weight markers are indicated on the 
left hand side.   
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Since the 9mer GP33-41 peptide refolded inefficiently with the H-2Kb molecule, we 
hypothesized that the trace amounts of refolded Kb from the 9mer GP33-41 peptide 
refolding, might actually be complexes of Kb with the shorter 8mer GP34-41 peptide.  This 
could occur if the 9mer GP33-41 peptide was cleaved at the amino terminus.  To determine 
if the 9mer GP33-41 peptide is bound by H-2Kb molecules as the 8mer GP34-41 peptide, we 
analyzed both refolded Kb complexes (from Figure V.D.2) by mass spectrometry.  The 
results of the mass spectroscopy experiment indicate that KbGP33-41 complex mostly 
contains the 8mer GP34-41 peptide (Mw = 916 da), as indicated by a peak at 938.7 da,, 
which contains a single sodium adduct.  However, the longer GP33-41 peptide (Mw = 
1044.2 da) was also observed in the KbGP33-41 complex, which is indicated by a peak at 
1066.2 da.  Analysis of the KbGP34-41 complex showed in a single peak at 938.7 da, which 
corresponds to the sole presence of the 8mer GP34-41 peptide with a single sodium adduct.   
Together, these results indicate that the 9mer GP33-41 peptide may bind to H-2Kb 
molecules as either the 9mer GP33-41 peptide or the truncated 8mer GP34-41 peptide.  
However, given that the 9mer GP33-41 peptide refolds very inefficiently with H-2Kb 
molecules, the trace amount of GP33-41 peptide detected could be due to residual peptide 
from the refolding mixture.  Further examination, including an in vitro peptide binding 
assay for Kb, will be needed to precisely determine if the 9mer GP33-41 peptide is bound 
and presented by the H-2Kb molecule.   
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Figure V.D.2 The 9mer GP33-41 Peptide Binds to H-2Kb Molecules as either GP33-41 
or the Truncated GP34-41 Peptide.  Mass spectroscopy using Matrix-Assisted Laser 
Desorption/Ionization (MALDI) of KbGP33-41 indicates that a portion of the 9mer GP33-41 
peptide is truncated, and bound to H-2Kb molecules as 8mer GP34-41.    
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